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INTRODUCTION
Hypertension is the leading cause of morbidity and mortality worldwide [1]. Starting from 
anecdotal evidence in the 40s [2] and observational studies in the 50s [3], it has taken more 
than 30 years to establish that high blood pressure is a major risk factor for the development 
of cardiovascular disease and death, and that blood pressure lowering is an e ective tool in 
reducing morbidity and mortality.
The relationship between high blood pressure and other risk factors and the occurrence of 
cardiovascular disease has been described  rst by the Framingham Heart Study [4], which 
was started in 1948. The residual lifetime risk of developing hypertension in middle aged and 
elderly individuals is 90% [5]. In particular in elderly normotensives, progression to hyperten-
sion may occur within only 4 years [6]. In industrialised countries with an aging population 
hypertension is therefore a growing public health concern.
With the exception of sub-Saharan Africa, cardiovascular disease is the leading cause of death 
in all other World Bank developing regions. In developing countries, hypertension is also a 
major risk factor for the development of cardiovascular disease [7]. Hence, developing coun-
tries are following the pattern of industrialised countries, although with a much steeper rise 
in cardiovascular disease – predominantly hypertension and stroke – followed by an increase 
in coronary heart disease [8]. With increasing urbanization, the prevalence of hypertension is 
expected to reach epidemic dimensions that will require cost-e ective treatment strategies 
also in sub-Saharan Africa [9].
In 1990, 14 million patients died from cardiovascular disease, 5 million in industrialised coun-
tries and 9 million in developing countries. It is estimated that the total number of cardiovas-
cular deaths will increase to 25 million worldwide, with an increase to 6 million in industria-
lised countries and a more than doubling to 19 million in developing countries [10]. About 
two thirds of the occurrence of stroke, one half of coronary heart disease, and about one 
sixth of other cardiovascular diseases can be attributed to above-optimal blood pressure [9]. 
Worldwide, 7.1 million deaths (about 12.8% of the total) and 64.3 million disability adjusted 
life years (DALYs) (4.4% of the total) are estimated to be lost due to above-optimal blood pres-
sure levels [11]. Globally, blood pressure is ranked as the third most important cause of DALYs 
lost, behind malnutrition and unsafe sex [1].
The costs of complications due untreated or sub-optimally treated hypertension are enor-
mous. In  ve western European countries, these costs add up to 1.2 billion US dollar because 
blood pressure control is not achieved in more than 26 million patients in the countries con-
cerned [12]. For hypertensives in the United States, inadequate blood pressure control was 
estimated to result in 39,702 cardiovascular events, 8,374 cardiovascular disease deaths, and 
964 million US dollars in direct medical expenditures. For the treated population with car-
diovascular disease, the incremental cost of the failure to attain blood pressure goals was ap-
proximately 467 million US dollars [13].
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Hypertension has been arbitrarily de ned as blood pressure levels equal or above 140/90 
mmHg. Earlier trials focused on diastolic blood pressure as the target for treatment, whereas 
newer trials have stressed the need to also control systolic blood pressure, which is usually 
more di  cult to achieve [14]. Research has shown that there is a gradual relationship be-
tween blood pressure and risk of cardiovascular complications (in particular of stroke) [15]. 
In the HOT trial, patients with the lowest diastolic blood pressure also had the lowest cardio-
vascular morbidity [16]. Clinical research has also demonstrated that patients with “normal” 
blood pressure levels, i.e. systolic between 125 and 135 mmHg, may be at risk of cardiovas-
cular complications due to other risk factors, such as hyperlipidemia, diabetes or renal dis-
ease [17]. Thus, the Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure de ned this particular group at risk as “pre-
hypertensive” patients [18] and urged control and treatment in the presence of additional risk 
factors for these patients.
It follows that the use of de nitions such as “hypertensive” and “normotensive” does not ad-
equately re ect the total burden of cardiovascular disease due to elevated blood pressure. In 
fact, most of the burden of vascular disease in elderly patients is estimated to occur in those 
with a “normal” systolic blood pressure of less than 140 mmHg [19,20]. Blood pressure levels 
should not be dichotomised into “hypertensive” and “normotensive”, as this gives the erro-
neous impression that those who are “normal” have no cause for concern and do not need 
therapy [19-21]. Indeed, recent European guidelines de ne the need for treatment based on 
the total cardiovascular risk: the higher the risk the lower the target blood pressure [17]. Re-
cent US guidelines continue to distinguish between “hypertensive”, “pre-hypertensive” and 
“normotensive” patients, although for certain high-risk groups such as diabetics and patients 
with renal disease lower target blood pressure levels are recommended [18]. This re ects that 
patients with diabetes and/or renal disease require particular attention because those with 
established target organ damage have a particularly high risk of developing cardiovascular 
complications. Mild renal failure (i.e. serum creatinine above 110 µmol/l in female and 120 
µmol/l in male patients) has been demonstrated to be associated with a signi cant increase 
in cardiovascular risk [22]. The target blood pressure in the patients with diabetes or renal 
disease is less than 135/75mmHg, which is di  cult to achieve even in randomized controlled 
clinical trials. 
Patients with established renal disease, e.g. with proteinuria or microalbuminria, require strict 
control of blood pressure to levels below 120 / 75mmHg. In these patients, the kidney becomes 
a secondary target of blood pressure control in order to prevent further deleterious e ects on 
renal function. It has also been demonstrated that the decline in renal function in diabetic 
patients can be stopped when blood pressure is “normalized” to levels below 120/75mmHg 
[23], and that strict blood pressure is bene cial [16]. 
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APPROACHES TO THE TREATMENT OF HYPERTENSION
A multitude of placebo-controlled clinical trials have demonstrated that drugs that reduce 
blood pressure also reduce cardiovascular risk. Assuming that newer drugs may be more 
e ective in reducing cardiovascular risk than older drugs (such as diuretics and β-blockers) 
given the same e ect on blood pressure, a new era of clinical trials in hypertension comparing 
older to newer drugs was initiated mainly by the pharmaceutical industry.
The INSIGHT (International Nifedipine GITS study: Intervention as a Goal in Hypertension 
Treatment) trial compared a calcium-channel blocker based regimen with a diuretic based 
regimen. The underlying assumption was that in patients with elevated blood pressure, the 
newer calcium-channel blocker based regimen is superior in reducing cardiovascular mortal-
ity and morbidity [24]. When the results of other trials comparing di erent treatments sug-
gested that the degree of blood pressure reduction is more important than the drug used, 
the initial superiority design of INSIGHT was changed into a non-inferiority design. INSIGHT 
recruited high-risk patients, i.e. patients with elevated blood pressure and at least one addi-
tional risk factor. In addition to the main analysis, pre-de ned analyses in subgroups at par-
ticularly high risk, such as patients with renal impairment (Chapter 4) and diabetes (Chapter 
6), were performed.
Despite moderate favourable e ects of newer drugs on intermediate endpoints, such as de-
velopment of new diabetes [25-28] and progression of atherosclerosis [29], no study has dem-
onstrated that for the same degree of blood pressure reduction there is a relevant di erence 
in outcome between newer and older drugs [24,30-33]. These  ndings have been con rmed 
by the largest ongoing prospective meta-analysis of hypertension trials [34].
The only study that showed that reduction of blood pressure is related in gradual manner to 
reduction of cardiovascular risk is the HOT (Hypertension Optimal Treatment) study [16]. Pa-
tients with diastolic blood pressure levels between 100 and 115 mmHg were randomised to 
diastolic blood pressure target levels of 90 mmHg or less, 85 mmHg or less, and 80 mmHg or 
less respectively. Cardiovascular risk was lowest in patients randomised to the lowest target. 
Importantly, this study con rmed that blood pressure and its reduction constitute a continu-
um rather than a threshold in cardiovascular risk reduction.
Studies of antihypertensive drugs in patients at increased risk of cardiovascular disease due to 
the presence of diabetes or nephropathy have con rmed that tighter control of blood pres-
sure is more e ective than less tight control in reducing morbidity and mortality [35]. A recent 
meta-analysis supports this hypothesis: e ects of drugs that inhibit the renin-angiotensin sys-
tem on renal outcomes observed in placebo-controlled trials seemed mainly due to blood 
pressure lowering e ects, rather than to e ects “beyond blood pressure lowering” [36].
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HYPERTENSION AND CORONARY HEART DISEASE
Although it is generally accepted that patients with coronary heart disease and hyperten-
sion have a higher cardiovascular risk than those without, there is little data from randomised 
placebo-controlled clinical trials other than subgroup analyses that show a bene t of blood 
pressure lowering in hypertensive patients with coronary heart disease.
One trial that did address the issue of blood pressure control in patients with coronary heart 
disease and hypertension is the International Verapamil-Trandolapril Study (INVEST) [37]. A 
verapamil-based calcium antagonist treatment strategy was compared to an atenolol-based 
β-blockade strategy in almost 23,000 patients with hypertension and coronary heart disease. 
The trial showed that control of in particular systolic blood pressure in patients with coronary 
heart disease and hypertension is di  cult and requires multiple antihypertensive drugs. Since 
there was no di erence in the combined primary endpoint [37], it does not seem to matter 
whether blood pressure control in a patient with coronary heart disease is started with vera-
pamil or with atenolol. A retrospective analysis by achieved blood pressure levels of data from 
the same study suggested that there may be a J-shaped relation between on-treatment blood 
pressure level and primary outcomes: reductions of diastolic pressure to below 60 mmHg – 
which was only achieved in a minority of patients – resulted in an increased risk of primary 
endpoints, in particular myocardial infarction [38]. 
Two placebo-controlled trials with drugs also used in the treatment of hypertension in pa-
tients with coronary heart disease have recently been completed. The EURopean trial On 
reduction of cardiac events with Perindopril in stable coronary Artery (EUROPA) compared 
the angiotensin-converting-enzyme inhibitor perindopril to placebo in 13,655 patients with 
proven stable coronary disease without apparent heart failure [39]. The ACTION (A Coronary 
disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system) 
study compared the calcium antagonist nifedipine in a long-acting once daily formulation 
to placebo in 7,665 patients with stable symptomatic angina pectoris and proven coronary 
heart disease (Chapter 2). Neither EUROPA nor ACTION restricted inclusion to patients who 
also had hypertension. 
AIM OF THIS THESIS
The general aim of this thesis is threefold:
1. To describe the long-term evolution of blood pressure (Chapters 2 and 3) and to examine 
the e ect of blood pressure reduction by the calcium antagonist nifedipine GITS on out-
come in patients with established stable symptomatic coronary heart disease and hyper-
tension, based on data from the ACTION trial (Chapter 3).
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2. To assess the evolution of renal function and the relationship of renal function with mortal-
ity and morbidity in patients with hypertension treated in INSIGHT with either nifedipine or 
the diuretic co-amilozide, and in patients with symptomatic coronary heart disease treated 
in ACTION with either nifedipine or placebo (Chapters 4 and 5).
3. To assess the impact of diabetes in patients with hypertension and diabetes who received 
either nifedipine or co-amilozide in INSIGHT, and in patients with symptomatic coronary 
heart disease treated in ACTION with either nifedipine or placebo (Chapters 6 and 7).
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SUMMARY
Background: Calcium antagonists are widely prescribed for angina pectoris but their e ect 
on clinical outcome is controversial. We aimed to investigate the e ect of the calcium antago-
nist nifedipine on long-term outcome in patients with stable angina pectoris.
Methods: We randomly assigned 3825 patients with treated stable symptomatic coronary 
disease to double-blind addition of nifedipine GITS (gastrointestinal therapeutic system) 60 
mg once daily and 3840 to placebo. The primary endpoint was the combination of death, 
acute myocardial infarction, refractory angina, new overt heart failure, debilitating stroke, and 
peripheral revascularisation. Mean follow-up was 4·9 years (SD 1·1). Analysis was by intention 
to treat.
Findings: 310 patients allocated nifedipine died (1.64 per 100 patient-years) compared with 
291 people allocated placebo (1·53 per 100 patient-years; hazard ratio 1·07 [95% CI 0·91-1·25], 
p=0·41). Primary endpoint rates were 4·60 per 100 patient-years for nifedipine and 4·75 per 
100 patient-years for placebo (0·97 [0·88-1·07], p=0·54). With nifedipine, rate of death and 
any cardiovascular event or procedure was 9·32 per 100 patient-years versus 10·50 per 100 
patient-years for placebo (0·89 [0·83-0·95], p=0·0012). The di erence was mainly attributable 
to a reduction in the need for coronary angiography and interventions in patients assigned 
nifedipine, despite an increase in peripheral revascularisation. Nifedipine had no e ect on the 
rate of myocardial infarction.
Interpretation: Addition of nifedipine GITS to conventional treatment of angina pectoris has 
no e ect on major cardiovascular event-free survival. Nifedipine GITS is safe and reduces the 
need for coronary angiography and interventions.
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INTRODUCTION
Angina pectoris is the most common symptom in patients with stable atherosclerotic coro-
nary disease. Despite advances in its management, current treatment provides no cure, and 
many patients remain symptomatic. Hence, continued therapy with antianginal drugs is usu-
ally needed.
For many years, nitrates, β blockers, and calcium antagonists have been the treatments of 
choice for angina. These drugs have been prescribed mainly on the basis of proof of e  cacy 
in reducing symptoms. Long-term safety has been of less concern, although safety of β block-
ers is lent support by positive results of trials in patients with a history of acute myocardial 
infarction. Before trials were done with nicorandil [1] and angiotensin-converting-enzyme 
(ACE) inhibitors,[2,3] no hard outcome data were available from clinical trials with drugs used 
in patients with angina or stable coronary disease. In the mid 1990s, considerable debate 
took place about the long-term safety of calcium antagonists.[4-12] Consensus arising from 
this discussion was the need for well-designed long-term trials in patients with hypertension 
or with manifestations of coronary disease such as angina. ACTION (A Coronary disease Trial 
Investigating Outcome with Nifedipine GITS) was designed to investigate the e ects of the 
long-acting calcium antagonist nifedipine on clinical outcomes in patients with stable symp-
tomatic coronary disease.
METHODS
ACTION was a multi-centre, randomised, placebo-controlled, double-blind trial to compare 
the e ect on clinical outcomes of long-acting nifedipine or placebo in patients with angina 
pectoris attributable to coronary disease. A detailed description of the trial has been pub-
lished elsewhere.[13] Planned follow-up ranged from 4·5 to 6 years. We undertook the study in 
accordance with the Declaration of Helsinki and International Conference on Harmonization 
guidelines for Good Clinical Practice, and all patients gave written informed consent. To pro-
tect patients’ safety, prede ned interim analyses were done by an independent safety moni-
toring committee that had access to the medication code. These analyses did not lead to early 
termination.
Patients
Between November, 1996, and December, 1998, we recruited patients in 291 centres from 
19 countries. Three categories of ambulatory patients who were age 35 years or older, had 
angina pectoris that had been stable for at least 1 month, and needed oral or transdermal 
treatment either to treat or prevent anginal attacks were eligible for the study: (1) those with 
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a history of myocardial infarction; (2) those with angiographic coronary artery disease but no 
history of myocardial infarction; and (3) those with a positive exercise test or perfusion defect 
who had never had coronary angiography and had no history of myocardial infarction. Locally 
measured left-ventricular ejection fraction had to be at least 40%. Reasons for exclusion were: 
overt heart failure; any major cardiovascular event or intervention within the past 3 months; 
planned coronary angiography or intervention; known intolerance to dihydropyridines; clini-
cally signi cant valvular or pulmonary disease; unstable insulin-dependent diabetes mellitus; 
any gastrointestinal disorder that could compromise absorption of nifedipine GITS or passage 
of the tablet; any condition other than coronary artery disease that limited life expectancy; 
symptomatic orthostatic hypotension or supine systolic blood pressure 90 mm Hg or less; sys-
tolic blood pressure at least 200 mm Hg, diastolic blood pressure at least 105mm Hg, or both; 
creatinine more than twice the local upper limit of normal; and alanine or aspartate transami-
nase greater than three times the local upper limit of normal. Women could only participate 
if pregnancy was not a risk.
Procedures
Investigators randomly assigned patients to addition of either nifedipine GITS or matching 
placebo to the basic regimen that they were taking. Randomisation was blocked and strati-
 ed by centre. The starting dose of nifedipine was 30 mg once daily, increasing to 60 mg once 
daily within 6 weeks if no evidence of intolerance was seen. Dose reduction or interruption 
was allowed. Investigators allocated treatment by means of sequentially numbered study 
medication packs that contained either nifedipine GITS or matching placebo in a concealed 
manner using identical packaging. The chair of the safety monitoring committee prepared 
the random allocation list. Only patients who actually took the  rst tablet of study drug were 
regarded as randomised.
We treated symptomatic angina with conventional drugs. Lipid-lowering therapy was either 
continued or started according to local guidelines. The following drugs could not be used in 
combination with study medication: calcium antagonists (2-week washout needed); cardiac 
glycosides (unless given for supraventricular arrhythmias); other positive inotropic agents 
class I or III antiarrhythmics other than amiodarone or sotalol; cimetidine; antipsychotic and 
antiepileptic drugs; and rifampicin.
Baseline assessments included echocardiography and a full medical history. We recorded 
blood pressure with a standard sphygmomanometer in the sitting position after 5 min of rest. 
Functional class was rated with the New York Heart Association (NYHA) scale. Patients were 
seen at the outpatient clinic at least every 6 months for routine clinical assessments that in-
cluded NYHA class, vital signs, and adverse events. Between visits, we contacted patients by 
telephone.
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The primary e  cacy outcome was major cardiovascular event-free survival, de ned as time to 
occurrence of the  rst of the following events: death from any cause, acute myocardial infarc-
tion, refractory angina, new overt heart failure, debilitating stroke, and peripheral revasculari-
sation (combined primary endpoint for e  cacy). The primary combined endpoint for safety, 
de ned for planned interim analyses,[13] was death from any cause, acute myocardial infarc-
tion, and debilitating stroke. Secondary prede ned outcomes were any cardiovascular event; 
any death, cardiovascular event, or procedure; and any vascular event or procedure.
The critical events committee classi ed serious adverse events that suggested a possible ma-
jor cardiovascular event with prede ned criteria, irrespective of the investigators’ diagnosis. 
Cause of death was categorised as unknown, cardiovascular, or non-cardiovascular. To de ne 
acute myocardial infarction the committee required two events of typical symptoms, raised 
enzymes or markers, and electrocardiographic criteria: in the context of an intervention, new 
Q waves were needed. A de nition of refractory angina required angina at rest, prolonged 
administration of intravenous nitrates or equivalent, and a coronary angiogram within 1 week 
after onset of symptoms. New overt heart failure was diagnosed when new or worsening 
symptoms suggesting heart failure required a change of heart failure treatment and (pro-
longed) admission and a non-cardiac cause could not be identi ed. Debilitating stroke re-
quired the presence of acute symptoms or signs suggesting stroke combined with functional 
impairment 30 days after onset of symptoms, or death within 30 days. Peripheral revasculari-
sation included any vascular intervention peripheral to the coronary circulation and amputa-
tion because of a vascular condition. When more than one event was diagnosed on the same 
date, the critical events committee also determined the order of occurrence.
Statistical analysis
Sample size estimation and interim analysis procedures have been described elsewhere.
[13] Based on the simvastatin-treated group in the Scandinavian Simvastatin Survival Study 
(4S),[14] the assumed rate of the primary e  cacy outcome in the placebo group was 5·6 per 
100patient-years (731 events). With 30 000 patient-years of follow-up, the study was estimated 
to have 95% power to detect an 18% reduction of the primary e  cacy outcome by nifedipine 
GITS relative to placebo at an overall 5% level of signi cance.
All analyses were done by intention to treat. Events with an onset date after the planned date 
of the end-of-study visit were not included. We regarded deaths of unknown cause as cardio-
vascular. Coronary angiography and percutaneous coronary intervention on the same day 
were counted only as percutaneous coronary intervention. We compared treatment groups 
with Kaplan-Meier plots and log rank tests without adjustment for covariates or interim analy-
sis. Event rates were taken as number of events divided by total time that patients had been 
at risk of the (combined) event concerned. Hazard ratios with 95% CIs were obtained with 
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Cox proportional-hazards models, with treatment allocation as the only covariate. Interaction 
tests for subgroup analyses were done with Cox proportional-hazards models.
We calculated an overall p value for comparison of mean heart rate and blood pressure levels 
between treatment groups from a mixed-e ects model for repeated measurements, with the 
SAS proc mixed procedure (SAS Institute, Cary, NC, USA).
Role of the funding source
An independent research institute (SOCAR Research SA) and an independent steering com-
mittee were responsible for study design, management, data analysis, and data interpreta-
tion. The role of the sponsor was restricted to study medication supply and on-site monitor-
For personal use. Only reproduce with permission from Elsevier Ltd 
7797 randomly
            allocated
            study drug
5 centres
(128 patients)
excluded*
4 study drug not
    started
7665 in intention-
            to-treat
            analyses
3825 nifedipine
            (intended
            follow-up
            19 411 years)
3334 completed
            study as
            intended
            (17 351 years
            of follow-up)
310 died 
          (931 years of
          follow-up)
181 terminated
         study earlier
         than intended
         (437 years of
         follow-up)
3840 placebo
            (intended
            follow-up
            19 508 years)
3370 completed
            study as
            intended
            (17 710 years
            of follow-up)
291 died
         (854 years of
          follow-up)
179 terminated
         study earlier
         than intended
         (404 years of
         follow-up)
Figure 1: Trial pro le
*Di  culties with source data veri cation noted during on-site audits.
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ing. A representative of the sponsor (non-voting) was in attendance at steering committee 
meetings. The chair of the safety monitoring committee prepared the random allocation list. 
The sponsor’s drug safety department had to contact this person to unmask adverse drug 
reactions for reporting to local regulatory authorities.
RESULTS
The ACTION study was completed as planned;  gure 1 shows the trial pro le. Centres contrib-
uted a median of 19 patients (range 1-107); 13 centres randomised fewer than four patients. 
Intended follow-up (either until death, until last visit or contact within 6 weeks before planned 
For personal use. Only reproduce with permission from Elsevier Ltd 
Nifedipine (n=3825) Placebo (n=3840)
Demographics
Age (years) 63·5 (9·3) 63·4 (9·3)
Men 3041 (80%) 3043 (79%)
Clinical features
History of myocardial infarction 1974 (52%) 1924 (50%)
With coronary revascularisation 944 (25%) 960 (25%)
Angiographic coronary artery disease, no myocardial infarction 1222 (32%) 1249 (33%)
With coronary revascularisation 766 (20%) 759 (20%)
Positive exercise or radionuclide test only 616 (16%) 646 (17%)
No history of coronary artery disease 13 (0·3%) 21 (0·5%)
Significant lesions on coronary angiogram 2632 (69%) 2634 (69%)
Normal coronary angiogram 50 (1%) 48 (1%)
Angiography not done or unknown 1143 (30%) 1158 (30%)
Past use of calcium antagonists 854 (22%) 823 (21%)
Current NYHA class II–III 1756 (46%) 1776 (46%)
Anginal attacks 3544 (93%) 3526 (92%)
History of peripheral cardiovascular disease* 494 (13%) 491 (13%)
Risk factors
Current smoker 686 (18%) 670 (17%)
Total cholesterol �5·0 mmol/L 2382 (62%) 2433 (63%)
Body-mass index �30·0 kg/m2 849 (22%) 895 (23%)
Blood pressure �140/90 mm Hg 1975 (52%) 2002 (52%)
Any of the above 3291 (86%) 3362 (88%)
Diabetes mellitus 565 (15%) 545 (14%)
Treated with insulin 86 (2%) 97 (3%)
Cardiovascular variables
Heart rate (beats per min) 64·3 (10·3) 64·4 (10·3)
Systolic blood pressure (mm Hg) 137·3 (18·8) 137·6 (18·6)
Diastolic blood pressure (mm Hg) 79·9 (9·4) 79·8 (9·5)
Ejection fraction core laboratory value (%)† 48·3 (6·4) 48·2 (6·4)
Ejection fraction local value only (%)‡ 56·6 (9·1) 57·8 (9·9)
Data are number of patients (%) or mean (SD). *Stroke, transient ischaemic attacks, or claudication. †7016 core laboratory
values (3519 nifedipine, 3497 placebo). ‡607 local values (286 nifedipine, 321 placebo).
Table 1: Baseline characteristics 
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end of follow-up, or until planned date of end-of-study visit) was 38 919 patient-years (19 
411nifedipine, 19 508 placebo). Actual follow-up was 37 867 patient-years (18 899 nifedipine, 
18 968 placebo). Follow-up was thus 97·3% complete.
Table 1 presents baseline characteristics. Mean age was 63·5 years (SD 9·3), 6084 (79%) pa-
tients were men, and 7540 (98%) were of white ethnic origin.
Table 2 shows treatments prescribed at the time of randomisation. Treatment groups were 
well balanced at baseline.
Addition of nifedipine GITS to the basic regimen was generally well tolerated. At 6 weeks, 
3366 (88%) patients allocated nifedipine and 3533 (92%) assigned placebo were on the full 
dose. Study drugs were taken for 79% of total follow-up time by individuals randomised to 
nifedipine and for 82% of follow-up for those allocated placebo. A reduction to half-dose hap-
pened for 16% of total follow-up for patients assigned nifedipine and for 6% of follow-up for 
those given placebo. Study drugs were withdrawn permanently 2 or more days before death 
or end of follow-up in 1305 (34%) started on nifedipine and 1179 (31%) allocated placebo. 
In 389 nifedipine and 172 placebo patients, the reason was occurrence of an adverse event, 
the most frequent events of which were peripheral oedema (139 nifedipine, 20 placebo) and 
For personal use. Only repr du e with permission from Elsevi r Ltd 
Nifedipine (n=3825) Placebo (n=3840)
Antianginal drug
� blocker 3032 (79%) 3066 (80%)
Organic nitrate, as needed 2157 (56%) 2175 (57%)
Organic nitrate, daily maintenance 1455 (38%) 1417 (37%)
Other vasodilator 158 (4%) 148 (4%)
Any of the above 3775 (99%) 3784 (99%)
Any two of the above 1888 (49%) 1960 (51%)
Any three or four of the above 563 (15%) 520 (14%)
Lipid-lowering
Statin 2409 (63%) 2389 (62%)
Fibrate 242 (6%) 246 (6%)
Other 45 (1%) 68 (2%)
Any of the above 2607 (68%) 2591 (67%)
Blood-pressure lowering
ACE inhibitor 771 (20%) 792 (21%)
Angiotensin-II antagonist 90 (2%) 93 (2%)
Diuretic 432 (11%) 447 (12%)
Other 113 (3%) 81 (2%)
Any of the above 1165 (30%) 1166 (30%)
Other cardiovascular
Acetylsalicylic acid 3293 (86%) 3304 (86%)
Vitamin K antagonist 156 (4%) 149 (4%)
Cardiac glycoside 30 (1%) 50 (1%)
Amiodarone, sotalol, or other antiarrhythmic 138 (4%) 157 (4%)
Data are number of patients (%).
Table 2: Concomitant treatments at baseline 
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headache (43 nifedipine, 20 placebo). As shown in  gure 2, nifedipine raised mean heart rate 
during follow-up by 1 beat per min (p<0·0001), and it was associated with signi cant mean 
reductions of systolic and diastolic blood pressure relative to placebo. During follow-up, the 
proportion of patients with blood pressure of 140/90 mm Hg or more (52% at baseline) aver-
aged 35% for patients assigned nifedipine, and 47% for those allocated placebo.For personal use. Only reproduce with permission from Elsevier Ltd 
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Figure 2: Change in mean heart rate and blood pressure
SEs were less than 0·5 bpm for heart rate and less than 1·0 mm Hg for both systolic blood pressure and 
diastolic blood pressure at all time points. P value calculated with test for repeated measurements.
32
Table 3 shows event rates for every outcome included in prede ned combined endpoints, and 
 gure 3 shows time-to-event data for all-cause mortality. 310 people started on nifedipine 
and 291 allocated placebo died; of these, 103 deaths in the nifedipine group and 97 in the pla-
cebo group happened while the patient was on study drug. Cardiovascular (including cause 
unknown) and non-cardiovascular death rates were similar between treatment groups (table 
3). Nifedipine signi cantly reduced the rate of new overt heart failure (p=0·015), and need for 
coronary angiography (p<0·0001) and bypass surgery (p=0·0021).
Table 4 presents results of the combined primary endpoints for e  cacy and safety and pre-
de ned secondary endpoints, and  gure 3 shows corresponding time-to-event plots for end-
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Nifedipine (n=3825) Placebo (n=3840) Hazard ratio* (95% CI) p
Total number of events Number of patients with event Total number of events Number of patients with event 
(incidence per 100 patient-years (incidence per 100 patient-years 
at risk) at risk)
All-cause mortality 310 310 (1·64) 291 291 (1·53) 1·07 (0·91–1·25) 0·41
Non-cardiovascular 132 132 (0·70) 114 114 (0·60) 1·16 (0·90–1·49) 0·24
Cardiovascular or unknown† 178 178 (0·94) 177 177 (0·93) 1·01 (0·82–1·24) 0·93
Myocardial infarction 320 267 (1·46) 296 257 (1·39) 1·04 (0·88–1·24) 0·62
Refractory angina 171 150 (0·81) 190 174 (0·94) 0·86 (0·69–1·07) 0·18
New overt heart failure 117 86 (0·46) 158 121 (0·65) 0·71 (0·54–0·94) 0·015
Debilitating stroke 82 77 (0·41) 108 99 (0·53) 0·78 (0·58–1·05) 0·10
Peripheral revascularisation 187 146 (0·79) 144 118 (0·63) 1·25 (0·98–1·59) 0·073
Coronary angiography 1200 895 (5·46) 1357 1068 (6·69) 0·82 (0·75–0·90) <0·0001
Percutaneous coronary intervention 512 385 (2·15) 548 417 (2·34) 0·92 (0·80–1·06) 0·25
Coronary bypass surgery 299 294 (1·62) 373 371 (2·06) 0·79 (0·68–0·92) 0·0021
*Comparison of nifedipine with placebo. †Includes cause unknown (24 nifedipine, 28 placebo).
Table 3: Incidence of clinical events
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Figure 3: Time to  rst occurrence of clinical events
MI=myocardial infarction. RA=refractory angina. CVA=debilitating stroke. HF=new overt heart failure. 
PREV=peripheral revascularisation. CAG=coronary angiography. PCI=percutaneous coronary intervention. 
CABG=coronary artery bypass grafting.
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points that include all-cause mortality. The frequency of the primary endpoint for e  cacy did 
not di er between patients assigned nifedipine and those allocated placebo (hazard ratio 
0·97 [95% CI 0·88-1·07], p=0·54). The primary endpoint for safety was similar in both groups 
(1·01 [0·90-1·14], p=0·86). Any death, cardiovascular event, or procedure was signi cantly less 
frequent in patients assigned nifedipine than in those allocated placebo (0·89 [0·83-0·95], 
p=0·0012), but the frequency of cardiovascular events alone did not di er between treatment 
groups (0·94 [0·85-1·05], p=0·26). Nifedipine prolonged mean event and procedure-free sur-
vival by 41days. The di erence between treatment groups for this combined endpoint was 
mainly attributable to fewer patients started on nifedipine who had coronary angiography 
as  rst event. Nifedipine also reduced the occurrence of any vascular event (0·91 [0·83-0·99], 
p=0·027).
Figure 4 shows prede ned subgroup analyses for the primary endpoint for e  cacy. Only blood 
pressure level seemed to be a modi er of the e ect of nifedipine (interaction test, p=0·02). In 
patients with systolic blood pressure of 140 mm Hg or more or diastolic blood pressure of 90 
mm Hg or more, the noted incidence of primary endpoints for e  cacy for nifedipine was less 
than for placebo.
DISCUSSION
ACTION has established the safety of nifedipine GITS, a long-acting dihydropyridine calcium 
antagonist, in the treatment of patients with stable angina pectoris already on conventional 
treatment. No signi cant di erence was noted with respect to the primary e  cacy endpoint, 
but secondary endpoints for all vascular events and procedures did show bene t.
Compared with short-acting compounds, long-acting calcium antagonists have been shown 
to reduce the risk of cardiovascular events in patients treated for hypertension.[15] Although 
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Primary endpoint Primary endpoint Cardiovascular Death, cardiovascular Vascular 
for efficacy for safety events events, or procedures events
Nifedipine Placebo Nifedipine Placebo Nifedipine Placebo Nifedipine Placebo Nifedipine Placebo 
(n=3825) (n=3840) (n=3825) (n=3840) (n=3825) (n=3840) (n=3825) (n=3840) (n=3825) (n=3840)
Mean follow-up at risk (days)* 1668 1660 1740 1739 1668 1660 1475 1434 1574 1556
Percentage of time at risk on 80% 85% 80% 84% 80% 85% 83% 88% 81% 86%
any dose of study drug (%)
Percentage of time at risk on full 60% 76% 60% 75% 60% 76% 62% 79% 61% 77%
dose of study drug (%)
Event that terminated event-free 
follow-up
Non-cardiovascular death 110 92 118 100 † † 98 79 † †
Cardiovascular or unknown death 82 92 111 112 82 92 77 74 88 92
Myocardial infarction 234 225 264 253 234 225 190 186 215 214
Refractory angina 135 154 † † 135 154 113 125 128 137
New overt heart failure 50 82 † † 50 82 44 60 † †
Debilitating stroke 64 83 69 93 64 83 58 72 64 81
Peripheral revascularisation 129 100 † † 129 100 109 77 115 92
Coronary angiography † † † † † † 629‡ 779‡ † †
Percutaneous coronary intervention † † † † † † 116 127 243 266
Coronary artery bypass grafting † † † † † † 5 4 173 239
Any of the above (rate§) 804 (4·60) 828 (4·75) 562 (3·08) 558 (3·05) 694 (3·97) 736 (4·22) 1439 (9·32) 1583 (10·50) 1026 (6·22) 1121 (6·85)
Any first event on study drug 528 552 313 331 507 536 1036 1206 734 829
*Until first of: any event considered; last visit or contact; planned date of end-of-study visit. †Not included in the combined endpoint concerned. ‡On same day as percutaneous coronary intervention, counted as percutaneous
coronary intervention only. §Number of patients with event per 100 patient-years at risk. 
Table 4: Incidence of combined endpoints
0·6 0·8 1·0 1·2 1·4 1·6
Favours nifedipine Favours placebo
  Number of patients Number of patients
with event (rate*)
Nifedipine/placebo Nifedipine/placebo p†
All 3825/3840 804 (4·60)/828 (4·75)
Age (years)
�65 2053/2064 337 (3·52)/362 (3·79) 0·42
�65 1772/1776 467 (5·93)/466 (5·90)
Sex
Men 3041/3043 638 (4·59)/681 (4·95) 0·070
Women 784/797 166 (4·66)/147 (4·00)
History of myocardial infarction
No 1851/1916 345 (4·01)/388 (4·43) 0·22
Yes 1974/1924 459 (5·18)/440 (5·06)
History of coronary revascularisation
No 2115/2121 418 (4·32)/420 (4·32) 0·52
Yes 1710/1719 386 (4·96)/408 (5·29)
Diabetes
No 3260/3295 640 (4·25)/658 (4·34) 0·59
Yes    565/545 164 (6·81)/170 (7·42)
Past use of calcium channel blockers
No 2971/3017 596 (4·39)/620 (4·51) 0·82
Yes    854/823 208 (5·34)/208 (5·63)
On β blockade at entry
No 793/774 154 (4·28)/166 (4·72) 0·49
Yes 3032/3066 650 (4·69)/662 (4·75)
On lipid-lowering drugs at entry
No 1218/1249 296 (5·50)/297 (5·39) 0·46
Yes 2607/2591 508 (4·21)/531 (4·45)
On ACE inhibitor or angiotensin-II antagonist at entry
No 2966/2960 620 (4·56)/615 (4·53) 0·19
Yes 859/880 184 (4·76)/213 (5·50)
Ejection fraction (%)
�45 1056/1074 284 (6·02)/281 (5·86) 0·45
�45 2749 / 2744 517 (4·08)/541 (4·31)
SBP �140 mmHg or DBP �90 mmHg
No 1847/1837 364 (4·28)/328 (3·84) 0·015
Yes 1975/2002 439 (4·90)/500 (5·61)
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several large trials in hypertension have shown the e  cacy and safety of nifedipine GITS [16] 
and other drugs in this class,[17,18] their e ect on long-term clinical outcome in patients with 
coronary disease was unknown. Two other large studies reported on the use of another class 
of drug, ACE inhibitors, in patients either at risk of coronary disease or with some manifesta-
tion of coronary disease.[2,3] A study that compared atenolol, nifedipine, and their combi-
nation in patients with stable angina [19] was not placebo controlled and lacked power for 
showing di erences between treatment groups with respect to clinical outcome.
ACTION started in 1996 and went to completion with no alteration of the protocol. Both the 
number of patients recruited and the number of events in the placebo group were higher 
than we anticipated. The di erence in blood pressure levels between treatment groups shows 
that we did achieve a contrast between nifedipine and placebo. The formulation of nifedipine 
used in ACTION was not the short-acting preparation but the GITS formulation, which modi-
 es release of the drug to provide stable long-term concentrations in plasma.
For personal use. Only reproduce with permission from Elsevier Ltd 
0·6 0·8 1·0 1·2 1·4 1·6
Favours nifedipine Favours placebo
  Number of patients Number of patients
with event (rate*)
Nifedipine/placebo Nifedipine/placebo p†
All 3825/3840 804 (4·60)/828 (4·75)
Age (years)
�65 2053/2064 337 (3·52)/362 (3·79) 0·42
�65 1772/1776 467 (5·93)/466 (5·90)
Sex
Men 3041/3043 638 (4·59)/681 (4·95) 0·070
Women 784/797 166 (4·66)/147 (4·00)
History of myocardial infarction
No 1851/1916 345 (4·01)/388 (4·43) 0·22
Yes 1974/1924 459 (5·18)/440 (5·06)
History of coronary revascularisation
No 2115/2121 418 (4·32)/420 (4·32) 0·52
Yes 1710/1719 386 (4·96)/408 (5·29)
Diabetes
No 3260/3295 640 (4·25)/658 (4·34) 0·59
Yes    565/545 164 (6·81)/170 (7·42)
Past use of calcium channel blockers
No 2971/3017 596 (4·39)/620 (4·51) 0·82
Yes    854/823 208 (5·34)/208 (5·63)
On β blockade at entry
No 793/774 154 (4·28)/166 (4·72) 0·49
Yes 3032/3066 650 (4·69)/662 (4·75)
On lipid-lowering drugs at entry
No 1218/1249 296 (5·50)/297 (5·39) 0·46
Yes 2607/2591 508 (4·21)/531 (4·45)
On ACE inhibitor or angiotensin-II antagonist at entry
No 2966/2960 620 (4·56)/615 (4·53) 0·19
Yes 859/880 184 (4·76)/213 (5·50)
Ejection fraction (%)
�45 1056/1074 284 (6·02)/281 (5·86) 0·45
�45 2749 / 2744 517 (4·08)/541 (4·31)
SBP �140 mmHg or DBP �90 mmHg
No 1847/1837 364 (4·28)/328 (3·84) 0·015
Yes 1975/2002 439 (4·90)/500 (5·61)
Figure 4: E ect of nifedipine on primary endpoint for e  cacy in prede ned subgroups
ACE=angiotensin-converting enzyme. SBP=systolic blood pressure. DBP=diastolic blood pressure.
*Number of events per 100 patient-years of follow-up at risk. †For e ect modi cation (interaction test).
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The chosen primary endpoint for e  cacy did not di er between treatment groups; however, 
we did show that nifedipine is not unsafe. Secondary endpoints showed a bene t of nife-
dipine on cardiovascular outcomes, largely manifested by a substantial reduction of the need 
for coronary procedures and interventions for symptoms. These  ndings were achieved in pa-
tients who were already receiving antianginal, blood pressure, and lipid-lowering treatment, 
as decided by the patient’s doctor.
ACTION con rmed that stable angina has a good prognosis. The mortality rate in the placebo 
group was just 1·53 per 100 patient-years and was essentially the same as the rate reported 
in a similar study in patients with presumed coronary disease.[3] In participants assigned 
nifedipine the mortality rate was 1·64 per 100 patient-years; hence, the absolute di erence 
in mortality was 1·1 deaths per 1000 patient-years of follow-up, which was almost all non-
cardiovascular and is well within the play of chance.
One reason we did not note a di erence between groups in the primary endpoint for e  cacy 
could be that a further reduction of cardiovascular events by addition of other drugs is not 
realistic in patients with stable angina who are already treated with antianginal, blood pres-
sure, and lipid-lowering drugs in near-optimum manner. In ACTION, 80% of patients were on 
β blockers compared with 39% [2]and 62% [3]in two trials of angiotensin-converting-enzyme 
inhibitors;[2,3] the proportion on lipid-lowering drugs was 68% in ACTION and 28% [2] and 
57% [3] in these trials. A second reason might be that use of nifedipine was associated with an 
increase in peripheral vascular procedures, which was a component of the combined primary 
endpoint. Peripheral vascular disease and coronary disease typically coexist. Patients whose 
angina is relieved by treatment might then manifest symptoms of peripheral vascular disease 
and seek treatment for that disorder.
Nifedipine GITS did have a positive e ect on two of the three prede ned secondary combined 
endpoints. The combined rate of death, major cardiovascular events, revascularisation, and 
coronary angiography was reduced by 11%, the main reason being the pronounced reduc-
tion in the need for coronary angiography (150 fewer coronary angiograms as  rst event in 
nifedipine than in placebo). Any vascular event was reduced by 9%, the main reason being the 
reduced need for percutaneous coronary interventions and bypass surgery (in total, 89 fewer 
procedures as  rst event in nifedipine than in placebo).
ACTION did not accord with past claims that nifedipine induces myocardial infarction or heart 
failure. Rates of myocardial infarction were similar in both groups. Although peripheral oe-
dema was more common in patients assigned nifedipine than in those assigned placebo, 
nifedipine reduced the incidence of new overt heart failure by 29%. We used strict criteria for 
diagnosis of heart failure, which required more symptoms than merely presence of periph-
eral oedema. This de nition could account for our seemingly unexpected result concerning 
heart failure, which might also be attributed to long-term reduction of ischaemic episodes or 
reduction of blood pressure by nifedipine. We excluded patients with left-ventricular systolic 
dysfunction because, at the time the trial was designed, nifedipine was contraindicated in 
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such patients. Our  ndings concerning heart failure suggest that a trial with nifedipine GITS in 
patients with coronary disease and left-ventricular systolic dysfunction might be of interest. 
The recorded 22% reduction of the incidence of debilitating stroke by nifedipine, although 
not signi cant, accords with results from trials and meta-analyses in hypertension.[17,18]
Several prede ned subgroup analyses were done in ACTION and caution is needed in their 
interpretation. Patients who had raised blood pressure levels at baseline seemed to bene t 
from addition of nifedipine to the basic regimen because the combined rate of death and 
major cardiovascular events in this subgroup was reduced by 13%. This argument is plausible 
since the bene t of blood pressure reduction is known.
The design of ACTION di ers from similar studies.[2,3] We did not use a run-in period to re-
move patients who did not tolerate nifedipine GITS, which must be taken into account when 
comparing withdrawal of study drugs and tolerance in ACTION with other studies that in-
corporated this design feature. Because of the fairly low total mortality expected, we used a 
combined outcome that incorporated non-fatal clinical events but we did not exclude non-
cardiovascular death from the primary outcome. We chose to do this because a reduction of 
cardiovascular death by treatment increases the total number of non-cardiovascular deaths 
even if the treatment does not a ect the rate of non-cardiovascular death per unit person-
time of follow-up; this e ect is directly related to the treatment and should therefore be ac-
counted for when assessing clinical bene t.[20] We included peripheral revascularisation in 
the primary outcome because of the putative anti-atherosclerotic action of nifedipine. Hence, 
the primary outcome included all clinically relevant events that might be a ected either posi-
tively or negatively by nifedipine, which allowed the net bene t of treatment with nifedipine 
to be assessed by one unequivocal criterion. Since we believe this conveys important addi-
tional information,[21] we also report for combined endpoints the events that terminated 
event-free survival.
Nifedipine GITS can be used safely for the long-term treatment of patients with coronary dis-
ease and angina pectoris because, in addition to relieving symptoms of angina, it prolongs 
cardiovascular event and procedure-free survival.
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E ect of long-acting nifedipine on mortality 
and cardiovascular morbidity in patients 
with symptomatic stable angina and 
hypertension: the ACTION trial
Jacobus Lubsena,b, Gilbert Wagenerc, Bridget-Anne Kirwana, Sophie de Brouwera and Philip 
A. Poole-Wilsond on behalf of ACTION (A Coronary disease Trial Investigating Outcome with 
Nifedipine GITS) investigators
aSOCAR Research, Nyon, Switzerland, bDepartment of Epidemiology and Biostatistics, Eras-
mus Medical Centre, Rotterdam, The Netherlands, cPharma Research Center, Bayer Health-
care AG, Wuppertal, Germany and dCardiac Medicine, Imperial College, London, UK. 
Objective: To examine the e ects of nifedipine GITS on clinical outcome in patients with con-
current stable angina and hypertension.
Methods: Data from the double-blind placebo-controlled ACTION trial was strati ed for hy-
pertension (blood pressure ≥ 140/90 mmHg), at baseline.
Results: A total of 52% of 7665 ACTION patients were hypertensive. Some 80% were on a β 
blocker; hypertensives were more often treated with other blood pressure-lowering drugs. 
Mean baseline blood pressure was 122/74 mmHg among normotensives and 151/85 mmHg 
among hypertensives. Follow-up blood pressures were reduced by nifedipine (P < 0.001) on 
the average by 3.9/2.4 and 6.6/3.5 mmHg among normotensives and hypertensives, respec-
tively. Nifedipine GITS signi cantly (P < 0.05) reduced the combined incidence of all-cause 
mortality, myocardial infarction, refractory angina, heart failure, stroke and peripheral revas-
cularization by 13% in hypertensives only. Nifedipine signi cantly reduced the incidence of 
any stroke or transient ischemic attack by almost 30% in both subgroups and the need for 
coronary angiography by 21% in normotensives and 16% in hypertensives. Among hyper-
tensives, the incidence of new overt heart failure was signi cantly reduced by 38% and of 
debilitating stroke by 33%. Among normotensives, the need for coronary bypass grafting was 
signi cantly reduced by 32%. Nifedipine did not a ect all-cause death, cardiovascular death 
and myocardial infarction in either normo- or hypertensives, but increased the need for pe-
ripheral revascularization.
Conclusion: The salutary e ects of the addition of nifedipine GITS to the basic regimen of 
patients with concurrent stable symptomatic coronary artery disease and hypertension em-
phasize the need for blood pressure control. J Hypertens 23:641-648 © 2005 Lippincott Wil-
liams & Wilkins. 
Journal of Hypertension 2005, 23:641-648
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INTRODUCTION
Hypertension is a leading cause of morbidity and mortality worldwide [1] and substantially 
contributes to the risk of the development of cardiovascular diseases [2]. A number of place-
bo-controlled clinical trials have shown that blood pressure reduction reduces morbidity and 
mortality both in younger [3,4] and in older patients with diastolic and systolic hypertension 
[5-7], and in patients with isolated systolic hypertension [8,9]. Clinical trials comparing di er-
ent blood pressure-lowering drugs in patients with hypertension after wash-out of previous 
therapy have not shown relevant di erences in outcome [10-12] and the notion that available 
treatment options are equally e ective is supported by a recent meta-analysis [13].
The dihydropyridine calcium antagonist nifedipine is widely used for the treatment of hyper-
tension. In one large clinical outcome trial, the long-acting gastrointestinal therapeutic sys-
tem (GITS) formulation of this compound was compared with co-amilozide. Both were equally 
e ective in preventing overall cardio- and cerebrovascular complications [10]. Placebo-con-
trolled trials with nifedipine GITS having adequate power to assess e ects on morbidity and 
mortality have not been undertaken. Recently, the placebo-controlled ACTION (A Coronary 
disease Trial Investigating Outcome with Nifedipine GITS) trial examining the e ects of the 
same compound on clinical outcomes in 7665 patients with stable symptomatic coronary dis-
ease has been completed [14]. The main conclusion was that nifedipine GITS is safe in patients 
with stable symptomatic coronary disease and reduces the occurrence of new overt heart fail-
ure and the need for coronary interventions. A total of 52% of ACTION patients had a baseline 
blood pressure ≥ 140/ 90 mmHg, and a pre-de ned subgroup analysis suggested that nife-
dipine GITS reduces the combined rate of death from any cause, acute myocardial infarction, 
refractory angina, new overt heart failure, debilitating stroke and peripheral revascularization 
in patients with stable angina who also have elevated blood pressure [14]. This paper reports 
this subgroup analysis in more detail.
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METHODS
Design
The ACTION design, methods and main results have been published previously [14,15]. Brie y, 
patients aged 35 years or older with stable symptomatic angina pectoris requiring treatment 
were randomized in equal proportions to the addition of either nifedipine GITS or matching 
placebo. In addition to angina, patients had to have either a history of myocardial infarction, 
or proven angiographic coronary artery disease, or a positive exercise test or perfusion de-
fect. The left-ventricular ejection fraction had to be at least 40%. Major exclusions were: clini-
cally signi cant heart failure, any major cardiovascular event or intervention within the last 3 
months, planned coronary angiography or intervention, known intolerance to dihydropyri-
dines, clinically signi cant valvular or pulmonary disease, unstable insulin-dependent diabe-
tes mellitus, any gastro-intestinal condition that prohibited the use of GITS tablets, any condi-
tion other than coronary artery disease that limited life expectancy, symptomatic orthostatic 
hypotension or supine systolic blood pressure 90 mmHg or less, systolic blood pressure at 
least 200 mmHg and/or diastolic blood pressure at least 105 mmHg, and elevated creatinine 
or aminotransferase levels. Women could only participate if there was no risk of pregnancy. 
Detailed selection criteria and de nitions have been described elsewhere [15].
The starting dose of nifedipine GITS or matching placebo was 30 mg once daily, increasing to 
60 mg once daily within 6 weeks. Physicians were encouraged to attempt risk factor modi -
cation and to treat symptomatic angina with compatible medications. Lipid-lowering treat-
ment was either continued or started at the same time as study medication according to in-
ternationally accepted guidelines. The following drugs could not be used in combination with 
study medication: calcium antagonists (2 week washout required), cardiac glycosides (unless 
given for supra-ventricular arrhythmias), other positive inotropic agents, class I or III anti-
arrhythmics other than amiodarone or sotalol, cimetidine, anti-psychotic and anti-epileptic 
drugs, rifampicin or rifampin. 
After baseline assessments and treatment allocation, patients were seen at the out-patient 
clinic 2 weeks, 6 weeks and 6 months after randomization; and from then onwards every 6 
months. Between visits, patients were contacted by telephone. At each clinic visit, blood pres-
sure was recorded with a standard sphygmomanometer in the sitting position after 5 min 
rest. 
Serious adverse events suggesting a possible major cardiovascular event were classi ed by 
the Critical Events Committee according to prede ned criteria without access to the study 
medication code. Cause of death was classi ed as unknown, cardiovascular or non-cardio-
vascular.
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STATISTICAL METHODS
Patients were excluded from the present analysis when the baseline blood pressure before 
start of ACTION study medication was missing. Those with available baseline blood pressures 
were classi ed as normotensive when the systolic blood pressure was below 140 and the dia-
stolic blood pressure was below 90 mmHg. Patients with baseline blood pressures that did not 
meet this criterion were classi ed as hypertensive.
Mean blood pressure changes from baseline at selected time points during follow-up were 
calculated using all blood pressure measurements that were actually performed irrespec-
tive of study medication intake or prior occurrence of non-fatal clinical events. Overall mean 
changes from baseline were obtained by subtracting for each patient the mean follow-up 
value from the baseline value, and then averaging the results.
The following composite outcomes were compared: the combined rate of death from any 
cause, myocardial infarction, refractory angina requiring coronary angiography, new overt 
heart failure requiring hospitalization and peripheral revascularization (i.e. the ACTION pri-
mary endpoint for e  cacy); the combined rate of death from any cause, myocardial infarction 
and debilitating stroke (i.e. the ACTION primary endpoint for safety); any cardiovascular event 
(i.e. the ACTION primary endpoint for e  cacy minus non-cardiovascular death); any death, 
cardiovascular event or procedure (i.e. the ACTION primary endpoint for e  cacy plus coro-
nary angiography, percutaneous coronary intervention and coronary bypass surgery); and 
any vascular event or procedure (i.e. the ACTION primary endpoint for e  cacy minus non-
cardiovascular death and new overt heart failure, plus percutaneous coronary intervention 
and coronary bypass surgery). In addition, the combination of disabling stroke, any stroke 
reported by investigators that did not meet the criteria for disabling stroke, and any reported 
transient ischaemic attack was considered.
All analyses for composite outcomes and clinical events were done based on intention-to-
treat. Deaths of unknown cause were considered as cardiovascular. Coronary angiography 
and percutaneous coronary intervention on the same day were counted only as percutane-
ous coronary intervention. Treatment groups were compared by the log-rank test without 
adjustment for covariates or interim analysis. Event rates were taken as number of patients 
with event divided by total time that patients had been ‘at risk’ of the event concerned. For 
composite outcomes, the time that the  rst component event occurred was used in event 
rate calculations. Hazard ratios with 95% con dence intervals (CI) were obtained using Cox 
proportional hazards models with treatment allocation as the only covariate. Interaction tests 
were performed by Cox proportional hazards models. An overall P-value for comparing blood 
pressure levels between treatment groups was obtained from a mixed e ects model for re-
peated measurements, using the SAS proc. mixed procedure (SAS Institute, Cary, North Caro-
lina, USA). Percentages were compared using chi-squared tests.
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RESULTS
As reported elsewhere [14], ACTION was completed as planned and 7665 patients were start-
ed on study medication (3825 nifedipine GITS; 3840 placebo). Follow-up was 97.3% complete 
and mean follow-up was 4.9 years. From the present analysis, four patients (three nifedipine, 
one placebo) were excluded because the baseline blood pressure was missing. Hence, the 
present report concerns 7661 patients. Of these, 3684 were normotensive and 3977 were hy-
pertensive at baseline. Baseline characteristics are given in Table 1. Patients with hypertension 
were older and were more often female. A history of myocardial infarction and signi cant 
lesions on a prior coronary angiogram were less frequent among patients with hypertension, 
while more of the latter had been treated before with a calcium antagonist. Both groups were 
equally frequent in NYHA class II - III and equal proportions reported anginal attacks. A his-
tory of peripheral vascular disease and of hypertension treated with drugs was more frequent 
among those with hypertension. Fewer patients with hypertension smoked but elevated total 
cholesterol and body mass index were more frequent than among normotensives. Hyperten-
sives were more often diabetic and had a higher heart rate at baseline than normotensives.
criteria for disabling stroke, and any reported transient
ischaemic attack was considered.
All analyses for composite outcomes and clinical events
were done based on intention-to-treat. Deaths of
unknown cause were considered as cardiovascular. Cor-
onary angiography and percutaneous coronary interven-
tion on the same day were counted only as percutaneous
coronary intervention. Treatment groups were compared
by the log-rank test without adjustment for covariates or
interim analysis. Event rates were taken as number of
patients with event divided by total time that patients
had been ‘at risk’ of the event concerned. For composite
outcomes, the time that the first component event
occurred was used in event rate calculations. Hazard
ratios with 95% confidence intervals (CI) were obtained
using Cox proportional hazards models with treatment
allocation as the only covariate. Interaction tests were
performed by Cox proportional hazards models. An over-
all P-value for comparing blood pressure levels between
treatment groups was obtained from a mixed effects
model for repeated measurements, using the SAS proc.
mixed procedure (SAS Institute, Cary, North Carolina,
USA). Percentages were compared using chi-squared
tests.
Results
As reported elsewhere [14], ACTION was completed as
planned and 7665 patients were started on study medica-
tion (3825 nifedipine GITS; 3840 placebo). Follow-up
was 97.3% complete and mean follow-up was 4.9 years.
From the present analysis, four patients (three nifedi-
pine, one placebo) were excluded because the baseline
blood pressure was missing. Hence, the present
report concerns 7661 patients. Of these, 3684 were
normotensive and 3977 were hypertensive at baseline.
Baseline characteristics are given in Table 1. Patients
with hypertension were older and were more often
female. A history of myocardial infarction and significant
lesions on a prior coronary angiogram were less frequent
among patients with hypertension, while more of the
latter had been treated before with a calcium antagonist.
Both groups were equally frequent in NYHA class II–III
and equal proportions reported anginal attacks. A history
of peripheral vascular disease and of hypertension treated
with drugs was more frequent among those with hyper-
tension. Fewer patients with hypertension smoked but
elevated total cholesterol and bodymass index weremore
frequent than among normotensives. Hypertensives were
more often diabetic and had a higher heart rate at baseline
than normotensives.
Data on the use of additional blood pressure-lowering
medication for normotensives and hypertensives at base-
line are given in Table 2 by assigned ACTION study
medication. The majority of patients were on a b blocker
and patients with hypertension were more often treated
with angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers and diuretics than normo-
tensives. Irrespective of the presence of hypertension,
patients assigned nifedipine or placebo were well
matched at baseline as regards use of additional blood
pressure-lowering medication.
The use of additional blood pressure-lowering drugs at
4 years after start of studymedication is shown inTable 2.
Normotensives were overall more often using non-b
blocking blood pressure-lowering drugs at 4 years than
at baseline, and normotensives assigned placebo were
more often on such blood pressure-lowering drugs than
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Table 1 Patient characteristics by baseline blood pressure classification
Normotensive Hypertensive P�
Total number of patients 3684 3977
Mean (SD) age (years) 61.8 (9.4) 65.0 (8.9) < 0.001
Male gender 83 76 < 0.001
History of MI 53 49 0.003
Angiographic CAD, no MI 32 33 0.4
Positive exercise or radionuclide test only 15 18 0.005
Significant lesions on coronary angiogram 71 66 < 0.001
Angiography not performed or unknown 28 32 < 0.001
Past use of calcium antagonists 19 24 < 0.001
Current NYHA class II–III 46 46 0.9
Anginal attacks 92 92 0.9
History of peripheral vascular diseasey 11 15 < 0.001
History of hypertension treated with drugs 28 54 < 0.001
Additional risk factors
Current smoker 20 16 < 0.001
Total cholesterol � 5.0 mmol/l 61 66 < 0.001
Body mass index � 30.0 kg/m2 19 26 < 0.001
Any of the above 73 77 < 0.001
Diabetes mellitus 12 17 < 0.001
Treated with insulin 2.0 2.7 0.04
Mean (SD) heart rate (beats/min) 63.5 (10.0) 65.1 (10.5) 0.003
Data are percentage of patients unless indicated otherwise. SD, standard deviation; MI, myocardial infarction; CAD, coronary artery disease; NYHA, New York Heart
Association. �P-values for comparing all normo- with all hypertensives. yStroke, transient ischemic attacks or claudication.
Data are percentage of patients unless indicated otherwise. SD, standard deviation; MI, myocardial 
infarction; CAD, coronary artery disease; NYHA, New York Heart Association.*P-values for comparing all 
normo- with all hypertensives. †Stroke, transient ischemic attacks or claudication.
Data on the use of additional blood pressure-lowering medication for normotensives and 
hypertensives at baseline are given in Table 2 by assigned ACTION study medication. The 
maj ri y of patients were on a β blocker and patients with hypertensio  were more often 
treated with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers 
and diuretics than normotensives. Irrespective of the presence of hypertension, patients as-
signed nifedipine or placebo w re well atched at baseline as regards use of additional blo d 
pressure-lowering medication.
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The use of additional blood pressure-lowering drugs at 4 years after start of study medication 
is shown in Table 2. Normotensives were overall more often using non-β blocking blood pres-
sure-lowering drugs at 4 years than at baseline, and normotensives assigned placebo were 
normotensives assigned nifedipine. Similar but more
pronounced differences were present among hyperten-
sives.
The evolution of mean systolic and diastolic blood pres-
sure over time by assigned treatment for normotensives
and hypertensives at baseline respectively are shown in
Figure 1. Mean follow-up blood pressures were consis-
tently lower among patients assigned nifedipine than
among those assigned placebo in both normotensives
and hypertensives at baseline. Blood pressure data at
baseline, and changes from baseline at 4 years and overall
are given in Table 3.
In Figure 2, the effects of nifedipine (relative to placebo)
on pre-defined ACTION combined end-points are com-
pared between normo- and hypertensives at baseline.
Numbers of events and event-rates (expressed as number
of patients with event per 100 patient-years at risk) are
given also. As evidenced by 95% confidence intervals that
do not include ‘no effect’ (hazard ratio ¼ 1), nifedipine
significantly reduced the hazard of all combined end-
points analysed among hypertensives at baseline, with
the exception of the primary endpoint for safety. For the
primary endpoint for efficacy and for cardiovascular
events, the effects of nifedipine differed significantly
among normo- and hypertensives at baseline.
Figure 3 shows results for separate clinical events in a
similar manner as Figure 2. The rates of new overt heart
failure and of debilitating stroke were significantly
reduced by nifedipine among hypertensives, but not
among normotensives. Rates of any stroke or transient
ischaemic attack and of coronary angiography were sig-
nificantly reduced by nifedipine both among normo- and
among hypertensives at baseline. Nifedipine significantly
increased the rate of peripheral revascularization among
normo- but not among hypertensives. The opposite was
the case for coronary artery bypass grafting.
Discussion
In addition to lowering blood pressure, calcium antago-
nists are known to be an effective treatment for symp-
toms of angina pectoris, and are widely used for this
indication. The ACTION study was initiated in response
to the debate in the 1990s about the safety of calcium
antagonists in particular in patients with coronary disease
[16,17], and was designed to assess the effect of nifedi-
pine GITS on clinical outcome in patients with stable
angina irrespective of blood pressure level at baseline. In
clinical practice, coronary disease and hypertension often
occur concurrently. In ACTION, 52% of patients had
baseline blood pressures � 140/90 mmHg. The presence
of so many patients provides an opportunity to examine
the effects of nifedipine, relative to placebo, on the
mortality and morbidity of patients who have both
stable symptomatic angina and hypertension.
The main findings from the current analysis are that
nifedipine GITS given to patients who were hyperten-
sive at baseline reduced the incidence of the combined
endpoints that were pre-specified for the ACTION study
with the exception of the primary endpoint for safety
(Fig. 2). As shown in Figure 3, the main reason for this is
the marked effect of nifedipine on new overt heart failure
(38% reduction; 95% CI hazard ratio 0.43–0.90), any
stroke or transient ischemic attack (28% reduction;
95% CI hazard ratio 0.57–0.91), debilitating stroke
(33% reduction; 95% CI hazard ratio 0.47–0.96), and
the need for coronary angiography (16% reduction;
95% CI hazard ratio 0.75–0.96). The rates of all-cause
death, cardiovascular death, and myocardial infarction
were not affected by nifedipine in both normotensive
and hypertensive patients at baseline. The preventive
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Table 2 Use of additional blood pressure-lowering drugs by baseline blood pressure classification
Normotensive Hypertensive
Nifedipine Placebo P� Nifedipine Placebo P�
Baseline
No. of patients 1847 1837 1975 2002
Any calcium ant.y 0.4% 0.2% – 0.6% 0.3% –
b blocker 82% 81% – 77% 79% –
ACE-i or ARB 17% 17% – 28% 28% –
Diuretic 7.5% 8.6% – 15% 14% –
Any BP lowering 87% 87% – 88% 88% –
At 4 years
No. of patients 1576 1554 1592 1623
Any calcium ant.z 83% 5.3% < 0.001 84% 10% < 0.001
b blocker 78% 78% 1.0 77% 79% 0.4
ACE-i or ARB 25% 28% 0.02 35% 49% < 0.001
Diuretic 13% 15% 0.1 26% 32% < 0.001
Any BP lowering 100% 87% < 0.001 100% 93% < 0.001
ant., antagonist; ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure. �P-values comparing nifedipine with placebo for
normo- and hypertensives, respectively. yIn the percentage of patients shown, calcium antagonists were not washed out before baseline assessments, as required by the
protocol. zEither active study medication (i.e. nifedipine GITS) or any other calcium antagonist.
ant., a tagoni t; ACE-i, angiotensi  converting e zyme inhibitor; ARB, angiot nsin receptor block r; BP, 
blood pressure. *P-values comparing nifedipine with placebo for normo- and hypertensives, respectively. 
†In the percentage of patients shown, calcium antagonists were not washed out before baseline 
assessments, as required by the protocol. ‡Either active study medication (i.e. nifedipin  GITS) r any other 
calcium antagonist.
Fig. 1
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Fig. 1
Evolution of mean blood pressure for normo- and hypertensives at baseline, respectively. SBP, systolic blood pressure; DBP, diastolic blood
pressure. Horizontal axis: time in years of follow-up. Standard errors of the means were too small to plot. Numbers of patients with blood pressure
measurements are given also.
Table 3 Evolution of blood pressure (BP) by baseline blood pressure classification
Normotensive Hypertensive
Nifedipine Placebo P� Nifedipine Placebo P�
No. of patients 1847 1837 1975 2002
Baseline
Mean SBP (SD) 122.3 (9.2) 122.4 (9.3) 151.3 (14.0) 151.5 (13.5)
Mean DBP (SD) 74.6 (7.2) 74.3 (7.2) 84.8 (8.6) 84.8 (8.6)
SBP � 140 mmHg – – 94% 94%
DBP � 90 mmHg – – 42% 42%
At 4 years
No. of patients 1576 1554 1592 1623
Mean D SBP (SD) 3.0 (15.0) 7.0 (16.0) < 0.001 �14.6 (19.1) �9.1 (19.2) < 0.001
Mean D DBP (SD) �0.3 (9.5) 2.1 (9.9) < 0.001 �7.6 (10.6) �4.5 (10.7) < 0.001
BP � 140/90 mmHg 23% 33% < 0.001 47% 64% < 0.001
SBP � 140 mmHg 21% 31% < 0.001 45% 62% < 0.001
DBP � 90 mmHg 6% 10% < 0.001 13% 21% < 0.001
Overall
Mean D SBP (SD) 1.9 (14.7) 5.8 (15.7) < 0.001 �14.5 (18.2) �7.9 (19.1) < 0.001
Mean D DBP (SD) �0.5 (9.3) 1.9 (9.6) < 0.001 �7.0 (10.0) �3.5 (10.3) < 0.001
SBP, systolic blood pressure; DBP, diastolic blood pressure (mmHg, cuff method); SD, standard deviation; D, change from baseline. �P-values comparing nifedipine with
placebo for normo- and hypertensives, respectively.
Evolution of mean blood pressure for normo- and hypertensives at baseline, respectively. SBP, systolic 
blood pressure; DBP, diastolic blood pressure. Horizontal axis: time in years of follow-up. Standard errors of 
the means were too small to plot. Numbers of patients with blood pressure measurements are given also.
47
E ect of long-acting nifedipine on mortality and cardiovascular morbidity: the ACTION trial
Ch
ap
te
r 3
more often on such blood pressure-lowering drugs than normotensives assigned nifedipine. 
Similar but more pronounced di erences were present among hypertensives.
The evolution of mean systolic and diastolic blood pressure over time by assigned treat-
ment for normotensives and hypertensives at baseline respectively are shown in Figure 1. 
Mean follow-up blood pressures were consistently lower among patients assigned nifedipine 
than among those assigned placebo in both normotensives and hypertensives at baseline. 
Blood pressure data at baseline, and changes from baseline at 4 years and overall are given 
in Table 3.
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Fig. 1
Evolution of mean blood pressure for normo- and hypertensives at baseline, respectively. SBP, systolic blood pressure; DBP, diastolic blood
pressure. Horizontal axis: time in years of follow-up. Standard errors of the means were too small to plot. Numbers of patients with blood pressure
measurements are given also.
Table 3 Evolution of blood pressure (BP) by baseline blood pressure classification
Normotensive Hypertensive
Nifedipine Placebo P� Nifedipine Placebo P�
No. of patients 1847 1837 1975 2002
Baseline
Mean SBP (SD) 122.3 (9.2) 122.4 (9.3) 151.3 (14.0) 151.5 (13.5)
Mean DBP (SD) 74.6 (7.2) 74.3 (7.2) 84.8 (8.6) 84.8 (8.6)
SBP � 140 mmHg – – 94% 94%
DBP � 90 mmHg – – 42% 42%
At 4 years
No. of patients 1576 1554 1592 1623
Mean D SBP (SD) 3.0 (15.0) 7.0 (16.0) < 0.001 �14.6 (19.1) �9.1 (19.2) < 0.001
Mean D DBP (SD) �0.3 (9.5) 2.1 (9.9) < 0.001 �7.6 (10.6) �4.5 (10.7) < 0.001
BP � 140/90 mmHg 23% 33% < 0.001 47% 64% < 0.001
SBP � 140 mmHg 21% 31% < 0.001 45% 62% < 0.001
DBP � 90 mmHg 6% 10% < 0.001 13% 21% < 0.001
Overall
Mean D SBP (SD) 1.9 (14.7) 5.8 (15.7) < 0.001 �14.5 (18.2) �7.9 (19.1) < 0.001
Mean D DBP (SD) �0.5 (9.3) 1.9 (9.6) < 0.001 �7.0 (10.0) �3.5 (10.3) < 0.001
SBP, systolic blood pressure; DBP, diastolic blood pressure (mmHg, cuff method); SD, standard deviation; D, change from baseline. �P-values comparing nifedipine with
placebo for normo- and hypertensives, respectively.
SBP, systolic blood pressure; DBP, diastolic blood pressure (mmHg, cu  method); SD, standard deviation; 
D, change from baseline. *P-values comparing nifedipine with placebo for normo- and hypertensives, 
respectively.
In Figure 2, the e ects of nifedipine (relative to placebo) on pre-de ned ACTION combined 
end-points are compared between normo- and hypertensives at baseline. Numbers of events 
and event-rates (expressed as number of patients with event per 100 patient-years at risk) are 
given also. As evidenced by 95% con dence intervals that do not include ‘no e ect’ (hazard 
ratio = 1), nifedipine signi cantly reduced the hazard of all combined endpoints analysed 
among hypertensives at baseline, with the exception of the primary endpoint for safety. For 
the primary endpoint for e  cacy and for cardiovascular events, the e ects of nifedipine dif-
fered signi cantly among normo- and hypertensives at baseline.
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Figure 3 shows results for separate clinical events in a similar manner as Figure 2. The rates 
of new overt heart failure and of debilitating stroke were signi cantly reduced by nifedipine 
among hypertensives, but not among normotensives. Rates of any stroke or transient ischae-
mic attack and of coronary angiography were signi cantly reduced by nifedipine both among 
normo- and among hypertensives at baseline. Nifedipine signi cantly increased the rate of 
peripheral revascularization among normo- but not among hypertensives. The opposite was 
the case for coronary artery bypass grafting. 
DISCUSSION 
In addition to lowering blood pressure, calcium antagonists are known to be an e ective 
treatment for symptoms of angina pectoris, and are widely used for this indication. The AC-
TION study was initiated in response to the debate in the 1990s about the safety of calcium 
antagonists in particular in patients with coronary disease [16,17], and was designed to assess 
the e ect of nifedipine GITS on clinical outcome in patients with stable angina irrespective of 
blood pressure level at baseline. In clinical practice, coronary disease and hypertension often 
occur concurrently. In ACTION, 52% of patients had baseline blood pressures 140/90 mmHg. 
The presence of so many patients provides an opportunity to examine the e ects of nife-
dipine, relative to placebo, on the mortality and morbidity of patients who have both stable 
symptomatic angina and hypertension. 
Fig. 2
effect of controlling hypertension on stroke is well-
established, also for dihydropyridines. This is the first
time however, that a similar effect on new overt heart
failure has been described for a calcium channel blocker.
These findings also emphasize the need for blood pres-
sure control, in particular in patients with t rget organ
damage, such as established coronary artery disease.
Corroborating similar findings for another dihydropyri-
dine [18], a positive effect of nifedipine on the need for
coronary angiography was present in both normo- and
hypertensives at baseline. In a similar study with an ACE
inhibitor [19] no such effect was observed even though
ACE inhibitors also reduce blood pressure. These find-
ings suggest t at the effect of nifedipine on the need for
coronary angiography as observed in ACTION is prob-
ably related to its well-established anti-anginal effect
rather than its effect on blood pressure. Another possible
explanation may be a positive effect of nifedipine GITS
on the progression of coronary atherosclerosis as has been
suggested previously [20,21].
As shown in Table 2, the majority of patients were at least
on a b blocker at baseline. Among hypertensives, 12%
of patients w re not receiving any additional blood
pressure-lowering medication. In this subgroup, follow-
up blood pressures trended downward relative to baseline
due to regression-to-the-mean (Fig. 1). As expected,
these reductions were consistently larger in patients
assigned nifedipine than in patients assigned pla ebo.
Overall, the reduction in hypertensive patients assigned
nifedipine was, relative to placebo, 6.6/3.5 mmHg
(Table 3). This reduction was achieved despite the
higher intensity of blood pressure-lowering treatment
at 4 years in hypertensive patients assigned placebo
(Table 2). Apparently, nifedipine reduced the need to
prescribe additional blood pressure-lowering me ication
in patients with hypertension and stable symptomatic
coronary disease. Considering active double-blind study
medication (i.e. nifedipine GITS) as blood pressure-
lowering medication, 100% of hypertensives assigned
nifedipine were on any blood pressure-lowering treat-
ment at 4 years. Nonetheless, 47% of patients with four-
year blood pressure measurements in this subgroup were
also hypertensive at that time. Recent surveys have
shown that hypertension in patients with coronary dis-
ease is not always controlled in clinical practice [22]. Our
results in hypertensive ACTION patients assigned nife-
dipine show how difficult it is to achieve control. One
reason for this must be the large within-subject variability
of blood pressure, causing the same patient to be ‘hyper-
tensive’ at one visit, but not at the next (Table 3).
Among normotensives at baseline, follow-up blood pres-
sure levels trended upwards (Fig. 1) and in pa ents
assigned placebo, 33% were hypertensive at 4 years
(Table 3). Again, this is partly attributable to regres-
sion-to-the-mean. At the same time, blood pressure levels
in patients assigned nifedipine were consistently lower
by 3.9/2.4 mmHg relative to patients assigned plac bo.
These reductions were not attenuated by differences in
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Fig. 2
Combined endpoint Number of patients with event
(rate*)
Hazard ratio (95% Cl)
Normotensive
Normotensive
Normotensive
Normotensive
Normotensive
Normotensive
Hypertensive
Hypertensive
Hypertensive
Hypertensive
Hypertensive
Hypertensive
(n=1847)
(n=1975)
(n=1837)
(n=2002)
P
Primary endpoint for efficacy
Primary endpoint for safety
364 (4.28)
439 (4.90)
368 (3.84)
500 (5.61)
244 (2.74) 213 (2.40)
317 (3.40) 345 (3.67)
317 (3.73)
376 (4.20)
286 (3.35)
450 (5.05)
Cardiovascular events
Death, cardiovascular events, or procedures
Vascular event or revascularization
670 (8.91)
768 (9.70)
737 (10.14)
846 (10.84)
479 (5.98)
546 (6.46)
511 (6.45)
610 (7.24)
Favours
Nifedipine Placebo
Favours
0.6       0.8      1.0      1.2        1.4      1.6
0.7
0.8
0.007
0.08
0.02
Nifedipine Placebo
Effect of nifedipine on predefined combined endpoints for normo- and hypertensives at baseline, respectively. �Rates in number of events per 100
patient years of follow-up ‘at risk’. P-values for effect modification (interaction test). CI, confidence interval.
E ect of nifedipine on prede ned combined endpoints for normo- and hypertensives at baseline, 
respectively. *Rates in number of events per 100 patient years of follow-up ‘at risk’. P-values for e ect 
modi cation (interaction test). CI, con dence interval.
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The main  ndings from the current analysis are that nifedipine GITS given to patients who 
were hypertensive at baseline reduced the incidence of the combined endpoints that were 
pre-speci ed for the ACTION study with the exception of the primary endpoint for safety (Fig. 
2). As shown in Figure 3, the main reason for this is the marked e ect of nifedipine on new overt 
heart failure (38% reduction; 95% CI hazard ratio 0.43 - 0.90), any stroke or transient ischemic 
attack (28% reduction; 95% CI hazard ratio 0.57 - 0.91), debilitating stroke (33% reduction; 
95% CI hazard ratio 0.47 - 0.96), and the need for coronary angiography (16% reduction; 95% 
CI hazard ratio 0.75 - 0.96). The rates of all-cause death, cardiovascular death, and myocardial 
infarction were not a ected by nifedipine in both normotensive and hypertensive patients at 
baseline. The preventive e ect of controlling hypertension on stroke is well-established, also 
Fig. 3
the intensity of additional blood pressure-lowering treat-
ment during follow-up as amo no motensives at base-
line the percentages of patients using blood pressure-
lowering medications other than calcium antagonists
were similar at 4 years (Table 2). There has been con-
siderable debate about the so-called J-shaped relation-
ship between blood pressure reduction and risk of
cardiovascular events [23], the implication being that
larger blood pressure reductions eventually may have
an untoward effect. The data presented here do not
directly address the relationship between blood pressure
reduction and event-risk. Nonetheless, our data for
normotensives are compatible with the existence of a
J-shaped relationship (or more correctly a reverse L-
shaped relationship) sinc in this subgroup there were
non-significant trends towards higher rates of the primary
combined endpoints for efficacy and safety, and of com-
bin d ardiovascular vents (Fig. 2). We doubt th t this is
clinically relevant because the combined rate of death,
cardiovascular events or procedures was significantly
reduced by nifedipine both in normo- and hypertensives
at baseline. We have no clear explanation as to why there
was no suggestion of a J-shaped relationship for new overt
heart failure, and why on the other hand the rate of
peripheral revascularization was significantly increased
by nifedipine in normotensives at baseline (Fig. 3). One
Nifedipine in angina and hypertension Lubsen et al. 647
Fig. 3
Effect of nifedipine on clinical events for normo- and hypertensives at baseline, respectively. �Rates in number of events per 100 patient years of
follow-up ‘at risk’. P-values for effect modification (interaction test). CI, confidence interval.
E ect of nifedipine on clinical events for normo- and hypertensives at baseline, respectively. *Rates in 
number of events per 100 patient years of follow-up ‘at risk’. P-values for e ect modi cation (interaction 
test). CI, con dence interval.
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for dihydropyridines. This is the  rst time however, that a similar e ect on new overt heart 
failure has been described for a calcium channel blocker. These  ndings also emphasize the 
need for blood pressure control, in particular in patients with target organ damage, such as 
established coronary artery disease. Corroborating similar  ndings for another dihydropyri-
dine [18], a positive e ect of nifedipine on the need for coronary angiography was present in 
both normo- and hypertensives at baseline. In a similar study with an ACE inhibitor [19] no 
such e ect was observed even though ACE inhibitors also reduce blood pressure. These  nd-
ings suggest that the e ect of nifedipine on the need for coronary angiography as observed in 
ACTION is probably related to its well-established anti-anginal e ect rather than its e ect on 
blood pressure. Another possible explanation may be a positive e ect of nifedipine GITS on 
the progression of coronary atherosclerosis as has been suggested previously [20,21].
As shown in Table 2, the majority of patients were at least on a β blocker at baseline. Among 
hypertensives, 12% of patients were not receiving any additional blood pressure-lowering 
medication. In this subgroup, follow-up blood pressures trended downward relative to base-
line due to regression-to-the-mean (Fig. 1). As expected, these reductions were consistently 
larger in patients assigned nifedipine than in patients assigned placebo. Overall, the reduction 
in hypertensive patients assigned nifedipine was, relative to placebo, 6.6/3.5 mmHg (Table 3). 
This reduction was achieved despite the higher intensity of blood pressure-lowering treat-
ment at 4 years in hypertensive patients assigned placebo (Table 2). Apparently, nifedipine 
reduced the need to prescribe additional blood pressure-lowering medication in patients 
with hypertension and stable symptomatic coronary disease. Considering active double-blind 
study medication (i.e. nifedipine GITS) as blood pressure-lowering medication, 100% of hyper-
tensives assigned nifedipine were on any blood pressure-lowering treatment at 4 years. None-
theless, 47% of patients with four-year blood pressure measurements in this subgroup were 
also hypertensive at that time. Recent surveys have shown that hypertension in patients with 
coronary disease is not always controlled in clinical practice [22]. Our results in hypertensive 
ACTION patients assigned nifedipine show how di  cult it is to achieve control. One reason for 
this must be the large within-subject variability of blood pressure, causing the same patient to 
be ‘hypertensive’ at one visit, but not at the next (Table 3).
Among normotensives at baseline, follow-up blood pressure levels trended upwards (Fig. 
1) and in patients assigned placebo, 33% were hypertensive at 4 years (Table 3). Again, this 
is partly attributable to regression-to-the-mean. At the same time, blood pressure levels in 
patients assigned nifedipine were consistently lower by 3.9/2.4 mmHg relative to patients 
assigned placebo. These reductions were not attenuated by di erences in the intensity of 
additional blood pressure-lowering treatment during follow-up as among normotensives at 
baseline the percentages of patients using blood pressure-lowering medications other than 
calcium antagonists were similar at 4 years (Table 2). There has been considerable debate 
about the so-called J-shaped relationship between blood pressure reduction and risk of car-
diovascular events [23], the implication being that larger blood pressure reductions eventually 
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may have an untoward e ect. The data presented here do not directly address the relationship 
between blood pressure reduction and event-risk. Nonetheless, our data for normotensives 
are compatible with the existence of a J-shaped relationship (or more correctly a reverse L-
shaped relationship) since in this subgroup there were non-signi cant trends towards higher 
rates of the primary combined endpoints for e  cacy and safety, and of combined cardiovas-
cular events (Fig. 2). We doubt that this is clinically relevant because the combined rate of 
death, cardiovascular events or procedures was signi cantly reduced by nifedipine both in 
normo- and hypertensives at baseline. We have no clear explanation as to why there was no 
suggestion of a J-shaped relationship for new overt heart failure, and why on the other hand 
the rate of peripheral revascularization was signi cantly increased by nifedipine in normoten-
sives at baseline (Fig. 3). One explanation may be that J-shaped relationships a ect di erent 
cardiovascular events in di erent manner. New overt heart failure may be prevented by after-
load reduction also in normotensives. On the other hand, hypo-perfusion of the peripheral 
circulation due to large drops in blood pressure in individual normotensive patients assigned 
nifedipine may have contributed to their increased need for peripheral revascularization. An 
alternative explanation in this regard is that patients had less angina as a consequence of 
taking nifedipine and, being able to exercise more, were more often limited by intermittent 
claudication.
In conclusion, the present analysis shows that the addition of nifedipine GITS to the basic 
treatment regimen of patients with symptomatic CAD and hypertension results in a signi -
cant reduction of cardiovascular morbidity. The fact that this analysis concerns a sub-group 
of patients in a trial that was not speci cally designed to assess the e ect of nifedipine in pa-
tients with concurrent symptomatic coronary artery disease and hypertension is a limitation. 
On the other hand, the sub-group of patients with hypertension at baseline consists of more 
than half of ACTION patients and was pre-speci ed. Hence, the present analysis provides sub-
stantial additional supporting evidence that long-acting calcium channel blockers such as 
nifedipine GITS are e ective in controlling high blood pressure and reducing major vascular 
events, even in patients who are already treated with other blood pressure-lowering drugs. 
This conclusion is supported by the recently published VALUE trial [24]. The data on patients 
in ACTION with hypertension at baseline supports the emphasis on blood pressure control in 
patients with a high global cardiovascular risk and/or established coronary artery disease in 
the current guidelines for the treatment of hypertension [25,26].
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Clinical Signi cance of Renal Function in 
Hypertensive Patients at High Risk
RESULTS FROM THE INSIGHT TRIAL
Peter W. de Leeuw, MD, PhD; Luis M. Ruilope, MD, PhD; Christopher R. Palmer, PhD; Morris J. 
Brown, MD, PhD; Alain Castaigne, MD, PhD; Giuseppe Mancia, MD, PhD; Talma Rosenthal, MD, 
PhD; Gilbert Wagener, MD 
Background: Increasing evidence suggests renal involvement in hypertension-related car-
diovascular and cerebrovascular complications. To assess this role of renal function in more 
detail, we studied the evolution of renal function and the relationship of renal function with 
mortality and morbidity in the Intervention as a Goal in Hypertension Treatment (INSIGHT) 
study.
Methods: The INSIGHT study was a double-blind, randomized, multicenter trial in patients 
with hypertension and at least 1 additional cardiovascular risk factor. Treatment consisted of 
nifedipine gastrointestinal therapeutic system, 30 mg/d, or hydrochlorothiazide-amiloride (25 
mg/d of hydrochlorothiazide and 2.5 mg/d of amiloride hydrochloride). Primary outcome was 
a composite of cardiovascular death, myocardial infarction, heart failure, and stroke. Renal 
function was assessed by measuring creatinine clearance, serum creatinine level, and serum 
uric acid level and by the presence of proteinuria.
Results: Creatinine clearance fell more in nifedipine recipients than in hydrochlorothiazide-
amiloride recipients. Renal insu  ciency developed in 2% of nifedipine recipients and 5% of 
hydrochlorothiazide-amiloride recipients. Primary outcomes occurred in 15% of patients with 
increased serum creatinine levels and 6% of patients with normal levels (odds ratio [OR] 2.89; 
95% con dence interval [CI], 1.92-4.36; P<.001). Primary outcomes were more likely in pa-
tients with low creatinine clearance (60 mL/min) than in those with higher clearances (9% vs. 
5%, respectively [OR 1.51, 95%CI 1.22-1.88; P<.001]).
Conclusions: Renal function is an important predictor of risk in hypertensive patients at high 
risk. Antihypertensive treatment with a long-acting dihydropyridine calcium channel blocker 
may better preserve renal function than would treatment with diuretics.
Arch Intern Med. 2004;164:2459-2464
Author A  liations are listed at the end of this article.
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Evidence is accumulating that the kidney contributes to the development of cardiac and ce-
rebral complications. Recent data indicate that, besides microalbuminuria, serum creatinine 
level also acts as a marker of risk.[1,2] Interestingly, the predictive power of serum creatinine is 
already demonstrable with relatively normal values.[2,3] In hypertensive populations, relation-
ships have been found between serum creatinine level and cardiovascular events, but in most 
of the studies either the type of treatment was not accounted for or patients were at relatively 
low risk. Consequently, only limited information is available regarding the e ect of renal func-
tion on cardiovascular prognosis in patients who are already at high risk. We have addressed 
this question using the results from the Intervention as a Goal in Hypertension Treatment (IN-
SIGHT) trial. The INSIGHT trial was a large, prospective, double-blind, randomized, controlled 
trial that compared the e ects of nifedipine gastrointestinal therapeutic system (GITS) with 
a diuretic combination (hydrochlorothiazide and amiloride hydrochloride) on cardiovascular 
outcome in hypertensive patients with additional cardiovascular risk factors. The main results 
of this trial have been described elsewhere.[4] In the present study, we report on the evolution 
of renal function during treatment and on the post hoc analysis of the relationship between 
renal function at baseline and cardiovascular complications. As markers of renal function, se-
rum creatinine, creatinine clearance, serum uric acid, and proteinuria were used.
METHODS
Trial design
Inclusion criteria for the INSIGHT trial were age 55 to 80 years, hypertension (blood pressure 
[BP]: ≥150 mm Hg systolic and ≥95 mm Hg diastolic, or ≥160 mm Hg systolic regardless of 
diastolic BP), and at least 1 additional cardiovascular risk factor. The design of the trial has 
been described previously.[4] Brie y, after 4 weeks of placebo treatment, during which base-
line measurements of BP and laboratory values were obtained, patients from 8 countries in 
Western Europe and Israel were randomized to either treatment with nifedipine, 30 mg/d, or 
hydrochlorothiazide-amiloride (25 mg/d of hydrochlorothiazide and 2.5 mg/d of amiloride 
hydrochloride) (step 1). Patients whose BP fell by less than 20/10 mm Hg or remained higher 
than 140/90 mm Hg received 1 of 4 dose titration steps (steps 2-5): dose doubling of the 
randomized drug; addition of 25 mg/d of atenolol (or 5 mg/d of enalapril maleate if atenolol 
was contraindicated); dose doubling of the additional drug; and addition of any other anti-
hypertensive drug except calcium channel blockers or diuretics. Renal function was never a 
contraindication to any of these drugs.
Blood pressure was always measured 3 times after a 5-minute rest, with a calibrated mercury 
sphygmomanometer. After dose titration, patients were seen 3 times a year for BP and heart 
rate assessment. Laboratory tests (including serum creatinine and serum uric acid measure-
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ments and urinalysis) were done during the titration phase and annually thereafter. The main 
marker of reduced renal function was a serum creatinine level higher than 1.5 mg/dL (133 
μmol/L) in men or higher than 1.4 mg/dL (124 μmol/L) in women. Other markers included 
creatinine clearance below 60 mL/min (1.00 mL/s) [1] (as calculated with the Cockcroft and 
Gault formula [5]), serum uric acid level of 7 mg/dL or higher (416 μmol/L), presence of protei-
nuria (de ned as protein excretion 0.5 g/24h) and any of these 4 measures. 
The primary outcome of the trial was the composite end point of incidence of cardiovascular 
death, myocardial infarction, heart failure, and stroke. Secondary outcomes were all-cause 
mortality, death from a vascular cause, and death from a nonvascular cause, including tran-
sient ischemic attacks, angina, and renal failure. The latter was de ned as a serum creatinine 
level of 2.94 mg/dL or higher (260 μmol/L) on 2 repeated measurements. All end points were 
validated from source documents by an independent critical events committee according to 
pre-speci ed diagnostic criteria.[6] The study complied with the principles of good clinical 
practice and the Declaration of Helsinki and was approved by the relevant ethics committees. 
All patients gave written informed consent. 
STATISTICAL ANALYSIS
We assessed di erences in group means or frequencies with the unpaired t test and the chi-
square test, respectively. Relative risks and 95% con dence intervals (CIs) are quoted for ran-
domized comparisons. Odds ratios (ORs) and 95% CIs are quoted for nonrandomized compari-
sons of patients with and without renal impairment at baseline. We used logistic regression to 
adjust for the possible e ects of confounding factors. Data are expressed as mean ±SD unless 
stated otherwise. 
RESULTS
Altogether, 6321 patients were included in the primary analysis of the INSIGHT trial. Base-
line serum creatinine levels were missing in 4 patients (2 in each treatment group) leaving 
6317 patients (2927 men and 3390 women) for analysis. Uric acid data were available for 6296 
patients (2914 men and 3382 women) and data on protein excretion for all patients. Serum 
creatinine was elevated at baseline in 192 patients (3%), while creatinine clearance was below 
60 mL/min (1.00 mL/s) in 1839 patients (29%). Increased serum uric acid level was present in 
934 patients (15%) and proteinuria was observed in 170 patients (3%). In 2550 patients (40%), 
at least 1 of the 4 markers of renal impairment was found.
Patients with increased serum creatinine level were slightly older, but the di erence was not 
statistically signi cant. While the prevalence of increased serum creatinine concentrations or 
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of reduced creatinine clearance increased with age, hyperuricemia and proteinuria were not 
related to age. As given in Table 1, demographic characteristics and risk factors were well 
balanced between the nifedipine and hydrochlorothiazide-amiloride treatment groups, irre-
spective of renal function. Patients with increased serum creatinine levels were more often 
men and smokers. In addition, they had a higher prevalence of diabetes mellitus, coronary 
heart disease, previous myocardial infarction, left ventricular hypertrophy or strain, peripheral 
vascular disease, and proteinuria. Essentially, the same results were obtained with the other 
markers of kidney function.
EVOLUTION OF CREATININE CLEARANCE DURING TREATMENT 
Estimated creatinine clearance at baseline averaged 74 ± 24 mL/min (1.24 ± 0.40 mL/s) in the 
nifedipine group and 73 ± 22 mL/min (1.22 ± 0.37 mL/s) in the hydrochlorothiazide-amiloride 
group. During the trial it decreased in both groups to 72 ± 24 mL/min (1.20 ± 0.40 mL/s) and 
68 ± 22mL/min (1.14 ± 0.37mL/s), respectively (Figure 1). The di erence between the groups 
was statistically signi cant (P<.05) and independent from baseline renal function. Renal in-
su  ciency occurred in 2% of patients receiving nifedipine and 5% of patients receiving the 
diuretic combination (P<.01).
172±15 mm Hg; P�.001) and at the end of the trial
(146±16 vs 142±16 mm Hg; P�.001). The fall in sys-
tolic BP was also greater in patients with proteinuria
(34±19 vs 30±18mmHg; P�.01), but no differences in
baseline and final measurements or change in diastolic
BP were observed.
During treatment, heart rate fell both in patients with
normal and reduced renal function. Changes were sig-
nificantly greater in patients with elevated serum creati-
nine levels (P�.02), probably because more of these pa-
tients progressed to the atenolol treatment step. However,
no significant differences emerged when patients were
divided on the basis of creatinine clearance, serum uric
acid level, or proteinuria.
Although changes in BPwere similar in nifedipine- and
hydrochlorothiazide-amiloride–treated patients, in both
groups more drugs were needed in the patients with re-
nal impairment. Ind ed, while 30% of patients with nor-
mal renal functionused 2drugs and9%used3drugs, these
figureswere 35%and19%, respectively, in the other group
(P�.001), with a similar proportion of patients using an
angiotensin-converting enzyme inhibitor.Moreover, in pa-
tients with reduced renal function there was no differ-
ence in add-onmedicationbetween the2 treatment groups.
Figure2 shows the proportions of patients who reached
a BP of 140/90mmHg or below at the end of the titration
phase. Both proteinuria and an elevated serum creatinine
concentration significantly reduced responsiveness,
whereas increased serumuric acid level or a creatinine clear-
ance below 60mL/min (�1.00mL/s) had no effect.When
all patients with at least 1 positivemarker of renal impair-
mentwere considered, response rateswere similar in those
with orwithout such an abnormality (70% inboth groups).
CARDIOVASCULAR COMPLICATIONS IN
RELATION TO BASELINE RENAL FUNCTION
Figure 3 summarizes risk estimates for increased serum
creatinine level, reduced creatinine clearance, and pres-
ence of proteinuria when patients with such abnormali-
ties were compared with those without. Primary out-
comes occurred in 15% of patients with increased serum
creatinine levels and in 6% of those with normal creati-
nine levels. This differencewashighly significant (OR,2.89;
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Figure 1. Creatinine clearance at baseline and at annual visits in patients
treated with either nifedipine gastrointestinal therapeutic system (GITS) or
hydrochlorothiazide–amiloride. The difference between groups is statistically
significant (P�.05). Error bars indicate SD. To convert creatinine clearance
to milliliters per second, multiply by 0.0167.
Table 1. Demographic Characteristics and Risk Factors at Baseline*
Characteristic
Normal Serum Creatinine Level Elevated Serum Creatinine Level†
P Value‡Nifedipine
Hydrochlorothiazide-
amiloride Combined Nifedipine
Hydrochlorothiazide-
amiloride Combined
Patients 3048 (97) 3077 (97) 6125 (97) 107 (3) 85 (3) 192 (3)
Men 1382 (45) 1409 (46) 2791 (46) 73 (68) 63 (74) 136 (71) �.001
Women 1666 (55) 1668 (54) 3334 (54) 34 (32) 22 (26) 56 (29) �.001
Age, y
�60 752 (25) 693 (23) 1445 (24) 7 (7) 9 (11) 16 (9) �.05
60-70 1455 (48) 1511 (49) 2966 (48) 52 (49) 42 (50) 94 (49) �.05
�70 835 (27) 869 (28) 1704 (28) 47 (44) 33 (39) 80 (42) �.05
Risk factor
Hypercholesterolemia 1595 (52) 1603 (52) 3198 (52) 51 (48) 40 (47) 91 (47) �.05
Smoker 868 (28) 885 (29) 1753 (29) 23 (22) 17 (20) 40 (21) �.05
Family history of MI§ 627 (21) 647 (21) 1274 (21) 19 (18) 12 (14) 31 (16) �.05
Diabetes mellitus 619 (20) 622 (20) 1241 (20) 30 (28) 31 (36) 61 (32) �.001
LVH 316 (10) 322 (10) 638 (10) 22 (21) 13 (15) 35 (18) �.001
Coronary heart disease 192 (6) 185 (6) 377 (6) 17 (16) 12 (14) 29 (15) �.001
Left-ventricular strain 188 (6) 181 (6) 369 (6) 13 (12) 15 (18) 28 (15) �.001
Previous MI 178 (6) 172 (6) 350 (6) 17 (16) 15 (18) 32 (17) �.001
Peripheral vascular disease 166 (5) 164 (5) 330 (5) 14 (13) 9 (11) 23 (12) �.001
Proteinuria 75 (2) 57 (2) 132 (2) 23 (22) 15 (18) 38 (20) �.001
Abbreviations: LVH, left ventricular hypertrophy; MI, myocardial infarction.
*Data are given as number (percentage) of patients unless otherwise specified.
†Men, higher than 1.5 mg/dL (�133 µmol/L); women, higher than 1.4 mg/dL (�124 µmol/L).
‡For the difference between all patients with an elevated serum creatinine level and all patients with a normal serum creatinine level.
§In parent or sibling before age 50 years.
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Abbreviations: LVH, left ventricular hypertrophy; MI, myocardial infarction.
* Data are given as number (percentage) of patients unless otherwise speci ed.
† Men, higher than 1.5 mg/dL (>133 μmol/L); women, higher than 1.4 mg/dL (>124 μmol/L).
‡  For the di erence between all patients with an elevated serum creatinine level and all patients with a 
normal serum creatinine level.
§ In parent or sibling before age 50 years.
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RENAL FUNCTION AND CONTROL OF BP AND HEART RATE 
At baseline, patients with increased serum creatinine levels had signi cantly higher values for sys-
tolic and diastolic BP compared with those with normal serum creatinine levels (Table 2). At the 
end of the trial, systolic BP was still higher in the patients with increased serum creatinine levels, 
but the di erence in diastolic BP was no longer statistically signi cant. When creatinine clearance 
was used to classify patients as those with normal or reduced renal function, systolic BP was again 
signi cantly higher in the latter at the time of randomisation (Table 2). Although the fall in systolic 
BP was greater in patients with reduced creatinine clearance, systolic BP remained higher in this 
group at the end of the trial. The opposite was found for diastolic BP, which was lower both at the 
start and at the end of the trial in patients with reduced creatinine clearance, with no di erence in 
the changes of diastolic BP.
Both systolic and diastolic BPs were slightly higher in patients with increased serum uric acid levels 
than in those with normal concentrations, but the changes in BP during treatment were similar. 
When patients with or without proteinuria were considered, systolic BP was signi cantly higher in 
the former, both at the start (180 ± 18 vs. 172 ± 15 mm Hg; P<.001) and at the end of the trial (146 
±16 vs. 142±16 mm Hg; P<.001). The fall in systolic BP was also greater in patients with proteinuria 
(34±19 vs. 30±18mmHg; P<.01), but no di erences in baseline and  nal measurements or change 
in diastolic BP were observed.
During treatment, heart rate fell both in patients with normal and reduced renal function. Changes 
were signi cantly greater in patients with elevated serum creatinine levels (P<.02), probably be-
cause more of these patients progressed to the atenolol treatment step. However, no signi cant 
172±15 mm Hg; P�.001) and at the end of the trial
(146±16 vs 142±16 mm Hg; P�.001). The fall in sys-
tolic BP was also greater in patients with proteinuria
(34±19 vs 30±18mmHg; P�.01), but no differences in
baseline and final measurements or change in diastolic
BP were observed.
During treatment, heart rate fell both in patients with
normal and reduced renal function. Changes were sig-
nificantly greater in patients with elevated serum creati-
nine levels (P�.02), probably because more of these pa-
tients progressed to the atenolol treatment step. However,
no significant differences emerged when patients were
divided on the basis of creatinine clearance, serum uric
acid level, or proteinuria.
Although changes in BPwere similar in nifedipine- and
hydrochlorothiazide-amiloride–treated patients, in both
groups more drugs were needed in the patients with re-
nal impairment. Indeed, while 30% of patients with nor-
mal renal functionused 2drugs and9%used3drugs, these
figureswere 35%and19%, respectively, in the other group
(P�.001), with a similar proportion of patients using an
angiotensin-converting enzyme inhibitor.Moreover, in pa-
tients with reduced renal function there was no differ-
ence in add-onmedicationbetween the2 treatment groups.
Figure2 shows the proportions of patients who reached
a BP of 140/90mmHg or below at the end of the titration
phase. Both proteinuria and an elevated serum creatinine
concentration significantly reduced responsiveness,
whereas increased serumuric acid level or a creatinine clear-
ance below 60mL/min (�1.00mL/s) had no effect.When
all patients with at least 1 positivemarker of renal impair-
mentwere considered, response rateswere similar in those
with orwithout such an abnormality (70% inboth groups).
CARDIOVASCULAR COMPLICATIONS IN
RELATION TO BASELINE RENAL FUNCTION
Figure 3 summarizes risk estimates for increased serum
creatinine level, reduced cre tinine clearance, and pres-
ence of proteinuria when patients with such abnormali-
ties were compared with those without. Primary out-
comes occur d in 15% of patients with increased serum
creatinine levels and in 6% of those with normal creati-
nine levels. This differencewashighly significant (OR,2.89;
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Figure 1. Creatinine clearance at baseline and at annual visits in patients
treated with either nifedipine gastrointestinal therapeutic system (GITS) or
hydrochlorothiazide–amiloride. The difference between groups is statistically
significant (P�.05). Error bars indicate SD. To convert creatinine clearance
to milliliters per second, multiply by 0.0167.
Table 1. Demographic Characteristics and Risk Factors at Baseline*
Characteristic
Normal Serum Creatinine Level Elevated Serum Creatinine Level†
P Value‡Nifedipine
Hydrochlorothiazide-
amiloride Combined Nifedipine
Hydrochlorothiazide-
amiloride Combined
Patients 3048 (97) 3077 (97) 6125 (97) 107 (3) 85 (3) 192 (3)
Men 1382 (45) 1409 (46) 2791 (46) 73 (68) 63 (74) 136 (71) �.001
Women 1666 (55) 1668 (54) 3334 (54) 34 (32) 22 (26) 56 (29) �.001
Age, y
�60 752 (25) 693 (23) 1445 (24) 7 (7) 9 (11) 16 (9) �.05
60-70 1455 (48) 1511 (49) 2966 (48) 52 (49) 42 (50) 94 (49) �.05
�70 835 (27) 869 (28) 1704 (28) 47 (44) 33 (39) 80 (42) �.05
Risk factor
Hypercholesterolemia 1595 (52) 1603 (52) 3198 (52) 51 (48) 40 (47) 91 (47) �.05
Smoker 868 (28) 885 (29) 1753 (29) 23 (22) 17 (20) 40 (21) �.05
Family history of MI§ 627 (21) 647 (21) 1274 (21) 19 (18) 12 (14) 31 (16) �.05
Diabetes mellitus 619 (20) 622 (20) 1241 (20) 30 (28) 31 (36) 61 (32) �.001
LVH 316 (10) 322 (10) 638 (10) 22 (21) 13 (15) 35 (18) �.001
Coronary heart disease 192 (6) 185 (6) 377 (6) 17 (16) 12 (14) 29 (15) �.001
Left-ventricular strain 188 (6) 181 (6) 369 (6) 13 (12) 15 (18) 28 (15) �.001
Previous MI 178 (6) 172 (6) 350 (6) 17 (16) 15 (18) 32 (17) �.001
Peripheral vascular disease 166 (5) 164 (5) 330 (5) 14 (13) 9 (11) 23 (12) �.001
Proteinuria 75 (2) 57 (2) 132 (2) 23 (22) 15 (18) 38 (20) �.001
Abbreviations: LVH, left ventricular hypertrophy; MI, myocardial infarction.
*Data are given as number (percentage) of patients unless otherwise specified.
†Men, higher than 1.5 mg/dL (�133 µmol/L); women, higher than 1.4 mg/dL (�124 µmol/L).
‡For the difference between all patients with an elevated serum creatinine level and all patients with a normal serum creatinine level.
§In parent or sibling before age 50 years.
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Figure 1. Creatinine clearance at baseline and at annual visits in patients treated with either nifedipine 
gastrointestinal therap utic syst m (GITS) or hydrochlorothiazide-amiloride. The di erence between 
groups is statistically signi cant (P<.05). Error bars indicate SD. To convert creatinine clearance to millilitres 
per second, multiply by 0.0167.
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di erences emerged when patients were divided on the basis of creatinine clearance, serum uric 
acid level, or proteinuria.
Although changes in BP were similar in nifedipine and hydrochlorothiazide-amiloride-treated pa-
tients, in both groups more drugs were needed in the patients with renal impairment. Indeed, 
while 30% of patients with normal renal function used 2 drugs and 9% used 3 drugs, these  g-
ures were 35% and 19%, respectively, in the other group (P<.001), with a similar proportion of pa-
tients using an angiotensin-converting enzyme inhibitor. Moreover, in patients with reduced renal 
function there was no di erence in add-on medication between the 2 treatment groups. Figure 2 
shows the proportions of patients who reached a BP of 140/90 mm Hg or below at the end of the 
titration phase. Both proteinuria and an elevated serum creatinine concentration signi cantly re-
duced responsiveness, whereas increased serum uric acid level or a creatinine clearance below 60 
mL/min (1.00 mL/s) had no e ect. When all patients with at least 1 positive marker of renal impair-
ment were considered, response rates were similar in those with or without such an abnormality 
(70% in both groups).
95%CI, 1.92-4.36; P�.001). A similar difference was ob-
served in the incidence of secondary outcomes (12% vs
33%; P�.001). In the group with increased serum creati-
nine levels at baseline, the percentages of patientswith pri-
mary outcomes did not differ between the nifedipine- and
hydrochlorothiazide-amiloride–treated groups (16% and
14%, respectively; relative risk, 1.04, 95%CI, 0.94-1.14).
Primary outcomes were noted in 5% of the patients with
a creatinine clearance above 60mL/min (�1.00mL/s) and
8% of the others (OR, 1.51; 95% CI, 1.22-1.88; P�.001).
Nonrenal secondary outcomeswere alsomore frequent in
patients with reduced creatinine clearance (17% vs 10%;
P�.001). When primary end points in patients receiving
randomized treatment were compared, the results were
slightly in favor of the nifedipine group (relative risk, 0.93;
95% CI, 0.92-0.94; P�.05). The risks of a primary event
associated with increased serum uric acid concentration
or the presence of proteinuria (OR, 3.82; 95% CI, 2.56-
5.70; P�.001) showed similar patterns to those for cre-
atinine.With regard to proteinuria, the comparison of end
points in patients receiving randomized treatment proved
nifedipine to be slightly worse than hydrochlorothiazide-
amiloride (relative risk, 1.16; 95%CI, 1.01-1.32;P�.001).
When cardiovascular complications were analyzed in re-
lation to any abnormality of renal function, the same find-
ings emerged as for the individual markers of renal func-
tion.
Logistic regression analysis was performed to evalu-
ate the effect of renal impairment on primary outcome
with adjustments for various other risk factors. In the first
model, we tested whether baseline serum creatinine is a
risk factor for primary events, independent of protein-
uria. This, indeed, appeared to be the case, with an OR
of 2.57 (95% CI, 1.68-3.93; P�.001) for the presence of
proteinuria and an OR of 1.38 (95% CI, 1.27-1.49;
P�.001) for each 0.2-mg/dL (20-µmol/L) increase in se-
Table 2. Changes in Blood Pressure (BP) and Heart Rate During Treatment in Patients With Normal or Reduced Renal Function*
BP and Heart Rate
Serum Creatinine Level
P Value
Creatinine Clearance Level
P ValueNormal Increased† Normal Reduced‡
Systolic BP, mm Hg
Start 172 ± 15 179 ± 18 �.001 171 ± 14 175 ± 16 �.001
Final 142 ± 15 147 ± 22 �.001 142 ± 15 143 ± 18 �.001
Change 30 ± 18 32 ± 22 �.05 30 ± 17 32 ± 20 �.001
Diastolic BP, mm Hg
Start 99 ± 8 100 ± 10 .01 99 ± 8 98 ± 9 �.001
Final 82 ± 9 84 ± 11 .09 83 ± 9 81 ± 10 �.001
Change 16 ± 10 17 ± 13 �.05 16 ± 10 16 ± 11 �.05
Heart rate, bpm
Start 76 ± 10 79 ± 12 �.05 76 ± 10 77 ± 10 �.05
Final 74 ± 11 74 ± 12 �.05 74 ± 11 74 ± 11 �.05
Change 3 ± 11 5 ± 14 .004 3 ± 11 3 ± 12 �.05
Abbreviation: bpm, beats per minute.
*Data are presented as mean ± SD unless otherwise specified. Renal function was determined from serum creatinine level or creatinine clearance at baseline.
†Men, higher than 1.5 mg/dL (�133 µmol/L); women, higher than 1.4 mg/dL (�124 µmol/L).
‡Below 60 mL/min (1.00 mL/s).
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Figure 2. Percentage of patients reaching the target blood pressure level at
the end of the titration phase in relation to several markers of renal
impairment as determined at baseline. The dotted line indicates overall
responsiveness in entire patient group (70%); the asterisk, P�.05 (vs
patients with normal serum creatinine levels); and the dagger, P�.005 (vs
patients without proteinuria).
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Figure 3. Risk estimates for primary end points (adjusted for other
cardiovascular risk factors) associated with increased serum creatinine level,
reduced creatinine clearance, or presence of proteinuria at baseline when
patients with such abnormalities are compared with those without. Serum
uric acid level did not e erge as an independent risk factor. The asterisks
indicate P�.001.
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Abbreviation: bp , beats per minute.
*Data are presented as mean±SD unless otherwise speci ed. Renal function was determined from serum 
creatinine level or creatinine clearance at baseline.
†Men, higher than 1.5 mg/dL (>133 μmol/L); women, higher than 1.4 mg/dL (>124 μmol/L).
‡Below 60 mL/min (1.00 mL/s).
Figure 2. Percentage of patients reaching 
the target blood pressure level at the end 
of the titration phase in relation to several 
markers of renal impairment as determined 
at baseline. The dotted line indicates overall 
responsiveness in entire patient group (70%); 
the asterisk, P<.05 (vs. patients with normal 
serum creatinine levels); and the dagger, P<.005 
(vs. patients without proteinuria).
95%CI, 1.92-4.36; P�.001). A similar difference was ob-
served in the incidence of secondary outcomes (12% vs
33%; P�.001). In the group with increased serum creati-
nine levels at baseline, the percentages of patientswith pri-
mary outcomes did not differ between the nifedipine- and
hydrochlorothiazide-amiloride–treated groups (16% and
14%, respectively; relative risk, 1.04, 95%CI, 0.94-1.14).
Primary outcomes were noted in 5% of the patients with
a creatinine clearance above 60mL/min (�1.00mL/s) and
8% of the others (OR, 1.51; 95% CI, 1.22-1.88; P�.001).
Nonrenal secondary outcomeswere alsomore frequent in
patients with reduced creatinine clearance (17% vs 10%;
P�.001). When primary end points in patients receiving
randomized treatment were compared, the results were
slightly in favor of the nifedipine group (relative risk, 0.93;
95% CI, 0.92-0.94; P�.05). The risks of a primary event
associated with increased serum uric acid concentration
or the presence of proteinuria (OR, 3.82; 95% CI, 2.56-
5.70; P�.001) showed similar patterns to those for cre-
atinine.With regard to proteinuria, the comparison of end
points in patients receiving randomized treatment proved
nifedipine to be slightly worse than hydrochlorothiazide-
amiloride (relative risk, 1.16; 95%CI, 1.01-1.32;P�.001).
When cardiovascular complications were analyzed in re-
lation to any abnormality of renal function, the same find-
ings emerged as for the individual markers of renal func-
tion.
Logistic regression analysis was performed to evalu-
ate the effect of renal impairment on primary outcome
with adjustments for various other risk factors. In the first
model, we tested whether baseline serum creatinine is a
risk factor for primary events, independent of protein-
uria. This, indeed, appeared to be the case, with an OR
of 2.57 (95% CI, 1.68-3.93; P�.001) for the presence of
proteinuria and an OR of 1.38 (95% CI, 1.27-1.49;
P�.001) for each 0.2-mg/dL (20-µmol/L) increase in se-
Table 2. Changes in Blood Pressure (BP) and Heart Rate During Treatment in Patients With Normal or Reduced Renal Function*
BP and Heart Rate
S rum Creatinine Level
P Value
Creatinine Clearance Level
P ValueNormal Increased† Normal Reduced‡
Systolic BP, mm Hg
Start 172 ± 15 179 ± 18 �.001 171 ± 14 175 ± 16 �.001
Final 142 ± 15 147 ± 22 �.001 142 ± 15 143 ± 18 �.001
Change 30 ± 18 32 ± 22 �.05 30 ± 17 32 ± 20 �.001
Diastolic BP, mm Hg
Start 99 ± 8 100 ± 10 .01 99 ± 8 98 ± 9 �.001
Final 82 ± 9 84 ± 11 .09 83 ± 9 81 ± 10 �.001
Change 16 ± 10 17 ± 13 �.05 16 ± 10 16 ± 11 �.05
Heart rate, bpm
Start 76 ± 10 79 ± 12 �.05 76 ± 10 77 ± 10 �.05
Final 74 ± 11 74 ± 12 �.05 74 ± 11 74 ± 11 �.05
Change 3 ± 11 5 ± 14 .004 3 ± 11 3 ± 12 �.05
Abbreviation: bpm, beats per minute.
*Data are presented as mean ± SD unless otherwise specified. Renal function was determined from serum creatinine level or creatinine clearance at baseline.
†Men, higher than 1.5 mg/dL (�133 µmol/L); women, higher than 1.4 mg/dL (�124 µmol/L).
‡Below 60 mL/min (1.00 mL/s).
∗
†
75
50
25
Increased Serum
Creatinine
Level
Reduced
Creatinine
Clearance
Increased
Serum
Uric Acid Level
Presence of
Proteinuria
Any
Marker
Pa
tie
nt
s,
 %
Figure 2. Percentage of patients reaching the target blood pressure level at
the end of the titration phase in relation to several markers of renal
impairment as determined at baseline. The dotted line indicates overall
responsiveness in entire patient group (70%); the asterisk, P�.05 (vs
patients with normal serum creatinine levels); and the dagger, P�.005 (vs
patients without proteinuria).
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Figure 3. Risk estimates for primary end points (adjusted for other
cardiovascular risk factors) associated with increased serum creatinine level,
reduced creatinine clearance, or presence of proteinuria at baseline when
patients with such abnormalities are compared with those without. Serum
uric acid level did not emerge as an independent risk factor. The asterisks
indicate P�.001.
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CARDIOVASCULAR COMPLICATIONS IN RELATION TO BASELINE RENAL 
FUNCTION 
Figure 3 summarizes risk estimates for increased serum creatinine level, reduced creatinine 
clearance, and presence of proteinuria when patients with such abnormalities were com-
pared with those without. Primary outcomes occurred in 15% of patients with increased se-
rum creatinine levels and in 6% of those with normal creatinine levels. This di erence was 
highly signi cant (OR 2.89; 95% CI 1.92-4.36; P<.001). A similar di erence was observed in the 
incidence of secondary outcomes (12% vs. 33%; P<.001). In the group with increased serum 
creatinine levels at baseline, the percentages of patients with primary outcomes did not dif-
fer between the nifedipine and hydrochlorothiazide-amiloride-treated groups (16% and 14%, 
respectively; relative risk 1.04, 95% CI 0.94-1.14). Primary outcomes were noted in 5% of the 
patients with a creatinine clearance above 60 mL/min (>1.00 mL/s) and 8% of the others (OR 
1.51; 95% CI 1.22-1.88; P<.001). Non-renal secondary outcomes were also more frequent in 
patients with reduced creatinine clearance (17% vs. 10%; P<.001). When primary endpoints in 
patients receiving randomized treatment were compared, the results were slightly in favour 
of the nifedipine group (relative risk 0.93; 95% CI 0.92-0.94; P<.05). The risks of a primary event 
associated with increased serum uric acid concentration or the presence of proteinuria (OR 
3.82; 95% CI 2.56-5.70; P<.001) showed similar patterns to those for creatinine. With regard to 
proteinuria, the comparison of endpoints in patients receiving randomized treatment proved 
nifedipine to be slightly worse than hydrochlorothiazide-amiloride (relative risk 1.16; 95% CI 
1.01-1.32; P<.001). When cardiovascular complications were analyzed in relation to any ab-
normality of renal function, the same  ndings emerged as for the individual markers of renal 
function.
Logistic regression analysis was performed to evaluate the e ect of renal impairment on pri-
mary outcome with adjustments for various other risk factors. In the  rst model, we tested 
whether baseline serum creatinine is a risk factor for primary events, independent of protei-
nuria. This, indeed, appeared to be the case, with an OR of 2.57 (95% CI 1.68-3.93; P<.001) for 
Figure 3. Risk estimates for primary end 
points (adjusted for other cardiovascular 
risk factors) associated with increased 
serum creatinine level, reduced creatinine 
clearance, or presence of proteinuria 
at baseline when patients with such 
abnormalities are compared with those 
without. Serum uric acid level did not 
emerge as an independent risk factor. The 
asterisks indicate P<.001.
95%CI, 1.92-4.36; P�.001). A similar difference was ob-
served in the incidence of secondary outcomes (12% vs
33%; P�.001). In the group with increased serum creati-
nine levels at baseline, the percentages of patientswith pri-
mary outcomes did not differ between the nifedipine- and
hydrochlorothiazide-amiloride–treated groups (16% and
14%, respectively; relative risk, 1.04, 95%CI, 0.94-1.14).
Primary outcomes were noted in 5% of the patients with
a creatinine clearance above 60mL/min (�1.00mL/s) and
8% of the others (OR, 1.51; 95% CI, 1.22-1.88; P�.001).
Nonrenal secondary outcomeswere alsomore frequent in
patients with reduced creatinine clearance (17% vs 10%;
P�.001). When primary end points in patients receiving
randomized treatment were compared, the results were
slightly in favor of the nifedipine group (relative risk, 0.93;
95% CI, 0.92-0.94; P�.05). The risks of a primary event
associated with increased serum uric acid concentration
or the presence of proteinuria (OR, 3.82; 95% CI, 2.56-
5.70; P�.001) showed similar patterns to those for cre-
atinine.With regard to proteinuria, the comparison of end
points in patients receiving randomized treatment proved
nifedipine to be slightly worse than hydrochlorothiazide-
amiloride (relative risk, 1.16; 95%CI, 1.01-1.32;P�.001).
When cardiovascular complications were analyzed in re-
lation to any abnormality of renal function, the same find-
ings emerged as for the individual markers of renal func-
tion.
Logistic regression analysis was performed to evalu-
ate the effect of renal impairment on primary outcome
with adjustments for various other risk factors. In the first
model, we tested whether baseline serum creatinine is a
risk factor for primary events, independent of protein-
uria. This, indeed, appeared to be the case, with an OR
of 2.57 (95% CI, 1.68-3.93; P�.001) for the presence of
proteinuria and an OR of 1.38 (95% CI, 1.27-1.49;
P�.001) for each 0.2-mg/dL (20-µmol/L) increase in se-
Table 2. Changes in Blood Pressure (BP) and Heart Rate During Treatment in Patients With Normal or Reduced Renal Function*
BP and Heart Rate
Serum Creatinine Level
P Value
Creatinine Clearance Level
P ValueNormal Increased† Normal Reduced‡
Systolic BP, mm Hg
Start 172 ± 15 179 ± 18 �.001 171 ± 14 175 ± 16 �.001
Final 142 ± 15 147 ± 22 �.001 142 ± 15 143 ± 18 �.001
Change 30 ± 18 32 ± 22 �.05 30 ± 17 32 ± 20 �.001
Diastolic BP, mm Hg
Start 99 ± 8 100 ± 10 .01 99 ± 8 98 ± 9 �.001
Final 82 ± 9 84 ± 11 .09 83 ± 9 81 ± 10 �.001
Change 16 ± 10 17 ± 13 �.05 16 ± 10 16 ± 11 �.05
Heart rate, bpm
Start 76 ± 10 79 ± 12 �.05 76 ± 10 77 ± 10 �.05
Final 74 ± 11 74 ± 12 �.05 74 ± 11 74 ± 11 �.05
Change 3 ± 11 5 ± 14 .004 3 ± 11 3 ± 12 �.05
Abbreviation: bpm, beats per minute.
*Data are presented as mean ± SD unless otherwise specified. Renal function was determined from serum creatinine l vel or creatinine clearance at baseline.
†Men, higher than 1.5 mg/dL (�133 µmol/L); women, higher than 1.4 mg/dL (�124 µmol/L).
‡Below 60 mL/min (1.00 mL/s).
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Figure 2. Percentage of patients reaching the target blood pressure level at
the end of the titration phase in relation to several markers of renal
impairment as determined at baseline. The dotted line indicates overall
responsiveness in entire patient group (70%); the asterisk, P�.05 (vs
patients with normal serum creatinine levels); and the dagger, P�.005 (vs
patients without proteinuria).
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Figure 3. Risk estimates for primary end points (adjusted for other
cardiovascular risk factors) associated with increased serum creatinine level,
reduced creatinine clearance, or presence of proteinuria at baseline when
patients with such abnormalities are compared with those without. Serum
uric acid level did not emerge as an independent risk factor. The asterisks
indicate P�.001.
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the presence of proteinuria and an OR of 1. 38 (95% CI 1.27-1.49; P<.001) for each 0.2 mg/dL 
(20 μmol/L) increase in serum creatinine level at baseline. In the second model, we adjusted 
also for other risk factors (age, sex, presence of diabetes mellitus, previous myocardial infarc-
tion, and smoking) besides proteinuria and found a high serum creatinine level to remain 
signi cant as a predictor of outcome (Table 3). With this type of analysis, however, serum uric 
acid level entirely lost its predictive power.
The percentages of patients with individual cardiovascular outcomes were generally similar 
between treatment groups within the subgroups with normal or abnormal kidney function. 
Meaningful statistical analyses could not be conducted for most individual cardiovascular 
events because of the small number of patients who had each event.
COMMENT
The  rst conclusion from the present study is that renal function is better preserved with 
the calcium channel blocker nifedipine GITS than with the diuretic combination hydrochlo-
rothiazide-amiloride. Few studies have addressed the e ects of long-term antihypertensive 
therapy on renal function in large cohorts of patients. In the European Working Party on High 
Blood Pressure in the Elderly trial, more than 800 patients received either placebo or a diuretic 
combination. Serum creatinine increased much more in the actively treated group than in 
the placebo group, and the risk of mild renal dysfunction was substantially higher in actively 
treated patients.[7,8] The increase in serum creatinine level correlated inversely with the fall 
in systolic BP, suggesting that reduced renal perfusion during diuretic treatment may underlie 
this phenomenon.[7] The same may be true for our data because the greatest disparity be-
tween the groups occurred during the  rst year with no evidence for a sustained damaging 
e ect thereafter. Other trials in hypertensive patients, mostly using diuretics or β-blockers, 
also showed that active treatment is associated with a greater increase in serum creatinine 
level than in placebo treatment.[9,10] However, Voyaki et al. [11] provided evidence that, com-
pared with placebo, treatment with the calcium channel blocker nitrendipine had a renopro-
rum creatinine level at baseline. In the secondmodel, we
adjusted also for other risk factors (age, sex, presence of
diabetes mellitus, previous myocardial infarction, and
smoking) besides proteinuria and found a high serumcre-
atinine level to remain significant as a predictor of out-
come (Table 3). With this type of analysis, however,
serum uric acid level entirely lost its predictive power.
The percentages of patients with individual cardio-
vascular outcomes were generally similar between treat-
ment groups within the subgroups with normal or ab-
normal kidney function. Meaningful statistical analyses
could not be conducted for most individual cardiovas-
cular events because of the small number of patients who
had each event.
COMMENT
The first conclusion from the present study is that renal
function is better preserved with the calcium channel
blocker nifedipine GITS than with the diuretic combina-
tion hydrochlorothiazide-amiloride. Few studies have ad-
dressed the effects of long-term antihypertensive therapy
on renal function in large cohorts of patients. In the Eu-
ropean Working Party on High Blood Pressure in the El-
derly trial, more than 800 patients received either pla-
ceboor a diuretic combination. Serumcreatinine increased
much more in the actively treated group than in the pla-
cebo group, and the risk ofmild renal dysfunctionwas sub-
stantially higher in actively treated patients.7,8 The in-
crease in serum creatinine level correlated inversely with
the fall in systolic BP, suggesting that reduced renal per-
fusion during diuretic treatment may underlie this phe-
nomenon.7 The samemay be true for our data because the
greatest disparity between the groups occurred during the
first year with no evidence for a sustained damaging effect
thereafter. Other trials in hypertensive patients,mostly us-
ing diuretics or �-blockers, also showed that active treat-
ment is associated with a greater increase in serum cre-
atinine level than inplacebo treatment.9,10However,Voyaki
et al11 providedevidence that, comparedwithplacebo, treat-
ment with the calcium channel blocker nitrendipine had
a renoprotective effect in patientswith isolated systolic hy-
pertension. Thus, it may be that the type of medication
plays an important role in determining renal outcomedur-
ing antihypertensive treatment.
Three trialshavecompared theeffectof a calciumchan-
nel blocker with alternative treatment on renal function
inhypertensivepatients. In theNational InterventionCo-
operative Study in ElderlyHypertensives, serumurea ni-
trogen level increased similarly inpatients treatedwithni-
cardipine hydrochloride or a diuretic.12However, abnor-
mally elevated levelswere less frequent in thenicardipine
group. In theTreatment ofMildHypertension Study, hy-
pertensive patients were randomized to placebo or 1 of 5
activedrugs,whichincludedchlorthalidoneandamlodipine
maleate.13 Serumcreatinine concentration increasedwith
chlorthalidone use but was reduced by the other types of
treatment.TheAntihypertensiveandLipid-LoweringTreat-
ment toPreventHeartAttackTrial (ALLHAT),whichcon-
cluded that thiazide-type diuretics should be considered
first-line therapy in patients with hypertension, also in-
cludedapost hoc analysis of the changes in estimatedglo-
merular filtration rate.14 In this trial, the incidenceof end-
stage renal disease was similar for the 3 treatment arms
(chlorthalidone, lisinopril, andamlodipine),butestimated
creatinineclearancewassignificantlybetterpreservedwith
amlodipine thanwithchlorthalidoneor lisinopril.Thepre-
sent findings thus corroborate thedata from the literature
that antihypertensive treatment with a long-acting dihy-
dropyridine calcium channel blocker may protect renal
function more effectively compared with diuretics. This
was true not only when changes in creatinine clearance
level over time were considered but also when compar-
ing thepercentageofpatients inbothgroupswhohadpro-
gressive renal deterioration. Taken together, it is fair to
state that dihydropyridine calciumchannel blockers con-
ferprognosticbenefit in termsof renal function.However,
the mechanisms whereby this may be accomplished re-
main uncertain.
The second conclusion from our analysis is that in hy-
pertensive patients at high risk, renal function is an im-
portant predictor of risk. In this respect, serum creati-
nine level, creatinine clearance, and urinary protein
excretion may all be taken as markers of renal function.
Although serumuric acid level also predicted outcome in
univariate analysis, it turned out not to be an indepen-
dent risk factor. Theobservation that serumcreatinine level
predicted cardiovascularmorbidity andmortality fits well
with data from other studies that showed an independent
ss ciation between serum creatinin level and cardiovas-
cular or overall prognosis. For example, the investigators
from the Hypertension Optimal Treatment trial recently
reported that in treated hyperte sive pa ients, an eleva-
tion in serum creatinine level above 1.5 mg/dL (�132.6
µmol/L) or a reduction in estimated creatinine clearance
below 60 mL/min (�1.00 mL/s) at baseline are powerful
predictors of cardiovascular events and death.1 Similar re-
sults have been described in patients with isolated sys-
tolic hypertension.2,15,16 Importantly, in hypertensive pa-
tients, creatinine levels that are still in the normal range
may already predict outcome.3 The INSIGHT trial, how-
ever, is the first trial to examine the prognostic signifi-
cance of renal function in hypertensive patients at high
risk. In addition, the impact of renal function was dem-
onstrated for the 2 treatment groups separately. More-
over, raised serum creatinine level and presence of pro-
Table 3. Odds Ratios for Several
Mutually Adjusted Risk Factors*
Variable
Odds Ratio
(95% Confidence Interval) P Value
Age 1.04 (1.02-1.05) �.001
Male sex 1.66 (1.31-2.12) �.001
Diabetes mellitus 1.59 (1.24-2.03) �.001
Previous myocardial infarction 2.38 (1.73-3.28) �.001
Smoking 1.57 (1.24-1.98) �.001
Proteinuria 2.35 (1.52-3.63) �.001
Creatinine level 1.23 (1.12-1.34) �.001
*Odds ratios refer to having or not having the risk factor for the
categorical variables (yes/no) or the odds ratios for a 1-unit change (1 year
for age and 0.2 mg/dL [20 µmol/L] for creatinine level).
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*Odds ratios refer to having or not having the 
risk factor for the categorical variables (yes/no) 
or the odds ratios for a 1-unit change (1 year for 
age and 0.2 mg/dL [20 μmol/L] for creatinine 
level).
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tective e ect in patients with isolated systolic hypertension. Thus, it may be that the type of 
medication plays an important role in determining renal outcome during antihypertensive 
treatment. 
Three trials have compared the e ect of a calcium channel blocker with alternative treatment 
on renal function in hypertensive patients. In the National Intervention Cooperative Study in 
Elderly Hypertensives, serum urea nitrogen level increased similarly in patients treated with 
nicardipine hydrochloride or a diuretic.[12] However, abnormally elevated levels were less fre-
quent in the nicardipine group. In the Treatment of Mild Hypertension Study, hypertensive pa-
tients were randomized to placebo or 1 of 5 active drugs, which included chlorthalidone and 
amlodipine maleate.[13] Serum creatinine concentration increased with chlorthalidone use 
but was reduced by the other types of treatment. The Antihypertensive and Lipid-Lowering 
Treatment to Prevent Heart Attack Trial (ALLHAT), which concluded that thiazide-type diuretics 
should be considered  rst-line therapy in patients with hypertension, also included a post hoc 
analysis of the changes in estimated glomerular  ltration rate.[14] In this trial, the incidence 
of end-stage renal disease was similar for the 3 treatment arms (chlorthalidone, lisinopril, and 
amlodipine), but estimated creatinine clearance was signi cantly better preserved with am-
lodipine than with chlorthalidone or lisinopril. The present  ndings thus corroborate the data 
from the literature that antihypertensive treatment with a long-acting dihydropyridine calci-
um channel blocker may protect renal function more e ectively compared with diuretics. This 
was true not only when changes in creatinine clearance level over time were considered but 
also when comparing the percentage of patients in both groups who had progressive renal 
deterioration. Taken together, it is fair to state that dihydropyridine calcium channel blockers 
confer prognostic bene t in terms of renal function. However, the mechanisms whereby this 
may be accomplished remain uncertain. 
The second conclusion from our analysis is that in hypertensive patients at high risk, renal 
function is an important predictor of risk. In this respect, serum creatinine level, creatinine 
clearance, and urinary protein excretion may all be taken as markers of renal function. Al-
though serum uric acid level also predicted outcome in univariate analysis, it turned out not 
to be an independent risk factor. The observation that serum creatinine level predicted car-
diovascular morbidity and mortality  ts well with data from other studies that showed an 
independent association between serum creatinine level and cardiovascular or overall prog-
nosis. For example, the investigators from the Hypertension Optimal Treatment trial recently 
reported that in treated hypertensive patients, an elevation in serum creatinine level above 
1.5 mg/dL (>132.6 μmol/L) or a reduction in estimated creatinine clearance below 60 mL/min 
(<1.00 mL/s) at baseline are powerful predictors of cardiovascular events and death.[1] Similar 
results have been described in patients with isolated systolic hypertension.[2,15,16] Impor-
tantly, in hypertensive patients, creatinine levels that are still in the normal range may already 
predict outcome.[3] The INSIGHT trial, however, is the  rst trial to examine the prognostic 
signi cance of renal function in hypertensive patients at high risk. In addition, the impact of 
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renal function was demonstrated for the 2 treatment groups separately. Moreover, raised se-
rum creatinine level and presence of proteinuria were independently related to the incidence 
of complications.
The 3 measurements (creatinine level, serum uric acid level, and protein excretion) that we 
used in this study are not very sensitive or very speci c markers of renal function. Moreover, 
they di er in strength regarding their prognostic power (greatest for proteinuria). Indeed, 
serum concentrations of creatinine and uric acid are also dependent on extra renal factors, 
and urinary protein excretion may re ect the hydraulic consequences of elevated (intra-renal) 
pressure rather than true glomerular damage. Despite this caveat, all markers were powerful 
predictors of future complications, suggesting that glomerular damage is somehow associ-
ated with progression of atherosclerotic lesions. While several investigators believe that pro-
teinuria or elevated serum creatinine level re ects generalized endothelial dysfunction or a 
prothrombotic state, others argue (on equally reasonable grounds) against these possibilities.
[17,18] Progression of atherosclerotic lesions in patients with reduced renal function has also 
been linked to enhanced oxidative stress and in ammation. Finally, increased levels of homo-
cysteine, which is normally cleared by the kidney, may play a role. Clearly, more work has to be 
done before the pathophysiological connection between renal function and atherosclerotic 
complications can be elucidated.
One of the limitations of this study is that there may be unmeasured confounders that could 
have in uenced our results. Although the observed relationships between renal function and 
cardiovascular prognosis remained statistically signi cant after adjustment for the other risk 
factors, we did not account for obesity or the newer risk factors, such as hyperhomocysteine-
mia, in ammation, or oxidative stress. In addition, one should bear in mind that our results ap-
ply only to hypertensive patients at high risk, treated with nifedipine GITS or hydrochlorothi-
azide-amiloride. Whether similar results apply to other types of treatment remains unknown. 
Likewise, the population we studied was predominantly white and, therefore, the implications 
for other races/ethnicities (e.g., African Americans) are di  cult to de ne. Finally, we have to be 
aware that selection bias may have occurred in the sense that patients with more advanced 
renal impairment were not recruited for clinical reasons. Despite these limitations, the pres-
ent  ndings suggest that antihypertensive treatment based on a long-acting dihydropyridine 
calcium channel blocker (nifedipine GITS) may o er better renoprotection compared with 
therapy based on the diuretic combination hydrochlorothiazide-amiloride.
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Uric acid and other renal function 
parameters in patients with stable angina 
pectoris participating in the ACTION trial: 
impact of nifedipine GITS (gastro-intestinal 
therapeutic system) and relation to outcome
Luis M. Ruilopea, Bridget-Anne Kirwanb, Sophie de Brouwerb, Nicolas Danchinc, Keith A.A. 
Foxd, Gilbert Wagenere, Julian Seguraa, Philip A. Poole-Wilsonf and Jacobus Lubsenb,g, on 
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aHypertension Unit, Hospital 12 de Octubre. Madrid, Spain, bSOCAR Research, Nyon, Swit-
zerland, cDepartment of Cardiology, Georges Pompidou European Hospital, Paris, France, 
dCardiovascular Research, Division of Medical & Radiological Sciences, The University of 
Edinburgh, UK, eD-659423 Unna, Germany, fCardiac Medicine, Imperial College, London, UK 
and gDepartment of Epidemiology and Biostatistics, Erasmus Medical Centre, Rotterdam, The 
Netherlands
Background: Little data is available concerning the prognostic implications of renal function 
abnormalities, their evolution over time and the e ects of nifedipine on such abnormalities in 
patients with stable angina pectoris.
Methods: The previously published ACTION trial compared long-acting nifedipine GITS 60 
mg once daily to placebo among 7665 patients. Standard laboratory tests including creatinine 
and uric acid were assessed at baseline, after 6 months, 2 and 4 years, and at the end of follow-
up. We assessed the impact of nifedipine on markers of renal dysfunction and determined 
whether evidence of renal failure alters the impact of nifedipine on the clinical outcome of 
patients with stable angina. 
Results: Uric acid was not while creatinine level and estimated creatinine clearance were 
potent conditionally independent predictors of total mortality and of cardiovascular clinical 
events. Relative to placebo, nifedipine reduced 6-month uric acid levels by 3% (P<0.001) of 
the baseline value. This di erence was maintained during long-term follow-up, was present 
both in normotensives and in hypertensives, and was not explained by di erences in diuretic 
therapy or allopurinol use. Nifedipine had no e ect on the occurrence of clinical renal failure. 
Relative to placebo, the e ects of nifedipine on cardiovascular death or myocardial infarction 
[hazard ratio (HR)=1.01, 95% con dence interval (CI) 0.88-1.17], any stroke or transient ischae-
mic attack (HR=0.73, 95% CI 0.60-0.88), new overt heart failure (HR=0.72, 95% CI 0.55-0.95), 
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and the need for any coronary procedure (HR=0.81, 95% CI 0.75-0.88) were consistent across 
strata of markers of renal dysfunction. 
Conclusions: We conclude that, in patients with stable angina, nifedipine reduces uric acid 
levels and does not a ect other markers of renal dysfunction. Renal dysfunction does not 
alter the e ects of nifedipine on clinical outcome. J Hypertens 25:1711-1718 © 2007 Lippincott 
Williams & Wilkins.
Journal of Hypertension 2007;25:1711-1718 
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INTRODUCTION
Renal dysfunction, recognized today as chronic kidney disease (CKD) [1], is an important pre-
dictor of outcome in patients with di erent cardiovascular (CV) conditions such as heart fail-
ure [2], myocardial infarction [3], established coronary artery disease (CAD) [4], and arterial 
hypertension [5,6]. Treatment of CV conditions may simultaneously in uence the evolution 
of renal function, and both angiotensin-converting enzyme (ACE)-inhibition and dieting have 
been shown to slow down progression of chronic renal failure in some conditions [7,8]. Dihy-
dropyridine calcium antagonists are both potent antihypertensive and antianginal medica-
tions widely used in the treatment of arterial hypertension and established CAD, in particular 
when the latter manifests itself clinically by symptoms of angina pectoris [9]. A recent review 
of data from hypertension trials [10] concluded that calcium channel blockers have no untow-
ard e ect on renal function and, when used in combination, do not alter the antiproteinuric 
e ects of ACE inhibitors or angiotensin receptor blockers. Furthermore, the treatment of hy-
pertensive patients with a dihydropyridine has been shown to increase estimated creatinine 
clearance or glomerular  ltration rate levels relative to treatment with a diuretic [11], or an 
ACE inhibitor [12,13]. Recent hypertension trials with calcium antagonists have established 
the e  cacy and safety of this class of drugs [14], and showed that earlier fears [15-19] were 
unjusti ed. Nonetheless, the evidence concerning the e  cacy and safety of calcium-antago-
nists from placebo-controlled studies was limited until the results of the ACTION (A Coronary 
disease Trial Investigating Outcome with Nifedipine GITS) study became available. Relative to 
placebo, ACTION examined the e ects on clinical outcomes of the dihydropyridine calcium 
antagonist nifedipine in a long-acting GITS (gastro-intestinal therapeutic system) formulation 
in 7665 patients with angina pectoris. The main conclusion was that the nifedipine GITS is 
safe in patients with stable symptomatic coronary disease and reduces both the occurrence 
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of new overt heart failure and the need for coronary interventions [20]. As ACTION was a 
randomized, double-blind, placebo-controlled trial, we could assess the impact of nifedipine 
GITS on markers of renal dysfunction and on renal failure, and clarify whether evidence of 
renal failure alters the impact of nifedipine on the clinical outcome of patients with stable 
angina as reported elsewhere.
METHODS
Design
The design, methods and main results of ACTION have been published previously [20,21]. 
Brie y, patients with stable symptomatic angina pectoris requiring treatment were random-
ized to the addition of either nifedipine GITS or matching placebo. The starting dose of nife-
dipine was 30 mg once daily, increasing to 60 mg once daily within 6 weeks if no evidence of 
intolerance was seen. In addition to angina, patients had to have either a history of myocardial 
infarction (MI), or proven angiographic CAD, or a positive exercise test or perfusion defect. The 
left-ventricular ejection fraction had to be at least 40%. The medical history at baseline was 
documented by prede ned entries in the case report form, or entered as free text. The latter 
were coded using the ICD-9 code [22]. After baseline assessments and treatment allocation, 
patients were seen at the outpatient clinic 2 weeks, 6 weeks and 6 months after randomiza-
tion; and from then onwards every 6 months. At each clinic visit, and at the end of the study, 
a standard 12-lead electrocardiogram was made. Blood pressure was recorded with a stan-
dard sphygmomanometer in the sitting position after 5 min of rest. Standard laboratory tests, 
which included sodium, potassium, creatinine and uric acid, were assessed in a casual blood 
sample at baseline, after 6 months, 2 years and 4 years and at the end of follow-up. Urinaly-
sis was not required by the ACTION protocol. The sponsor’s standard (serious) adverse event 
forms, based on the Council for International Organizations of Medical Sciences recommen-
dations, were used to report and document clinical events during follow-up. Adverse events 
were coded using the COSTART dictionary [23].
OUTCOMES
Following de nitions that have been used before [11], we de ned a serum creatinine level 
above 1.5 mg/dl (>133 µmol/l) in men or above 1.4 mg/dl (>124 µmol/l) in women, an estimat-
ed creatinine clearance below 60 ml/min (<1.00 ml/s) as estimated by the Cockroft and Gault 
formula [24], and a uric acid level of 7 mg/dl or higher (416 µmol/l) as markers of reduced renal 
function. In addition, we de ned potassium of 5 mmol/l or higher as hyperkalaemia, potas-
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sium below 3.5 mmol/l as hypokalaemia, sodium of 142 mmol/l or higher as hypernatraemia, 
sodium below 138 mmol/l as hyponatraemia and haemoglobin below 12.5 g/dl in men, or 
below 11.5 g/dl in women, as anaemia. 
Clinical events that occurred during ACTION follow-up were ascertained and classi ed as de-
scribed elsewhere [21]. 
Any stroke or transient ischaemic attack included disabling stroke as con rmed by the critical 
events committee, and uncon rmed stroke or transient ischaemic attack as reported by the 
investigator. Any coronary procedure included angiography, percutaneous intervention and 
bypass surgery. We de ned clinical renal failure as any adverse event coded by the following 
COSTART terms: acute kidney failure, creatinine clearance decreased, kidney failure, kidney 
function abnormal or uraemia. We de ned albuminuria as any adverse event coded by the 
COSTART terms albuminuria or proteinuria. 
STATISTICAL ANALYSIS.
We used standard statistical methods to analyse changes from baseline at 6 months. In ad-
dition, we obtained an overall P-value for comparing laboratory test levels between treat-
ment groups from a mixed e ects model for repeated measurements, using the SAS PROC 
mixed procedure (SAS Institute, Cary, North Carolina, USA). To assess whether nifedipine af-
fects long-term trends in the evolution of the laboratory tests considered, we used the slope 
adjusted for intercept (SLAIN) method [25]. SLAIN analysis estimates the slope and intercept 
for each patient, using the laboratory test values measured at baseline and during follow-up 
as dependent, and time as an independent variable. The slopes are then correlated with study 
drug treatment while adjusting for intercept. We used the same method to assess whether 
the long-term trend in estimated creatinine clearance was related to other patient character-
istics.
We used uni- and multivariate Cox proportional hazards analysis to assess whether creati-
nine, estimated creatinine clearance and uric acid were conditionally independent predictors 
of outcome. Multivariate analyses were always adjusted for age and gender, and for other 
predictors that contributed signi cantly to prediction of outcomes. As the formula used to 
estimate creatinine clearance takes age and gender into account, we did not adjust analyses 
for estimated creatinine clearance for these covariates.
To assess the impact of the three markers of renal dysfunction considered on outcomes and 
the e ect of nifedipine, we strati ed patients for the presence of the markers concerned at 
baseline using three strata: (i) none of the markers considered present; (ii) any one marker 
present; and (iii) two or three present. We took stratum-speci c and overall event rates as the 
total number of patients who had the event concerned, divided by the total person-years of 
follow-up ‘at risk’ of event. To assess the e ects of nifedipine relative to placebo, we used Cox 
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proportional hazards analysis with assigned treatment as the only covariate and obtained 
stratum-speci c and overall hazard ratios and their 95% con dence intervals (CI).
All analyses were performed based on intention-to-treat, using for laboratory tests all avail-
able values.
HJH/200759; Total nos of Pages: 8;
To assess the impact of the threemarkers of renal dysfunc-
tion considered on outcomes and the effect of nifedipine,
we stratified patients for the presence of the markers
concerned at baseline using three strata: (i) none of the
markers considered present; (ii) any one marker present;
and (iii) two or three present.We took stratum-specific and
overall event rates as the total number of patients who had
the event concerned, divided by the total person-years of
follow-up ‘at risk’ of event. To assess the effects of
nifedipine relative to placebo, we used Cox proportional
hazards analysis with assigned treatment as the only
covariate and obtained stratum-specific and overall hazard
ratios and their 95% confidence intervals (CI).
All analyses were performed based on intention-to-treat,
using for laboratory tests all available values.
Results
ACTION was completed as planned [21]; 7665 patients
were started on study medication (3825 nifedipine, 3840
placebo). Mean follow-up was the same for both treat-
ment groups, and was 4.94 years. Overall, follow-up was
97.3% complete [21].
The key baseline clinical features and laboratory test data
are given in Table 1. Few patients had a history of renal
failure or proteinuria reported as a concomitant medical
condition. Less than 5% of patients had an elevated base-
line creatinine level. Nonetheless, almost 40% of patients
had evidence of renal dysfunction based either on baseline
creatinine, or estimated creatinine clearance, or uric acid
values. Both treatment groups were well matched.
Changes from baseline at 6months of blood pressure and
the laboratory tests considered are given in Table 2. As
expected, nifedipine lowered blood pressure significantly
relative to placebo. Mean creatinine rose at 6months in
both treatment arms, and 0.007mg/dl more so in patients
assigned nifedipine than in patients assigned placebo.
Consequently, nifedipine also significantly reduced esti-
mated creatinine clearance. Themean change of uric acid
was 0.164mg/dl lower in patients assigned nifedipine
than in patients assigned placebo (P< 0.001), which
represents 3% of the baseline value. The change can
not be explained by a different percentage of patients
receiving diuretic therapy or allopurinol, as can be seen in
Table 3. Relative to placebo, nifedipine reduced potas-
sium by 0.035mmol/l (P< 0.001), which represents less
than 1% of the baseline value. Nifedipine had no effect
on sodium at 6months, and reduced haemoglobin by
0.122 g/dl (P< 0.001, less than 1% of the baseline value).
The long-term evolution of the renal function parameters
and laboratory tests considered is shown in Figs 1 and 2.
Differences between treatment groups in changes from
baseline at 6months for creatinine and creatinine clear-
ance in favour of placebo reversed to differences in favour
of nifedipine towards the end of the study. Follow-up uric
acid levels were significantly lower (P< 0.001, test for
repeated measurements) in patients assigned nifedipine
than in patients assigned placebo. The follow-up pattern
of potassium levels was similar to that of uric acid
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Table 1 Key clinical features and renal function parameters at
baseline
Nifedipine
(n¼3825)
Placebo
(n¼3840)
Mean (SD) age (years) 63.5 (9.3) 63.4 (9.3)
Male gender, n (%) 3041 (80) 3043 (79)
History of myocardial infarction, n (%) 1974 (52) 1924 (50)
History of coronary revascularisation, n (%) 1710 (45) 1719 (45)
Significant lesions on coronary angiogram, n (%)a 2632 (69) 2634 (69)
Normal coronary angiogram, n (%) 50 (1.3) 48 (1.3)
Angiography not performed or unknown, n (%) 1143 (30) 1158 (30)
Current NYHA class II–III, n (%) 1756 (46) 1776 (46)
History of peripheral CV disease, n (%)b 494 (13) 491 (13)
History of atrial fibrillation, n (%) 145 (3.8) 168 (4.4)
History of heart failure, n (%) 84 (2.2) 86 (2.2)
Ejection fraction <45%, n (%) 1056 (28) 1074 (28)
History of renal failure, n (%)c 43 (1.1) 49 (1.3)
History of proteinuriad 3 2
Risk factors
Any diabetes mellitus, n (%) 567 (15) 546 (14)
Treated with insulin, n (%) 86 (2.2) 97 (2.5)
Current smoker, n (%) 686 (18) 670 (17)
Mean (SD) total cholesterol (mg/dl) 208.3 (41.6) 209.4 (39.9)
Total cholesterol �193mg/dl (5.0mmol/l) 2382 (62) 2433 (63)
Mean (SD) systolic blood pressure (mmHg) 137.3 (18.8) 137.6 (18.6)
Mean (SD) diastolic blood pressure (mmHg) 79.9 (9.4) 79.8 (9.5)
Blood pressure 140/90mmHg or higher, n (%) 1975 (52) 2002 (52)
History of hypertension treated with drugs, n (%) 1602 (42) 1596 (42)
Blood pressure >140/90mmHg or history of
hypertension treated with drugs, n (%)
2509 (66) 2499 (65)
Mean (SD) body mass index (kg/m2) 27.5 (3.8) 27.5 (3.9)
Body mass index �30.0 kg/m2, n (%) 849 (22) 895 (23)
Treatment
b-blocker, n (%) 2979 (78) 3024 (79)
Any organic nitrate or vasodilator, n (%) 2911 (76) 2949 (77)
ACE-inhibitor or ARB, n (%) 847 (22) 865 (23)
Diuretic, n (%) 436 (11) 454 (12)
Lipid-lowering, n (%) 2384 (62) 2370 (62)
ASA or antiplatelet, n (%) 3405 (89) 3400 (89)
Vitamin K antagonist, n (%) 153 (4.0) 148 (3.9)
Digoxin, n (%) 32 (0.8) 51 (1.3)
Renal function parameters
Mean (SD) creatinine (mg/dl)e 1.09 (0.22) 1.09 (0.21)
>1.5 mg/dl (men) or >1.4 mg/dl
(women), n (%)
153 (4.1) 130 (3.4)
Mean (SD) creatinine clearance (ml/min)f 78.3 (23.6) 78.7 (24.3)
<60 ml/min, n (%) 811 (22) 837 (22)
Mean (SD) uric acid (mg/dl)g 5.90 (1.42) 5.92 (1.43)
�7mg/dl, n (%) 773 (21) 803 (22)
Any of the above abnormal, n (%) 1398 (37) 1443 (38)
Other laboratory tests
Mean (SD) potassium (mmol/l) 4.44 (0.41) 4.45 (0.40)
�5mmol/l, n (%) 356 (9.6) 382 (10.1)
<3.5mmol/l, n (%) 26 (0.7) 15 (0.4)
Mean (SD) sodium (mmol/l) 140.8 (2.75) 140.8 (2.58)
�142mmol/l, n (%) 1463 (39) 1501 (40)
<138mmol/l, n (%) 390 (10) 348 (9.2)
Mean (SD) haemoglobin (g/dl)h 14.5 (1.23) 14.4 (1.22)
<12.5 g/dl (men) or <11.5 g/dl (women), n (%) 103 (2.7) 117 (3.1)
Values in means and standard deviations (SD) or in numbers of patients and
percentages. NYHA, New York Heart Association; CV, cardiovascular; ACE,
angiotensin-converting enzyme; ARB, angiotensin receptor blocker. a Significant
lesions in any major coronary artery; b Stroke, transient ischemic attacks or
claudication; c ICD-9 581.9, 582.9, 583.0, 583.9, 585-587, 593.9; d ICD-9
791.0; e To convert values to micromole per liter, multiply by 88.339; f Cockroft
and Gault formula [24]; g To convert values to micromole per litre, multiply by
59.488; h To convert values to mmol/l, multiply by 0.6207.
Values in means and standard 
deviations (SD) or in numbers of 
patients and percentages. NYHA, 
New York Heart Association; CV, 
cardiovascular; ACE, angiotensin-
converting enzyme; ARB, angiotensin 
receptor blocker. aSigni cant 
lesions in any major coronary 
artery; bStroke, transient ischemic 
attacks or claudication; cICD-9 581.9, 
582.9, 583.0, 583.9, 585-587, 593.9; 
dICD-9 791.0; eTo convert values 
to micromole per liter, multiply by 
88.339; fCockroft and Gault formula 
[24]; gTo convert values to micromole 
per litre, multiply by 59.488; hTo 
convert values to mmol/l, multiply by 
0.6207.
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RESULTS
ACTION was completed as planned [21]; 7665 patients were started on study medication 
(3825 nifedipine, 3840 placebo). Mean follow-up was the same for both treatment groups, 
and was 4.94 years. Overall, follow-up was 97.3% complete [21].
The key baseline clinical features and laboratory test data are given in Table 1. Few patients 
had a history of renal failure or proteinuria reported as a concomitant medical condition. Less 
than 5% of patients had an elevated baseline creatinine level. Nonetheless, almost 40% of 
patients had evidence of renal dysfunction based either on baseline creatinine, or estimated 
creatinine clearance, or uric acid values. Both treatment groups were well matched.
Changes from baseline at 6 months of blood pressure and the laboratory tests considered 
are given in Table 2. As expected, nifedipine lowered blood pressure signi cantly relative to 
placebo. Mean creatinine rose at 6 months in both treatment arms, and 0.007 mg/dl more so 
in patients assigned nifedipine than in patients assigned placebo. Consequently, nifedipine 
also signi cantly reduced estimated creatinine clearance. The mean change of uric acid was 
0.164 mg/dl lower in patients assigned nifedipine than in patients assigned placebo (P<0.001), 
which represents 3% of the baseline value. The change cannot be explained by a di erent per-
centage of patients receiving diuretic therapy or allopurinol, as can be seen in Table 3. Relative 
to placebo, nifedipine reduced potassium by 0.035 mmol/l (P<0.001), which represents less 
than 1% of the baseline value. Nifedipine had no e ect on sodium at 6 months, and reduced 
haemoglobin by 0.122 g/dl (P<0.001, less than 1% of the baseline value).
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(P< 0.001, test for repeated measurements) but the
difference at 6months between treatment groups in
haemoglobin disappeared towards the end of the study.
SLAIN analysis showed that nifedipine had no effect on
the trend over time of any of the parameters shown.
The occurrence of laboratory test abnormalities among
patients with normal values at baseline who had at least
one measurement for the parameter concerned during
follow-up are shown in Table 4. Nifedipine significantly
reduced the occurrence of elevated creatinine (P¼ 0.018)
and uric acid (P< 0.001), but had no effect on the
occurrence of other abnormalities considered at any time
during follow-up.
Nifedipine had no effect on the incidence of clinical renal
failure (c.f. outcomes) during follow-up, which occurred
in total in 298 patients [155 nifedipine, 143 placebo,
hazard ratio (HR) 1.09, 95% CI¼ 0.87–1.37].
Results of unadjusted and adjusted Cox-regression
analysis (adjusted for age, gender, history of MI, atrial
fibrillation, peripheral cardiovascular disease, diabetes,
current smoking, left ventricular ejection fraction <45%,
and study treatment) showed that baseline creatinine level
was a significant predictor of total mortality (unadjusted
HR¼ 3.18, 95%CI¼ 2.31–4.37; adjustedHR¼ 1.61, 95%
CI¼ 1.14–2.28 per mg/dl increase), of cardiovascular
death or confirmed myocardial infarction (unadjusted
HR¼ 2.58, 95% CI¼ 1.92–3.45; adjusted HR¼ 1.75,
95% CI¼ 1.27–2.40 per mg/dl increase), and of new overt
heart failure (unadjusted HR¼ 4.13, 95% CI¼ 2.47–6.91,
adjusted HR¼ 1.98, 95% CI¼ 1.11–3.54 per mg/dl
increase). Unadjusted baseline creatinine was a significant
predictor of any stroke or transient ischaemic attack but
adjusted was not (unadjusted HR¼ 1.91, 95% CI¼ 1.27–
2.87, adjusted HR¼ 1.10, 95% CI¼ 0.71–1.70 per mg/dl
increase). Baseline creatinine was not a predictor of the
need for any coronary procedure.
Baseline estimated creatinine clearance was a significant
unadjusted and adjusted (as for creatinine but not for age
and sex) predictor of total mortality (unadjusted
HR¼ 1.20, 95% CI¼ 1.15–1.24; adjusted HR¼ 1.19,
4 Journal of Hypertension 2007, Vol 25 No
Table 2 Changes from baseline at 6months
Nifedipine (n¼3825) Placebo (n¼3840) P
Systolic blood pressure (mmHg)
Number of values at 6months 3628 3666
Mean change (SD) �6.26 (17.7) �0.48 (17.8) <0.001
Mean effect of nifedipine (95% CI) �5.78 (�6.60,�4.97)
Diastolic blood pressure (mmHg)
Number of values at 6months 3628 3666
Mean change (SD) �3.06 (9.6) 0.10 (9.8) <0.001
Mean effect of nifedipine (95% CI) �3.16 (�3.61, �2.72)
Creatinine (mg/dl)
Number of values at 6months 3494 3548
Mean change (SD) 0.014 (0.14) 0.007 (0.13) 0.02
Mean effect of nifedipine (95% CI) 0.007 (0.001, 0.014)
Creatinine clearance (ml/min)
Number of values at 6months 3454 3500
Mean change (SD) �1.38 (10.4) �0.81 (10.2) 0.02
Mean effect of nifedipine (95% CI) �0.56 (�1.05, �0.08)
Uric acid (mg/dl)
Number of values at 6months 3364 3418
Mean change (SD) �0.109 (0.99) 0.055 (0.99) <0.001
Mean effect of nifedipine (95% CI) �0.164 (�0.211, �0.116)
Potassium (mmol/l)
Number of values at 6months 3412 3482
Mean change (SD) �0.063 (0.41) �0.028 (0.41) <0.001
Mean effect of nifedipine (95% CI) �0.035 (�0.054, �0.015)
95% CI, 95% confidence interval.
Table 3 Percentage of patients receiving diuretics or allopurinol at baseline in both groups and mean percentage of time of administration
during follow-up
Baseline Follow-up
Nifedipine, n (%) Placebo, n (%) Nifedipine mean % of time (SD) Placebo mean % of time (SD)
Any diuretics, including aldosterone antagonists 435 (11.4) 448 (11.7) 17.97 (33.49) 20.21 (34.36)
Thiazides 257 (6.7) 281 (7.3) 8.68 (24.50) 11.80 (27.28)
Low-ceiling diuretics, excluding thiazides 73 (1.9) 47 (1.2) 1.90 (12.09) 1.80 (11.50)
High-ceiling diuretics 106 (2.8) 121 (3.2) 7.65 (22.35) 7.10 (21.35)
Potassium-sparing agents 88 (2.3) 93 (2.4) 3.94 (16.82) 3.67 (16.28)
Diuretics and potassium-sparing agents in combination 79 (2.1) 86 (2.2) 2.93 (14.93) 2.91 (15.00)
Allopurinol 117 (3.1) 100 (2.6) 3.98 (18.03) 3.68 (16.95)
95  CI, 95% con dence interval.
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(P< 0.001, test for repeated measurements) but the
difference at 6months between treatment groups in
haemoglobin disappeared towards the end of the study.
SLAIN analysis showed that nifedipine had no effect on
the trend over time of any of the parameters shown.
The occurrence of laboratory test abnormalities among
patients with normal values at baseline who had at least
one measurement for the parameter concerned during
follow-up are shown in Table 4. Nifedipine significantly
reduced the occurrence of elevated creatinine (P¼ 0.018)
and uric acid (P< 0.001), but had no effect on the
occurrence of other abnormalities considered at any time
during follow-up.
Nifedipine had no effect on the incidence of clinical renal
failure (c.f. outcomes) during follow-up, which occurred
in total in 298 patients [155 nifedipine, 143 placebo,
hazard ratio (HR) 1.09, 95% CI¼ 0.87–1.37].
Results of unadjusted and adjusted Cox-regression
analysis (adjusted for age, gender, history of MI, atrial
fibrillation, peripheral cardiovascular disease, diabetes,
current smoking, left ventricular ejection fraction <45%,
and study treatment) showed that baseline creatinine level
was a significant predictor of total mortality (unadjusted
HR¼ 3.18, 95%CI¼ 2.31–4.37; adjustedHR¼ 1.61, 95%
CI¼ 1.14–2.28 per mg/dl increase), of cardiovascular
death or confirmed myocardial infarction (unadjusted
HR¼ 2.58, 95% CI¼ 1.92–3.45; adjusted HR¼ 1.75,
95% CI¼ 1.27–2.40 per mg/dl increase), and of new overt
heart failure (unadjusted HR¼ 4.13, 95% CI¼ 2.47–6.91,
adjusted HR¼ 1.98, 95% CI¼ 1.11–3.54 per mg/dl
increase). Unadjusted baseline creatinine was a significant
predictor of any stroke or transient ischaemic attack but
adjusted was not (unadjusted HR¼ 1.91, 95% CI¼ 1.27–
2.87, adjusted HR¼ 1.10, 95% CI¼ 0.71–1.70 per mg/dl
increase). Baseline creatinine was not a predictor of the
need for any coronary procedure.
Baseline estimated creatinine clearance was a significant
unadjusted and adjusted (as for creatinine but not for age
and sex) predictor of total mortality (unadjusted
HR¼ 1.20, 95% CI¼ 1.15–1.24; adjusted HR¼ 1.19,
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Table 2 Changes from baseline at 6months
Nifedipine (n¼3825) Placebo (n¼3840) P
Systolic blood pressure (mmHg)
Number of values at 6months 3628 3666
Mean change (SD) �6.26 (17.7) �0.48 (17.8) <0.001
Mean effect of nifedipine (95% CI) �5.78 (�6.60,�4.97)
Diastolic blood pressure (mmHg)
Number of values at 6months 3628 3666
Mean change (SD) �3.06 (9.6) 0.10 (9.8) <0.001
Mean effect of nifedipine (95% CI) �3.16 (�3.61, �2.72)
Creatinine (mg/dl)
Number of values at 6months 3494 3548
Mean change (SD) 0.014 (0.14) 0.007 (0.13) 0.02
Mean effect of nifedipine (95% CI) 0.007 (0.001, 0.014)
Creatinine clearance (ml/min)
Number of values at 6months 3454 3500
Mean change (SD) �1.38 (10.4) �0.81 (10.2) 0.02
Mean effect of nifedipine (95% CI) �0.56 (�1.05, �0.08)
Uric acid (mg/dl)
Number of values at 6months 3364 3418
Mean change (SD) �0.109 (0.99) 0.055 (0.99) <0.001
Mean effect of nifedipine (95% CI) �0.164 (�0.211, �0.116)
Potassium (mmol/l)
Number of values at 6months 3412 3482
Mean change (SD) �0.063 (0.41) �0.028 (0.41) <0.001
Mean effect of nifedipine (95% CI) �0.035 (�0.054, �0.015)
95% CI, 95% confidence interval.
Table 3 Percentage of patients receiving diuretics or allopurinol at baseline in both groups and mean percentage of time of administration
during follow-up
Baseline Follow-up
Nifedipine, n (%) Placebo, n (%) Nifedipine mean % of time (SD) Placebo mean % of time (SD)
Any diuretics, including aldosterone antagonists 435 (11.4) 448 (11.7) 17.97 (33.49) 20.21 (34.36)
Thiazides 257 (6.7) 281 (7.3) 8.68 (24.50) 11.80 (27.28)
Low-ceiling diuretics, excluding thiazides 73 (1.9) 47 (1.2) 1.90 (12.09) 1.80 (11.50)
High-ceiling diuretics 106 (2.8) 121 (3.2) 7.65 (22.35) 7.10 (21.35)
Potassium-sparing agents 88 (2.3) 93 (2.4) 3.94 (16.82) 3.67 (16.28)
Diuretics and potassium-sparing agents in combination 79 (2.1) 86 (2.2) 2.93 (14.93) 2.91 (15.00)
Allopurinol 117 (3.1) 100 (2.6) 3.98 (18.03) 3.68 (16.95)
The long-term evolution of the renal function parameters and laboratory tests considered is 
shown in Figs 1 and 2. Di erences between treatment groups in changes from baseline at 6 
months for creatinine and creatinine clearance in favour of placebo reversed to di erences 
in favour of nifedipine towards the end of the study. Follow-up uric acid levels were signi -
cantly lower (P<0.001, test for repeated measurements) in patients assigned nifedipine than 
in patients assigned placebo. The follow-up pattern of potassium levels was similar to that of 
uric acid (P<0.001, test for repeated measurements) but the di erence at 6 months between 
treatment groups in haemoglobin disappeared towards the end of the study. SLAIN analysis 
showed that nifedipine had no e ect on the trend over time of any of the parameters shown.
Fig. 2
HJH/200759; Total nos of Pages: 8;
95% CI¼ 1.14–1.24 per 10ml/min decrease), of cardio-
vascular death or confirmed myocardial infarction
(unadjusted HR¼ 1.11, 95% CI¼ 1.07–1.15; adjusted
HR¼ 1.11, 95% CI¼ 1.07–1.14 per 10ml/min decrease),
of new overt heart failure (unadjusted HR¼ 1.16, 95%
CI¼ 1.09–1.24, adjusted HR¼ 1.13, 95% CI¼ 1.06–1.20
per 10ml/min decrease) and of any stroke or transient
ischaemic attack (unadjusted HR¼ 1.16, 95% CI¼ 1.11–
1.22, adjusted HR¼ 1.13, 95% CI¼ 1.08–1.18 per 10ml/
min decrease). Baseline estimated creatinine clearance
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Table 4 Laboratory tests abnormalities at any time during follow-up among patients with normal values at baseline
Abnormality
Nifedipine Placebo
P
Abnormality absent
at baseline
Present at any time
during follow-up (%)
Abnormality absent
at baseline
Present at any time
during follow-up (%)
Creatinine >1.5mg/dl (men) or >1.4mg/dl (women) 3514 268 (7.6) 3591 330 (9.2) 0.018
Creatinine clearance <60ml/min 2870 639 (22) 2881 627 (22) 0.65
Uric acid �7mg/dl 2844 702 (25) 2844 838 (29) <0.001
Any of above 2237 911 (41) 2219 977 (44) 0.026
Potassium �5mmol/l 3271 554 (17) 3298 605 (18) 0.13
Potassium <3.5mmol/l 3592 104 (2.9) 3659 82 (2.2) 0.078
Sodium �142mmol/l 2247 1257 (56) 2246 1306 (58) 0.14
Sodium <138mmol/l 3288 729 (22) 3370 755 (22) 0.82
Haemoglobin <12.5 g/dl (men) or <11.5 g/dl (women) 3554 315 (8.9) 3594 337 (9.4) 0.45
Long-term evolution of the laboratory tests. Nif, 
nifedipine; Pla, placebo.
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95% CI¼ 1.14–1.24 per 10ml/min decrease), of cardio-
vascular death or confirmed myocardial infarction
(unadjusted HR¼ 1.1 , 95% CI¼ 1.07–1.15; adjusted
HR¼ 1.1 , 95% CI¼ 1.07–1.14 per 10ml/min decrease),
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Table 4 Laboratory tes s abnormalities at any time during follow-up among patients with normal values at baseline
Abnormality
Nifed pine Placebo
P
Abnormality absent
at b selin
Present at any time
during follow-up (%)
Abnormality absent
at b selin
Present at any time
during follow-up (%)
Creatinine >1.5mg/dl (men) or >1.4mg/dl (women) 3514 268 (7.6) 3591 330 (9.2) 0.018
Creatinine cl arance <60ml/min 2870 639 (22) 2881 627 (22) 0.65
Uric acid �7mg/dl 2844 702 (25) 2844 838 (29) <0.0 1
Any of above 2237 911 (41) 2219 977 (44) 0.026
Potassium �5mmol/l 3271 554 (17) 3298 605 (18) 0.13
Potassium <3.5mmol/l 3592 104 (2.9) 3659 82 (2.2) 0.078
Sodium �142mmol/l 2247 1257 (56) 2246 1306 (58) 0.14
Sodium <138mmol/l 3288 729 (22) 3370 755 (22) 0.82
Haemoglobin <12.5 g/dl (men) or <11.5 g/dl (women) 3554 315 (8.9) 3594 337 (9.4) 0.45
Long-term evolutio  of the renal functio  
parameters. Nif, nifedipine; Pla, placebo.
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The occurrence of laboratory test abnormalities among patients with normal values at base-
line who had at least one measurement for the parameter concerned during follow-up are 
shown in Table 4. Nifedipine signi cantly reduced the occurrence of elevated creatinine 
(P=0.018) and uric acid (P<0.001), but had no e ect on the occurrence of other abnormalities 
considered at any time during follow-up.
Nifedipine had no e ect on the incidence of clinical renal failure (c.f. outcomes) during follow-up, which 
occurred in total in 298 patients [155 nifedipine, 143 placebo, hazard ratio (HR) 1.09, 95% CI=0.87-1.37].
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95% CI¼ 1.14–1.24 per 10ml/min decrease), of cardio-
vascular death or confirmed myocardial infarction
(unadjusted HR¼ 1.11, 95% CI¼ 1.07–1.15; adjusted
HR¼ 1.11, 95% CI¼ 1.07–1.14 per 10ml/min decrease),
of new overt heart failure (unadjusted HR¼ 1.16, 95%
CI¼ 1.09–1.24, adjusted HR¼ 1.13, 95% CI¼ 1.06–1.20
per 10ml/min decrease) and of any stroke or transient
ischaemic attack (unadjusted HR¼ 1.16, 95% CI¼ 1.11–
1.22, adjusted HR¼ 1.13, 95% CI¼ 1.08–1.18 per 10ml/
min decrease). Baseline estimated creatinine clearance
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Table 4 Laboratory tests abnormalities at any time during follow-up among patients with normal values at baseline
Abnormality
Nifedipine Placebo
P
Abnormality absent
at baseline
Present at any time
during follow-up (%)
Abnormality absent
at baseline
Present at any time
during follow-up (%)
Creatinine >1.5mg/dl (men) or >1.4mg/dl (women) 3514 268 (7.6) 3591 330 (9.2) 0.018
Creatinine clearance <60ml/min 2870 639 (22) 2881 627 (22) 0.65
Uric acid �7mg/dl 2844 702 (25) 2844 838 (29) <0.001
Any of above 2237 911 (41) 2219 977 (44) 0.026
Potassium �5mmol/l 3271 554 (17) 3298 605 (18) 0.13
Potassium <3.5mmol/l 3592 104 (2.9) 3659 82 (2.2) 0.078
Sodium �142mmol/l 2247 1257 (56) 2246 1306 (58) 0.14
Sodium <138mmol/l 3288 729 (22) 3370 755 (22) 0.82
Haemoglobin <12.5 g/dl (men) or <11.5 g/dl (women) 3554 315 (8.9) 3594 337 (9.4) 0.45
Results of unadjusted and adjusted Cox-regression analysis (adjusted for age, gender, history 
of MI, atrial  brillation, peripheral cardiovascular disease, diabetes, current smoking, left ven-
tricular ejection fraction <45%, and study treatment) showed that baseline creatinine level 
was a signi cant predictor of total mortality (unadjusted HR=3.18, 95% CI=2.31-4.37; adjusted 
HR=1.61, 95% CI=1.14-2.28 per mg/dl increase), of cardiovascular death or con rmed myocar-
dial infarction (unadjusted HR=2.58, 95% CI=1.92-3.45; adjusted HR=1.75, 95% CI=1.27-2.40 
per mg/dl increase), and of new overt heart failure (unadjusted HR=4.13, 95% CI=2.47-6.91, 
adjusted HR=1.98, 95% CI=1.11-3.54 per mg/dl increase). Unadjusted baseline creatinine was 
a signi cant predictor of any stroke or transient ischaemic attack but adjusted was not (unad-
justed HR=1.91, 95% CI=1.27-2.87, adjusted HR=1.10, 95% CI=0.71-1.70 per mg/dl increase). 
Baseline creatinine was not a predictor of the need for any coronary procedure.
Baseline estimated creatinine clearance was a signi cant unadjusted and adjusted (as for 
creatinine but not for age and sex) predictor of total mortality (unadjusted HR=1.20, 95% 
CI=1.15-1.24; adjusted HR=1.19, 95% CI=1.14-1.24 per 10 ml/min decrease), of cardiovascular 
death or con rmed myocardial infarction (unadjusted HR=1.11, 95% CI =1.07-1.15; adjusted 
HR=1.11, 95% CI=1.07-1.14 per 10 ml/min decrease), of new overt heart failure (unadjusted 
HR =1.16, 95% CI =1.09-1.24, adjusted HR=1.13, 95% CI=1.06-1.20 per 10 ml/min decrease) 
and of any stroke or transient ischaemic attack (unadjusted HR=1.16, 95% CI=1.11-1.22, ad-
justed HR=1.13, 95% CI=1.08-1.18 per 10 ml/ min decrease). Baseline estimated creatinine 
clearance was also a predictor of the need for any coronary procedure (unadjusted and ad-
justed HR=0.96, 95% CI 0.95-0.98 per 10 ml/min decrease).
Baseline uric acid was a signi cant predictor of total mortality only, and only when not ad-
justed for other predictors (unadjusted HR=1.07, 95% CI=1.01-1.13).
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E ects of nifedipine relative to placebo on clinical outcomes after strati cation for markers of 
renal dysfunction at baseline are shown in Fig. 3. Overall, nifedipine had no e ect on cardio-
vascular death or con rmed myocardial infarction (HR=1.01, 95% CI=0.88-1.17) and there was 
no evidence for an adverse e ect in patients with markers of renal dysfunction. Similarly, there 
was no evidence that the positive e ects of nifedipine on any stroke or transient ischaemic 
attack (overall HR=0.73, 95% CI=0.60-0.88), on new overt heart failure (overall HR=0.72, 95% 
CI=0.55-0.95), and on the need for coronary procedures (overall HR=0.81, 95% CI=0.75-0.88) 
as reported earlier [21,26] depended on the presence of markers of renal dysfunction.
Fig. 3
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predictors (unadjusted HR¼ 1.07, 95% CI¼ 1.01–1.13).
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comes after stratification for markers of renal dysfunction
at baseline are shown in Fig. 3. Overall, nifedipine had no
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markers of renal dysfunction. Similarly, there was no
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Cardiovascular death or confirmed myocardial infarction
Markers of renal dysfunction
None 226 (1.96)/205 (1.79)2389/2371
One 113 (2.09)/139 (2.45)1129/1181
Two or three 54 (4.46)/47 (4.01)269/262
All patients 393 (2.16)/391 (2.13)3787/3814
Hazard ratio (95% CI)
No. of patients
Nif/Pla
No. of patients with event (rate)
No. of patients No. of patients with event (rate)
No. of patients No. of patients with event (rate)
No. of patients No. of patients with event (rate)
Nifedipine/Placebo
2.01.51.00.5
Any stroke or transient ischaemic attack
Markers of renal dysfunction
None 102 (0.87)/131 (1.15)2389/2371
One 56 (1.04)/97 (1.72)1129/1181
Two or three 28 (2.34)/28 (2.42)269/262 
All patients 186 (1.02)/256 (1.40)3787/3814
Hazard ratio (95% CI)Nif/Pla Nifedipine/Placebo
2.01.51.00.50.0
Confirmed new overt heart failure
Markers of renal dysfunction
None 49 (0.42)/67 (0.58)2389/2371
One 21 (0.38)/40 (0.69)1129/1181
Two or three 16 (1.30)/13 (1.08)269/262 
All patients 86 (0.46)/120 (0.64)3787/3814
Hazard ratio (95% CI)Nif/Pla Nifedipine/Placebo
3.02.01.00.0
Any coronary procedure
Markers of renal dysfunction
None 654 (6.54)/762 (7.98)2389/2371
One 293 (6.15)/377 (7.77)1129/1181
Two or three 63 (5.84)/77 (7.58)269/262 
All patients 1010 (6.37)/1216 (7.89)3787/3814
Hazard ratio (95% CI)Nif/Pla Nifedipine/Placebo
1.21.00.80.60.4
Favours 
Nifedipine
Favours 
Placebo
Effects of nifedipine relative to placebo on clinical outcomes after stratification for markers of renal dysfunction at baseline. CI, confidence interval;
Nif, nifedipine; Pla, placebo.
E ects of nifedipine relative to placebo on clinical outcomes after strati cation for markers of renal 
dysfunction at baseline. CI, con dence interval; Nif, nifedipine; Pla, placebo.
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DISCUSSION
Our main  nding is that four out of ten patients have any of the three markers of reduced renal 
function that we could assess: (i) an elevated creatinine level; (ii) a reduced estimated creati-
nine clearance; and/or (iii) an elevated uric acid level. We emphasize that we were unable to 
include urinary albumin excretion in the present analysis as this was not measured in ACTION. 
Nonetheless, our  ndings con rm those from the HOPE study [27], and support the notion 
that coronary artery disease and chronic kidney disease are related phenomena [28,29]. 
We found that an elevated creatinine level and a reduced estimated creatinine clearance are 
independent predictors of death, MI, stroke and overt heart failure in patients with stable an-
gina. In addition, we found a marked relationship between cardiovascular clinical events and 
the number of renal function markers that was abnormal (Fig. 3). This con rms earlier  ndings 
in patients with a variety of cardiovascular conditions [30]. Interestingly, no such relationship 
was observed for the need for any coronary procedure. This suggests that recurrent angina, 
the primary indication for coronary revascularisation, is not related to renal dysfunction. The 
rate of reduction of estimated creatinine clearance in the present study was approximately 1 
ml/min/year, which is less than the rapid reduction observed after myocardial infarction [31], 
and is similar to that accompanying natural aging [32].
Nifedipine is known to have renal vasodilatory e ects [33] and may therefore lower uric acid 
levels. Our data show that this is indeed the case as uric acid levels in patients assigned nife-
dipine were signi cantly below those of patients assigned placebo throughout the study de-
spite both treatment groups receiving similar amounts of diuretic therapy and allopurinol. 
Nifedipine lowered uric acid levels, both in hypertensives and in normotensives at baseline. 
In all patients combined, the di erence between mean uric acid changes from baseline at 6 
months was 3% of the baseline value (Table 2). In the LIFE trial, which compared losartan with 
atenolol in patients with hypertension, the mean baseline uric acid level was 330.09 µmol/l, 
which is equivalent to 5.55 mg/dl and is similar to the baseline level in ACTION (Table 1). In 
LIFE the baseline-to-end-of-study increase in uric acid in patients assigned atenolol was 27.4 
µmol/l more than in patients assigned losartan, which represents 8% of the baseline value. 
This di erence has been claimed to account for a 29% of the bene t in CV outcome of patients 
assigned losartan in LIFE, and was attributed to the ‘unique uric-acid lowering e ect of losar-
tan’ [34]. Although the e ect of nifedipine on uric acid levels may be less marked, our data 
show that losartan is not alone in this regard. Relative to placebo, nifedipine also signi cantly 
reduced the number of patients who developed an elevated uric acid level at any time during 
follow-up (Table 4).
Nifedipine had no e ect on the incidence of clinical renal failure during follow-up. This is in 
agreement with the fact that in our data nifedipine had little or no e ect on renal function 
parameters other than on uric acid (Table 4). In a trial comparing nifedipine with diuretics in 
patients with hypertension, nifedipine was associated with lower creatinine values than di-
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uretics [11]. These two  ndings together imply that diuretics negatively a ect renal function, 
whereas nifedipine does not. 
The presence of renal function abnormalities did not a ect the e ect of nifedipine on out-
comes in the ACTION trial (c.f. Figure 3). The addition of nifedipine GITS to conventional 
treatment of angina pectoris had no e ect on major cardiovascular event-free survival while 
reducing the need for coronary angiography and interventions [21]. In patients with blood 
pressures of 140/90 mmHg or higher, the combined incidence of all-cause mortality, myocar-
dial infarction, refractory angina, heart failure, stroke, and peripheral revascularisation was 
reduced by 13% [26]. The fact that we could not show that these e ects depend on the pres-
ence of renal function abnormalities is important clinically because this shows that impaired 
renal function is not a contra-indication when administering nifedipine to patients with stable 
angina pectoris.
In conclusion, our data con rm that in patients with stable angina, creatinine and estimat-
ed creatinine clearance are potent independent predictors of total mortality, cardiovascular 
death or myocardial infarction, new overt congestive heart failure, and stroke or transient 
ischemic attack. On the other hand, uric acid is not a predictor of any of these.
In these patients, nifedipine reduces uric acid levels both in patients with and without hyper-
tension. Otherwise, nifedipine has little e ect on renal function parameters and its e ects on 
outcome do not depend on their presence. These properties may be clinically relevant. 
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Outcomes With Nifedipine GITS or Co-
Amilozide in Hypertensive Diabetics and 
Nondiabetics in Intervention as a Goal in 
Hypertension (INSIGHT)
Giuseppe Mancia, Morris Brown, Alain Castaigne, Peter de Leeuw, Christopher R. Palmer, Talma 
Rosenthal, Gilbert Wagener, Luis M. Ruilope
Abstract—To investigate the impact of treatment on cardiovascular mortality and morbidity, 
we assessed outcomes in patients with hypertension and diabetes who received co-amilozide 
or nifedipine in the International Nifedipine GITS Study: Intervention as a Goal in Hyperten-
sion. Participants had to be 55 to 80 years of age, with hypertension (≥150/95 or ≥160 mm Hg) 
and at least one additional cardiovascular risk factor. Patients received 30 mg nifedipine once 
daily or co-amilozide (25 mg hydrochlorothiazide and 2.5 mg amiloride) daily. Doses were 
doubled if target blood pressures (<140/90 mm Hg) were not achieved. Primary (composite 
of cardiovascular death, myocardial infarction, heart failure, and stroke) and secondary out-
comes (composite of primary outcomes, including all-cause mortality and death from vascu-
lar and nonvascular causes) were assessed by means of intent-to-treat analyses. There was no 
signi cant di erence in the incidence of primary outcomes between nifedipine-treated and 
co-amilozide-treated patients with diabetes at baseline (n=1302) (8.3% versus 8.4%; relative 
risk 0.99, 95% CI 0.69 to 1.42; P=1.00). A signi cant bene t for nifedipine-treated patients was 
seen for the composite secondary outcome (14.2% versus 18.7%; relative risk 0.76, 95% CI 0.59 
to 0.97; P=0.03). Among patients without diabetes at baseline (n=5019), there was a signi -
cant di erence in the incidence of new diabetes (nifedipine 4.3% versus co-amilozide 5.6%, 
P=0.023). Nifedipine GITS once daily is as e ective as diuretic therapy in reducing cardiovas-
cular complications in hypertensive diabetics. Nifedipine-treated patients were also less likely 
to have diabetes or have secondary events (a composite of all-cause mortality, death from a 
vascular cause, and death from a nonvascular cause) than co-amilozide recipients. Our results 
suggest that nifedipine could be considered as  rst-line therapy for hypertensive diabetics. 
(Hypertension. 2003;41:431-436.)
Key Words: calcium channel blockers, diabetes mellitus, diuretics, nifedipine, mortality, mor-
bidity
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Hypertensive patients with diabetes mellitus must receive antihypertensive drugs because 
this therapeutic intervention substantially lowers their high absolute risk of cardiovascular 
morbidity and mortality.[1,2] Whether the bene t depends on the reduction in blood pres-
sure itself or is due (at least in part) to the di erent protective properties of the drugs used 
is a matter of debate. This is because trials have so far provided con icting results: In some 
trials, diabetic patients receiving treatment with ACE inhibitors or angiotensin II antagonists 
had lower rates of cardiovascular morbidity and mortality than patients receiving diuret-
ics, β-blockers, or calcium antagonists.[3- 6] This has also been the case in the Appropriate 
Blood pressure Control in Diabetes (ABCD) trial, in which a comparison of the calcium channel 
blocker nisoldipine and the ACE inhibitor enalapril in patients with diabetes and hyperten-
sion revealed a signi cantly higher incidence of fatal and nonfatal myocardial infarction in 
the nisoldipine recipients.[4] However, further analysis of patients enrolled in the ABCD trial 
identi ed additional myocardial infarctions in both treatment groups that reduced the above 
di erence without altering the overall conclusions of the study.[7] Furthermore, in several 
other trials, comparisons between new and conventional treatments as well as between ACE 
inhibitors and calcium antagonists have shown no substantial di erences in cardiovascular 
morbidity and mortality rates.[8 -12] In a review of trials completed between 1990 and 2000, 
Kaplan[13] concluded that there are no concerns about the use of calcium channel blockers 
in patients with diabetes. 
The intervention as a Goal in Hypertension (INSIGHT) study demonstrated that nifedipine and 
diuretic therapy with co-amilozide had comparable e  cacy in preventing overall cardiovas-
cular or cerebrovascular complications in patients with hypertension and at least one addi-
tional cardiovascular risk factor.[14] In this report, we describe cardiovascular outcomes in 
patients enrolled in INSIGHT who had diabetes at baseline.
METHODS
Design of the Trial
The design of INSIGHT has been described previously.[14] In brief, patients were randomly as-
signed to receive either 30 mg nifedipine daily or co-amilozide (25 mg hydrochlorothiazide and 
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2.5 mg amiloride) daily (step 1). Patients whose blood pressure fell by <20/10 mm Hg or remained 
>140/90 mm Hg could receive 1 of 4 dose-titration steps (steps 2 to 5): dose doubling of the ran-
domized drug; addition of 25 mg atenolol daily (or 5 mg enalapril daily if atenolol was contraindi-
cated); dose doubling of the additional drug; and addition of any other antihypertensive drug ex-
cept calcium channel blockers or diuretics. Use of add-on medications (steps 3 to 5) was recorded 
during the study. The inclusion criteria for INSIGHT have been described previously and included 
age 55 to 80 years, hypertension (blood pressure ≥150/95 or ≥160 mm Hg), and at least one ad-
ditional cardiovascular risk factor, which could include diabetes mellitus.[14] 
All end points were assessed by an independent critical events committee. The progress of the 
study was monitored by an independent data and safety monitoring committee. The study was 
performed according to the principles of good clinical practice and the declaration of Helsinki and 
was approved by the relevant ethics committees. All patients gave informed written consent.
Blood pressure was measured 3 times after a 5-minute rest. After the initial dose-titration period, 
patients returned for assessment 3 times per year when blood pressure and heart rate were record-
ed. The primary outcome was the composite end point of incidence of cardiovascular death, myo-
cardial infarction, heart failure, and stroke. The secondary outcome was the composite of all-cause 
death, death from a vascular cause, and death from a nonvascular cause. As part of our analysis, 
we also assessed the number of patients in whom diabetes mellitus developed during treatment. 
Diabetes at baseline was diagnosed using the 1985 World Health Organization (WHO) de nition 
(i.e., the most recent de nition available at the time of the initiation of the INSIGHT study), that is, a 
random capillary blood glucose measurement >11.0 mmol/L or use of antidiabetic drugs. 
STATISTICAL ANALYSIS
The subgroup analyses in the diabetic population in INSIGHT and of the development of dia-
betes within the nondiabetic population were prespeci ed in the study protocol. INSIGHT was 
designed to have 90% power to detect a 25% relative di erence between treatment groups 
at the 5% (2-sided) level of signi cance.[14] In the present study, relative risks and 95% CIs 
are quoted for the randomized comparisons. Odds ratios and 95% CIs are quoted for the non-
randomized comparisons of patients who had diabetes at baseline with those who were not 
diabetic. Logistic regression was used to compare multivariate and univariate results to adjust 
for possible e ects of age and proteinuria (variables shown to be modestly imbalanced within 
the diabetic and nondiabetic subgroups). The Fisher exact test was used to compare all cat-
egoric data. All analyses were carried out using SPSS version 10.0 (SPSS Inc, 2001).
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RESULTS
Patient Characteristics
A total of 6321 patients were enrolled in INSIGHT, of whom 1302 had diabetes at baseline. 
Demographic characteristics and risk factors were well balanced between the nifedipine and 
co-amilozide treatment groups. Combining the treatment groups revealed some di erences 
between diabetics and nondiabetics. Diabetics were less likely than nondiabetics to have a 
family history of cardiovascular disease, to have hypercholesterolemia, or to be smokers but 
were more likely to have proteinuria (Table 1). Mean age was slightly lower in the nifedipine-
treated patients with diabetes than in the co-amilozide recipients (66.0 versus 65.1 years), 
whereas among nondiabetics, patients in the nifedipine group were more likely to have pro-
teinuria than patients in the co-amilozide group (Table 1). 
failure, major cardiovascular events, cardiovascular deaths, or
total deaths (P�0.05 in all cases) (Table 4).
Because of the slight imbalances in baseline characteristics
(Table 1), logistic regression analyses were performed to
compare primary and secondary outcomes, with adjustment
for age and proteinuria. Conclusions remained unchanged in
both cases, so only the univariate analyses are reported.
In the group without diabetes at baseline, the percentages
of patients with primary outcomes were similar in nifedipine-
treated and co-amilozide–treated patients (Figure). In the
nifedipine-treated group, 5.8% of patients had primary out-
comes, compared with 5.1% in the co-amilozide–treated
group (relative risk, 1.15; 95% CI, 0.91, 1.45; P�0.24).
There was also no significant difference in the percentages of
nifedipine-treated and co-amilozide–treated patients who had
secondary outcomes (11.6% versus11.0%; relative risk, 1.06;
95% CI, 0.91, 1.24; P�0.48) (Figure).
In the combined nifedipine-treated and co-amilozide–
treated groups, nondiabetic patients were less likely to have
primary outcomes than diabetic patients (5.4% versus 8.4%;
odds ratio, 1.54, 95% CI, 1.24, 1.90; P�0.001) (Figure).
Similarly, significantly fewer nondiabetic patients had sec-
ondary outcomes than diabetic patients (11.3% versus 16.4%;
odds ratio, 1.46; 95% CI, 1.26, 1.68; P�0.001) (Figure).
The percentages of patients with individual cardiovascular
outcomes were generally similar between the treatment
groups within the diabetic and nondiabetic subgroups. Mean-
ingful statistical analyses could not be conducted for most
individual cardiovascular events because of the small number
of patients who had each event. Nondiabetic patients were
more likely to have no primary or secondary events, and there
was no significant difference between the nifedipine-treated
and co-amilozide–treated patients (11.6% versus 11.0%, re-
spectively; P�0.48).
Incidence of New Diabetes Mellitus
The number of patients with no diabetes at baseline who had
newly diagnosed diabetes mellitus during the study was
significantly lower in the nifedipine-treated group (n�136,
4.3%) than in the co-amilozide–treated group (n�176, 5.6%;
P�0.023). Among patients with newly diagnosed diabetes, 5
nifedipine-treated patients (0.2%) and 6 co-amilozide–treated
patients (0.2%) had primary events during the INSIGHT
follow-up.
Discussion
The present analysis of data collected from a relatively large
subgroup of diabetic hypertensive patients enrolled in IN-
SIGHT showed that the incidence of the composite end point
of myocardial infarction, stroke, congestive heart failure, and
cardiovascular death in patients receiving antihypertensive
treatment with nifedipine GITS was similar to that seen with
co-amilozide (a combination of a thiazide and a potassium-
retaining diuretic). However, compared with diuretics, treat-
ment with nifedipine-GITS was associated with a lower
incidence of (1) vascular and nonvascular deaths combined
and (2) new cases of diabetes mellitus. This suggests that a
long-acting dihydropyridine calcium channel blocker is as
TABLE 1. Demographic Characteristics and Risk Factors at Baseline
Diabetes* No Diabetes*
Nifedipine
n (%)
Co-Amilozide
n (%)
Combined
n (%)
Nifedipine
n (%)
Co-Amilozide
n (%)
Combined
n (%)
Patients, n 649 653 1302 2508 2511 5019
Demographic characteristics
Gender
Men 309 (47.6) 315 (48.2) 624 (47.9) 1147 (45.7) 1158 (46.1) 2305 (45.9)
Women 340 (52.4) 338 (51.8) 678 (52.1) 1361 (54.3) 1353 (53.9) 2714 (54.1)
Age, y
�60 144 (22.2) 130 (19.9) 274 (21.0) 617 (24.6) 573 (22.8) 1190 (23.7)
60–70 327 (50.4) 318 (48.7) 645 (49.5) 1186 (47.3) 1238 (49.3) 2424 (48.3)
�70 178 (27.4) 205 (31.4) 383 (29.4) 705 (28.1) 700 (27.9) 1405 (28.0)
Risk factors
Hypercholesterolemia 225 (34.7) 220 (33.7) 445 (34.2) 1421 (56.7) 1424 (56.7) 2845 (56.7)
Smoker 89 (13.7) 86 (13.2) 175 (13.4) 802 (32.0) 816 (32.5) 1618 (32.2)
Family history of MI† 72 (11.1) 55 (8.4) 127 (9.8) 576 (23.0) 605 (24.1) 1181 (23.5)
LVH 77 (11.9) 69 (10.6) 146 (11.2) 261 (10.4) 267 (10.6) 528 (10.5)
Coronary heart disease 39 (6.0) 47 (7.2) 86 (6.6) 170 (6.8) 150 (6.0) 320 (6.4)
Left-ventricular strain 43 (6.6) 35 (5.4) 78 (6.0) 158 (6.3) 162 (6.5) 320 (6.4)
Previous MI 41 (6.3) 38 (5.8) 79 (6.1) 154 (6.1) 150 (6.0) 304 (6.1)
Peripheral vascular disease 37 (5.7) 39 (6.0) 76 (76) 143 (5.7) 134 (5.3) 277 (5.5)
Proteinuria 45 (6.9) 38 (5.8) 83 (6.4) 53 (2.1) 34 (1.4) 87 (1.7)
*No significant differences between the nifedipine- and co-amilozide–treated groups.
†In parent or sibling before 50 years of age.
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*No signi cant di erences between the nifedipine- and co-amilozide-treated groups.
†In parent or sibling before 50 years of age.
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BLOOD PRESSURE CONTROL AND HEART RATE
Decreases in blood pressure were similar in nifedipine-treated and co-amilozide-treated pa-
tients in the subgroups with and without diabetes (Table 2). In patients with diabetes, systolic 
blood pressure decreased from 175 mm Hg in nifedipine-treated patients and 176 mm Hg 
in co-amilozide-treated patients at baseline to 144 and 145 mm Hg, respectively, at the  nal 
visit. In both the nifedipine-treated and co-amilozide-treated groups, diastolic blood pressure 
decreased from 98 mm Hg at baseline to 82 mm Hg at the  nal visit. Similar changes in systolic 
and diastolic blood pressure were noted in the patients who did not have diabetes at baseline. 
Heart rate decreased to a similar slight extent in nifedipine-treated and co-amilozide-treated 
patients both in the subgroups with and without diabetes (Table 2). 
effective as conventional antihypertensive drugs for prevent-
ing major nonfatal and fatal cardiovascular events in patients
with diabetes and hypertension. It also suggests that calcium
channel blockers may have some advantages when all events
are taken into account and that they are better than conven-
tional treatments at counteracting the greater tendency in
hypertensive patients for the development of diabetes
mellitus.15
In nondiabetic patients enrolled in INSIGHT, the absolute
difference in the percentages of patients with new diabetes
between the 2 treatment groups was 1.3% over a treatment
duration of �4 years. This was not due to differences in the
number of patients who received an ACE inhibitor as added
treatment because this was similar in the nifedipine and
diuretic group. The difference in the development of new
diabetes was not sufficient to cause a difference in cardio-
vascular morbidity and mortality rates over the same period.
However, if the trend continues, it is likely to lead to risk
reductions over 10 to 20 years because (1) the increased risk
of cardiovascular disease brought about by diabetes is con-
siderable,16 and (2) this is the case both for native diabetes
and for diabetes induced by antihypertensive drugs.17 A
number of studies have reported increased risks for the
development of diabetes in patients treated with diuretics and
�-blockers,15,18–20 but it appears that ACE inhibitors and
calcium channel blockers have either no effect or reduce the
likelihood of new diabetes.21,22 Assessing the incidence of
new diabetes should therefore be part of all trials t at aim to
determine the protective effect of antihypertensive drugs and
predict the benefits beyond the actual trial duration. To date,
this has been done only in some trials, most of which have
shown that the incidence of new diabetes is less with calcium
antagonists,14 ACE inhibitors, and angiotensin II antago-
nists3,5,23 than with diuretics and �-blockers, which appear to
increase the incidence of new diabetes beyond that seen in
untreated hypertensive individuals.24 This may be accounted
for by the different effects on insulin sensitivity, which are
favorable with calcium antagonists, ACE inhibitors, and
angiotensin II antagonists and unfavorable with diuretics and
�-blockers.25,26
The reduction in systolic and diastolic blood pressure was
similar in the diabetic and nondiabetic subgroups of IN-
SIGHT, regardless of whether treatment was based on nifed-
ipine or diuretics. In the nondiabetic subgroup, however,
on-treatment systolic blood pressure was slightly
(1.8 mm Hg) but significantly less in the diuretic than in the
nifedipine-treated patients, with no difference in the inci-
dence of primary or secondary outcomes. This could be due
to the fact that nifedipine has direct organ-protective proper-
ties in addition to the protection provided by the blood
pressure lowering per se. It could also mean, however, that
even in the high-risk patients enrolled in the INSIGHT study,
a blood pressure difference of 1.8 mm Hg was too small to
have a pathophysiological effect, that the duration of the
study was too short for differences in outcome to become
TABLE 2. Changes in Blood Pressure and Heart Rate
From Baseline
Nifedipine Co-Amilozide P
Diabetes
Systolic blood pressure, mm Hg
Baseline 174.7 (15.8) 175.7 (15.1) 0.263
Final 144.6 (16.1) 143.6 (17.0) 0.272
Change 30.1 (18.4)* 32.1 (20.0)* 0.065
Diastolic blood pressure, mm Hg
Baseline 98.2 (9.2) 97.7 (9.1) 0.329
Final 81.9 (9.4) 82.4 (9.7) 0.426
Change 16.3 (10.4)* 15.4 (10.8)* 0.119
Heart rate, bpm
Baseline 78.0 (10.5) 78.3 (10.0) 0.559
Final 75.9 (11.1) 75.4 (11.0) 0.386
Change 2.1 (11.9)* 2.9 (11.6)* 0.186
No diabetes
Systolic blood pressure, mm Hg
Baseline 172.0 (14.7) 171.7 (14.9) 0.500
Final 142.6 (15.6) 140.8 (15.1) �0.001
Change 29.4 (17.8)* 30.9 (18.0)* 0.002
Diastolic blood pressure, mm Hg
Baseline 99.0 (8.3) 99.0 (8.3) 0.771
Final 82.6 (8.9) 82.5 (8.6) 0.541
Change 16.4 (10.2)* 16.5 (10.2)* 0.773
Heart rate, bpm
Baseline 76.3 (9.7) 76.0 (9.8) 0.303
Final 73.7 (10.7) 72.7 (10.5) 0.001
Change 2.6 (11.4)* 3.3 (11.0)* 0.024
Values are mean (SD).
*P�0.001 for within-group comparisons.
TABLE 3. Use of Add-On Medications to Achieve Blood Pressure Targets
Diabetes No Diabetes
Nifedipine n (%) Co-Amilozide n (%) Nifedipine n (%) Co-Amilozide n (%)
Patients receiving add-on medication 279 (43.0) 320 (49.0) 906 (36.1) 959 (38.2)
Steps 3–5
One additional drug, steps 3–4* 214 (33.0) 239 (36.5) 726 (28.9) 708 (28.2)
Two or more additional drugs, step 5† 65 (10.0) 81 (12.4) 180 (7.2) 251 (10.0)
P�0.027‡ P�0.008‡
*Enalapril (or atenolol if enalapril was contraindicated); †enalapril (or atenolol) and any other antihypertensive drug except
calcium-channel blockers or diuretics.
‡�2 test for trend.
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Values are mean (SD).
*P<0.001 for within-group comparisons.
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Diabetic patients treated with co-amilozide required signi cantly more add-on medication 
than patients treated with nifedipine (P=0.027). Patients with diabetes required more add-on 
therapy (steps 3 to 5) than nondiabetic patients (Table 3). Among the patients with diabetes 
at baseline, 57% of nifedipine-treated patients and 51% of co-amilozide recipients received 
no additional drugs, compared with 64% and 62%, respectively, among nondiabetics. ACE 
inhibitors were administered to 1933 patients (61%) in the nifedipine group and 1880 pa-
tients (59%) in the co-amilozide group. Among patients with diabetes at baseline, 697 (54%) 
received an ACE inhibitor, compared with 1811 (36%) of the patients with no diabetes. 
effective as conventional antihyp rtensive drugs for prevent-
ing major nonfatal and fatal cardiovascular events in patients
with diabetes and hypertension. It also suggests that calcium
channel blockers may have some advantages when all events
are taken into account and that they are better than conven-
tional treatments at counteracting the greater tendency in
hypertensive patients for the development of diabetes
mellitus.15
In nondiabetic patients enrolled in INSIGHT, the absolute
difference in the percentages of patients with new diabetes
between the 2 treatment groups was 1.3% over a treatment
duration of �4 years. This was not due to differences in the
number of patients who received an ACE inhibitor as added
treatment because this was similar in the nifedipine and
diuretic group. The difference in the development of new
diabetes was not sufficient to cause a difference in cardio-
vascular morbidity and mortality rates over the same period.
However, if the trend continues, it is likely to lead to risk
reductions over 10 to 20 years because (1) the increased risk
of cardiovascular disease brought about by diabetes is con-
siderable,16 and (2) this is the case both for native diabetes
and for diabetes induced by antihypertensive drugs.17 A
number of studies have reported increased risks for the
development of diabetes in patients treated with diuretics and
�-blockers,15,18–20 but it appears that ACE inhibitors and
calcium channel blockers have either no effect or reduce the
likelihood of new diabetes.21,22 Assessing the incidence of
new diabetes should therefore be part of all trials that aim to
determine the protective effect of antihypertensive drugs and
predict the benefits beyond the actual trial duration. To date,
this has been done only in some trials, most of which have
shown that the incidence of new diabetes is less with calcium
antagonists,14 ACE inhibitors, and angiotensin II antago-
nists3,5,23 than with diuretics and �-blockers, which appear to
increase the incidence of new diabetes beyond that seen in
untreated hypertensive individuals.24 This may be accounted
for by the different effects on insulin sensitivity, which are
favorable with calcium antagonists, ACE inhibitors, and
angiotensin II antagonists and unfavorable with diuretics and
�-blockers.25,26
The reduction in systolic and diastolic blood pressure was
similar in the diabetic and nondiabetic subgroups of IN-
SIGHT, regardless of whether treatment was based on nifed-
ipine or diuretics. In the nondiabetic subgroup, however,
on-treatment systolic blood pressure was slightly
(1.8 mm Hg) but significantly less in the diuretic than in the
nifedipine-treated patients, with no difference in the inci-
dence of primary or secondary outcomes. This could be due
to the fact that nifedipine has direct organ-protective proper-
ties in addition to the protection provided by the blood
pressure lowering per se. It could also mean, however, that
even in the high-risk patients enrolled in the INSIGHT study,
a blood pressure difference of 1.8 mm Hg was too small to
have a pathophysiological effect, that the duration of the
study was too short for differences in outcome to become
TABLE 2. Changes in Blood Pressure and Heart Rate
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Final 81.9 (9.4) 82.4 (9.7) 0.426
Change 16.3 (10.4)* 15.4 (10.8)* 0.119
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Baseline 78.0 (10.5) 78.3 (10.0) 0.559
Final 75.9 (11.1) 75.4 (11.0) 0.386
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TABLE 3. Use of Add-On Medications to Achieve Blood Pressure Targets
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Nifedipine n (%) Co-Amilozide n (%) Nifedipine n (%) Co-Amilozide n (%)
Patients receiving add-on medication 279 (43.0) 320 (49.0) 906 (36.1) 959 (38.2)
Steps 3–5
One additional drug, steps 3–4* 214 (33.0) 239 (36.5) 726 (28.9) 708 (28.2)
Two or more additional drugs, step 5† 65 (10.0) 81 (12.4) 180 (7.2) 251 (10.0)
P�0.027‡ P�0.008‡
*Enalapril (or atenolol if enalapril was contraindicated); †enalapril (or atenolol) and any other antihypertensive drug except
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*Enalapril (or atenolol if enalapril was contraindicated); †enalapril (or atenolol) and any other 
antihypertensive drug except calcium-channel blockers or diuretics.
‡ χ2 test for trend.
OUTCOMES IN DIABETIC AND NONDIABETIC PATIENTS
In the group with diabetes at baseline, the percentages of patients with primary outcomes 
were similar in the nifedipine-treated and co-amilozide-treated groups (Figure). Among pa-
tients given ACE inhibitors, there were no signi cant di erences in the percentage of patients 
with primary or secondary end points between the nifedipine and co-amilozide groups. Simi-
larly, there was no signi cant di erence in primary and secondary outcomes between the 
treatment groups within the subgroup of patients who were not given ACE inhibitors. In the 
nifedipine-treated group, 8.3% of patients had primary outcomes, compared with 8.4% in the 
co-amilozide-treated group (relative risk 0.99; 95% CI 0.69, 1.42; P=1.00). Signi cantly fewer 
nifedipine-treated patients had secondary outcomes (a composite of all-cause death, death 
from a vascular cause, and death from a nonvascular cause) than co-amilozide-treated pa-
tients (14.2% versus 18.7%; relative risk 0.76; 95% CI 0.59, 1.42; P=0.03) (Figure). There were 
no signi cant di erences between the nifedipine-treated and co-amilozide-treated groups in 
the incidence of stroke, coronary heart disease, congestive heart failure, major cardiovascular 
events, cardiovascular deaths, or total deaths (P>0.05 in all cases) (Table 4). 
93
Outcomes with nifedipine GITS or Co-amilozide in Intervention as a Goal in Hypertension (INSIGHT)
Ch
ap
te
r 6
apparent, or that the sample size was insufficient to determine
differences in outcome in these subgroups.
Diabetic patients had slightly higher average blood pres-
sures at baseline, which resulted in slightly higher on-
treatment values. Furthermore, add-on medications were
more frequently needed in diabetic than in nondiabetic
patients. Finally, in diabetic patients diastolic blood pressure
was reduced well below 90 mm Hg (82 mm Hg) but systolic
blood pressure remained around 140 mm Hg. These results
are consistent with the conclusions of other studies that
effective antihypertensive treatment in diabetic patients re-
quires more drugs, with a limited chance of reaching the
perhaps too ambitious target systolic blood pressure values
(130 mm Hg) which, according to current guidelines, provide
the greatest degree of protection.27–29
Three further points should be mentioned. First, our data
on the differential incidence of new diabetes and on com-
bined primary and secondary end points add to the evidence
provided by recent studies that similar reductions in blood
pressure may be accompanied by different degrees of mor-
bidity and mortality, thereby supporting the independent roles
of the blood pressure–specific and organ-protective proper-
ties of the drugs used. Second, they provide further evidence
that calcium antagonists are suitable for diabetic hypertensive
patients, contrary to the contention that treatment should
make selective use of drugs that interfere with the renin-an-
giotensin system. To date, this contention does not appear to
be supported by the available data, because treating diabetic
patients with systolic hypertension using a calcium antagonist
markedly reduced cardiovascular morbidity and mortality
rates compared with placebo.30 Furthermore, in patients with
diabetic nephropathy, administration of an angiotensin II
antagonist did not affect cardiovascular morbidity to a differ-
ent degree than administration of a calcium antagonist.31
Finally, patients included in studies showing the marked renal
and cardiovascular protective effects of angiotensin II antag-
onists or ACE inhibitors in diabetes have usually required
chronic administration of a calcium antagonist to achieve
effective blood pressure control.23,32,33
The final point concerns the fact that although diabetes is
associated with greater cardiovascular morbidity, there were
insufficient events in the diabetic subgroup of INSIGHT to
make an adequately powered comparison of the primary end
point between nifedipine and diuretic-based treatments. In the
Losartan Intervention For Endpoint reduction in hypertension
(LIFE) study, losartan was more effective than atenolol at
reducing cardiovascular and all-cause morbidity and mortal-
ity in patients with hypertension, diabetes, and left ventricular
hypertrophy.34 However, the majority of studies and substud-
ies have been inadequately powered to compare cardiovas-
cular protection with different antihypertensive drug regi-
mens in diabetes.3–6,11,12 Meta-analysis of the available data
will therefore be needed to give comparisons adequate
statistical power.
Acknowledgments
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Incidence (box) and relative risks and
95% CIs (figure) for primary and second-
ary outcomes in diabetic and nondiabetic
patients. *Fisher exact test.
TABLE 4. Patients With Primary or Secondary Outcomes in the
Diabetic Subgroup
Nifedipine
(n�649) n (%)
Co-Amilozide
(n�653) n (%)
Relative Risk
(95% CI)
Stroke 17 (2.6) 19 (2.9) 0.90 (0.47, 1.72)
CHD: MI and sudden death 28 (4.3) 25 (3.8) 1.13 (0.66, 1.91)
CHF 9 (1.4) 6 (0.9) 1.51 (0.54, 4.22)
Major cardiovascular events 46 (7.1) 49 (7.5) 0.95 (0.64, 1.39)
Cardiovascular mortality 19 (2.9) 19 (2.9) 1.01 (0.54, 1.88)
Total mortality 44 (6.8) 59 (9.0) 0.75 (0.52, 1.09)
CHD indicates coronary heart disease; MI, myocardial infarction; CHF, congestive heart failure; MI,
myocardial infarction; and SD, standard deviation.
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Incidence (box) and relative risks and 95% CIs ( gure) for primary and secondary outcomes in diabetic and 
nondiabetic patients. *Fisher exact test.
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Because of the slight imbalances in baseline characteristics (Table 1), logistic regression analy-
ses were performed to compare primary and secondary outcomes, with adjustment for age 
and proteinuria. Conclusions remained unchanged in both cases, so only the univariate analy-
ses are reported.
In the group without diabetes at baseline, the percentages of patients with primary out-
comes were similar in nifedipine- treated an  co-amilozide-treated patients (Figure). In the 
nifedipi e-trea ed group, 5.8% of patien s had primary outcomes, compared with 5.1% in the 
co-amilozide-treated group (relative risk 1.15; 95% CI 0.91, 1.45; P=0.24). There was also no 
signi cant di erence in the percentages of nifedipine-treated and co-amilozide-treated pa-
tients who had secondary outcomes (11.6% versus11.0%; relative risk 1.06; 95% CI 0.91, 1.24; 
P=0.48) (Figur )
In the combined nife ipine-treated and co-amilozide-treated groups, nondiabetic patients 
were less likely to have primary outcomes than diabetic patients (5.4% versus 8.4%; odds ratio 
1.54, 95% CI 1.24, 1.90; P<0.001) (Figure). Similarly, signi cantly fewer nondiabetic patients 
had secondary outcomes than diabetic patients (11.3% versus 16.4%; odds ratio 1.46; 95% CI 
1.26, 1.68; P<0.001) (Figure).
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The percentages of patients with individual cardiovascular outcomes were generally similar 
between the treatment groups within the diabetic and nondiabetic subgroups. Meaningful 
statistical analyses could not be conducted for most individual cardiovascular events because 
of the small number of patients who had each event. Nondiabetic patients were more likely 
to have no primary or secondary events, and there was no signi cant di erence between 
the nifedipine-treated and co-amilozide-treated patients (11.6% versus 11.0%, respectively; 
P=0.48).
INCIDENCE OF NEW DIABETES MELLITUS
The number of patients with no diabetes at baseline who had newly diagnosed diabetes mel-
litus during the study was signi cantly lower in the nifedipine-treated group (n=136, 4.3%) 
than in the co-amilozide-treated group (n=176, 5.6%; P=0.023). Among patients with newly 
diagnosed diabetes, 5 nifedipine-treated patients (0.2%) and 6 co-amilozide-treated patients 
(0.2%) had primary events during the INSIGHT follow-up.
DISCUSSION
The present analysis of data collected from a relatively large subgroup of diabetic hyperten-
sive patients enrolled in INSIGHT showed that the incidence of the composite end point of 
myocardial infarction, stroke, congestive heart failure, and cardiovascular death in patients 
receiving antihypertensive treatment with nifedipine GITS was similar to that seen with co-
amilozide (a combination of a thiazide and a potassium-retaining diuretic). However, com-
pared with diuretics, treatment with nifedipine-GITS was associated with a lower incidence 
of (1) vascular and nonvascular deaths combined and (2) new cases of diabetes mellitus. This 
suggests that a long-acting dihydropyridine calcium channel blocker is as e ective as conven-
tional antihypertensive drugs for preventing major nonfatal and fatal cardiovascular events in 
patients with diabetes and hypertension. It also suggests that calcium channel blockers may 
have some advantages when all events are taken into account and that they are better than 
conventional treatments at counteracting the greater tendency in hypertensive patients for 
the development of diabetes mellitus.[15]
In nondiabetic patients enrolled in INSIGHT, the absolute di erence in the percentages of pa-
tients with new diabetes between the 2 treatment groups was 1.3% over a treatment duration 
of ≈4 years. This was not due to di erences in the number of patients who received an ACE 
inhibitor as added treatment because this was similar in the nifedipine and diuretic group. 
The di erence in the development of new diabetes was not su  cient to cause a di erence 
in cardiovascular morbidity and mortality rates over the same period. However, if the trend 
95
Outcomes with nifedipine GITS or Co-amilozide in Intervention as a Goal in Hypertension (INSIGHT)
Ch
ap
te
r 6
continues, it is likely to lead to risk reductions over 10 to 20 years because (1) the increased 
risk of cardiovascular disease brought about by diabetes is considerable,[16] and (2) this is 
the case both for native diabetes and for diabetes induced by antihypertensive drugs.[17] A 
number of studies have reported increased risks for the development of diabetes in patients 
treated with diuretics and β-blockers,[15,18-20] but it appears that ACE inhibitors and calcium 
channel blockers have either no e ect or reduce the likelihood of new diabetes.[21,22] Assess-
ing the incidence of new diabetes should therefore be part of all trials that aim to determine 
the protective e ect of antihypertensive drugs and predict the bene ts beyond the actual 
trial duration. To date, this has been done only in some trials, most of which have shown that 
the incidence of new diabetes is less with calcium antagonists,[14] ACE inhibitors, and angio-
tensin II antagonists[3,5,23] than with diuretics and β-blockers, which appear to increase the 
incidence of new diabetes beyond that seen in untreated hypertensive individuals.[24] This 
may be accounted for by the di erent e ects on insulin sensitivity, which are favourable with 
calcium antagonists, ACE inhibitors, and angiotensin II antagonists and unfavourable with di-
uretics and β-blockers.[25,26] 
The reduction in systolic and diastolic blood pressure was similar in the diabetic and non-
diabetic subgroups of INSIGHT, regardless of whether treatment was based on nifedipine or 
diuretics. In the nondiabetic subgroup, however, on treatment systolic blood pressure was 
slightly (1.8 mm Hg) but signi cantly less in the diuretic than in the nifedipine-treated pa-
tients, with no di erence in the incidence of primary or secondary outcomes. This could be 
due to the fact that nifedipine has direct organ-protective properties in addition to the pro-
tection provided by the blood pressure lowering per se. It could also mean, however, that 
even in the high-risk patients enrolled in the INSIGHT study, a blood pressure di erence of 1.8 
mm Hg was too small to have a pathophysiological e ect, that the duration of the study was 
too short for di erences in outcome to become apparent, or that the sample size was insuf-
 cient to determine di erences in outcome in these subgroups.
Diabetic patients had slightly higher average blood pressures at baseline, which resulted in 
slightly higher on-treatment values. Furthermore, add-on medications were more frequently 
needed in diabetic than in nondiabetic patients. Finally, in diabetic patients diastolic blood 
pressure was reduced well below 90 mm Hg (82 mm Hg) but systolic blood pressure remained 
around 140 mm Hg. These results are consistent with the conclusions of other studies that 
e ective antihypertensive treatment in diabetic patients requires more drugs, with a limited 
chance of reaching the perhaps too ambitious target systolic blood pressure values (130 mm 
Hg) which, according to current guidelines, provide the greatest degree of protection.[27-29] 
Three further points should be mentioned. First, our data on the di erential incidence of new 
diabetes and on combined primary and secondary end points add to the evidence provided 
by recent studies that similar reductions in blood pressure may be accompanied by di erent 
degrees of morbidity and mortality, thereby supporting the independent roles of the blood 
pressure-speci c and organ-protective properties of the drugs used. Second, they provide 
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further evidence that calcium antagonists are suitable for diabetic hypertensive patients, con-
trary to the contention that treatment should make selective use of drugs that interfere with 
the renin-angiotensin system. To date, this contention does not appear to be supported by 
the available data, because treating diabetic patients with systolic hypertension using a cal-
cium antagonist markedly reduced cardiovascular morbidity and mortality rates compared 
with placebo.[30] Furthermore, in patients with diabetic nephropathy, administration of an 
angiotensin II antagonist did not a ect cardiovascular morbidity to a di erent degree than 
administration of a calcium antagonist.[31] Finally, patients included in studies showing the 
marked renal and cardiovascular protective e ects of angiotensin II antagonists or ACE in-
hibitors in diabetes have usually required chronic administration of a calcium antagonist to 
achieve e ective blood pressure control.[23,32,33] 
The  nal point concerns the fact that although diabetes is associated with greater cardiovas-
cular morbidity, there were insu  cient events in the diabetic subgroup of INSIGHT to make an 
adequately powered comparison of the primary end point between nifedipine and diuretic-
based treatments. In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) 
study, losartan was more e ective than atenolol at reducing cardiovascular and all-cause mor-
bidity and mortality in patients with hypertension, diabetes, and left ventricular hypertrophy.
[34] However, the majority of studies and sub-studies have been inadequately powered to 
compare cardiovascular protection with di erent antihypertensive drug regimens in diabetes.
[3-6,11,12] Meta-analysis of the available data will therefore be needed to give comparisons 
adequate statistical power.
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ABSTRACT
Background: Data from placebo-controlled trials with calcium antagonists in patients with 
symptomatic coronary artery disease and diabetes is limited.
Aims: To assess the e  cacy and safety of adding long-acting nifedipine to the conventional 
treatment of patients with stable symptomatic angina with and without diabetes mellitus.
Methods: Results of the ACTION trial, which compared nifedipine GITS 60 mg once daily to 
placebo in patients who required anti-anginal treatment but had preserved left-ventricular 
function, were strati ed for diabetes at baseline.
Results: 14.5% of 7,665 patients in ACTION were diabetics. Both among non-diabetics and 
diabetics, nifedipine signi cantly reduced blood pressure by 6/3 mm Hg. During the study, 
signi cantly fewer diabetics assigned nifedipine required insulin or additional blood pressure 
lowering medication. The evolution of blood glucose and serum creatinine was not a ected 
by nifedipine. Irrespective of diabetes, nifedipine had no e ect on total mortality, cardiovas-
cular mortality or myocardial infarction but signi cantly reduced the combined rate of death, 
any cardiovascular event or procedure by 11% (p=0.001), the incidence of new overt heart 
failure by 29% (p=0.02), and the need for coronary angiography by 18% (p<0.0001). Among 
non-diabetics, nifedipine signi cantly reduced the incidence of any stroke or transient isch-
eamic attack stroke by 34% (p=0.0001), and the need for bypass surgery by 24% (p=0.002). 
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Conclusion: The addition of nifedipine is safe both in diabetic and non-diabetic patients with 
stable symptomatic coronary artery disease, does not improve major cardiovascular event-
free survival but reduces cardiovascular events and the need for interventions.
INTRODUCTION
Patients with coronary artery disease (CAD) and diabetes mellitus are at particularly high risk 
of developing further cardiovascular (CV) complications [1]. Angiotensin converting enzyme 
(ACE) inhibitors have been shown to be e ective in preventing complications of diabetes [2], 
but these drugs do not have anti-anginal e ects. Patients with CAD often need anti-anginal 
drugs either to prevent or to treat anginal attacks. No conclusive data exist on the long-term 
e  cacy and safety of anti-anginal medications in patients with concurrent diabetes and sta-
ble symptomatic CAD irrespective of the presence of hypertension or previous myocardial 
infarction (MI). Current guidelines recommend a low target for arterial blood pressure, which 
may require the use of multiple antihypertensive medications [3,4]. Among these, dihydro-
pyridines o er the advantage of being both potent anti-anginal and antihypertensive medi-
cations. In the mid-1990s there was considerable debate on the safety of calcium antagonists, 
and in particular dihydropyridines, in patients with CAD [5,9]. More recently, a meta-analysis 
on the safety of mostly long-acting calcium antagonists in hypertension suggested that, al-
though these medications had overall bene cial e ects in hypertensive patients similar to 
other antihypertensive medications, they were associated with a higher risk of heart failure 
(HF) [10]. The ACTION trial [11] was designed to assess the e  cacy of long-acting nifedipine 
GITS (gastro-intestinal therapeutic system) in stable symptomatic patients with CAD and pre-
served left-ventricular function. In total 7,665 patients were included, and were followed for a 
mean of almost 5 years. The main conclusion was that nifedipine GITS is safe in patients with 
stable symptomatic CAD and reduces the need for coronary interventions [12]. Almost 15% 
of ACTION patients were diabetics. This paper reports the e ects of nifedipine GITS in a large 
population of diabetic patients with stable CAD, and assesses whether this compound a ects 
diabetes-related outcomes in non-diabetics.
METHODS
Design
The design, methods and main results of ACTION have been published previously [11,12]. 
Brie y, patients aged 35 years or older with stable symptomatic angina pectoris requiring 
treatment were randomized in equal proportions to the addition of either nifedipine GITS or 
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matching placebo. In addition to angina, patients had to have either a history of MI, or proven 
angiographic CAD, or a positive exercise test or perfusion defect. The left-ventricular ejec-
tion fraction had to be at least 40%. Major exclusions were: clinically signi cant heart failure, 
any major CV event or intervention within the last three months, planned coronary angiog-
raphy or intervention, known intolerance to dihydropyridines, clinically signi cant valvular 
or pulmonary disease, unstable insulin-dependent diabetes mellitus, any gastro-intestinal 
condition that prohibited the use of GITS tablets, any condition other than CAD that limited 
life expectancy, hypotension or uncontrolled hypertension, and elevated creatinine or amin-
otransferase levels. Women could only participate if there was no risk of pregnancy. Detailed 
selection criteria and de nitions have been described elsewhere [11].
The starting dose of nifedipine GITS or matching placebo was 30 mg once daily, increasing to 
60 mg once daily within six weeks. Physicians were encouraged to attempt risk factor modi-
 cation and to treat symptomatic angina with compatible medications. Lipid-lowering treat-
ment was either continued or started at the same time as study medication according to in-
ternationally accepted guidelines. The following drugs could not be used in combination with 
study medication: calcium antagonists (2-week washout required), cardiac glycosides (unless 
given for supra-ventricular arrhythmias), other positive inotropic agents, class I or III anti-
arrhythmics other than amiodarone or sotalol, cimetidine, anti-psychotic and anti-epileptic 
drugs, rifampicin or rifampine.
At baseline, investigators recorded whether or not diabetes was present but no speci c diag-
nostic criteria were given. After baseline assessments and treatment allocation, patients were 
seen at the out-patient clinic two weeks, six weeks and six months after randomization; and 
from then onwards every six months. Between visits, patients were contacted by telephone. 
At each clinic visit, blood pressure was recorded with a standard sphygmomanometer in the 
sitting position after 5 minutes of rest. Blood glucose and other standard laboratory tests were 
measured in routine non-fasting blood samples at baseline, after 26 weeks, 2 and 4 years, and 
at the end of the study. Haemoglobin A1c was not routinely assessed.
Serious adverse events suggesting a possible major CV event were classi ed by the Critical 
Events Committee events according to prede ned criteria without access to the study medi-
cation code. Cause of death was classi ed as unknown, CV or non-cardiovascular. 
STATISTICAL METHODS
As no speci c diagnostic criteria for the presence of diabetes were given, patients were strati-
 ed for diabetes at baseline based on the investigator’s diagnosis. Mean changes from baseline 
at selected time points during follow-up were calculated using all available measurements irre-
spective of study medication intake or prior occurrence of non-fatal clinical events. Overall mean 
changes from baseline were obtained by subtracting for each patient the mean follow-up value 
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from the baseline value, and then averaging the results. An overall p-value for comparing blood 
pressure levels between treatment groups was obtained from a mixed e ects model for repeated 
measurements, using the SAS® proc mixed procedure. Percentages were compared using chi-
square tests.
In addition to CV clinical events and procedures, the following composite endpoints were com-
pared: the combined rate of death from any cause, MI, refractory angina requiring coronary 
angiography, new overt HF requiring hospitalization and peripheral revascularization (i.e. the 
ACTION primary endpoint for e  cacy); the combined rate of death from any cause, MI and debili-
tating stroke (i.e. the ACTION primary endpoint for safety); any CV event (i.e. the ACTION primary 
endpoint for e  cacy minus non-CV death); any death, CV event or procedure (i.e. the ACTION 
primary endpoint for e  cacy plus coronary angiography, percutaneous coronary intervention 
and coronary bypass surgery); and any vascular event or procedure (i.e. the ACTION primary end-
point for e  cacy minus non-CV death and new overt heart failure, plus percutaneous coronary 
intervention and coronary bypass surgery). In addition, the combined rate of disabling stroke, 
any stroke reported by investigators that did not meet the criteria for disabling stroke, and any 
reported transient ischaemic attack was considered.
All analyses for clinical events and composite endpoints were based on intention-to-treat. CV 
deaths and deaths of unknown cause were combined. Coronary angiography and percutaneous 
coronary intervention on the same day were counted only as percutaneous coronary interven-
tion. Event rates were taken as number of events divided by total time that patients had been ‘at 
risk’ of the event concerned. For composite endpoints, the time that the  rst component event 
occurred was used in event rate calculations. Hazard ratios comparing patients assigned nife-
dipine to patients assigned placebo and their 95% con dence intervals were obtained using Cox 
proportional hazards models with treatment allocation as the only covariate. Interaction tests 
were performed by Cox proportional hazards models, using the SAS® proc phreg procedure. 
RESULTS
ACTION was completed as planned [12]; 7,665 patients were started on study medication (3,825 
nifedipine GITS, 3,840 placebo). At baseline, 1,113 (14.5%) ACTION patients were diagnosed as 
diabetic by the investigator, three more than reported earlier [12]. Mean follow-up was 5.0 years 
for non-diabetics and 4.8 years for diabetics, and did not depend on assigned treatment. Dou-
ble-blind medication was taken by non-diabetics assigned nifedipine during 79%, and by those 
assigned placebo during 83% of total follow-up time. Diabetics used double-blind medication 
during 78% of total follow-up time, with no di erence between nifedipine and placebo. Overall, 
follow-up was 97.3% complete [12].
Baseline characteristics for non-diabetics and diabetics respectively are given in Table 1. Both 
groups were similar with respect to, age, sex, NYHA class, presence of anginal attacks and history 
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of MI. Diabetics had more often signi cant lesions in a known prior coronary angiogram, more 
commonly a history of bypass surgery, and were more often already on drug treatment for hy-
Table 1: Baseline characteristics of non-diabetics and diabetics
Non-Diabetic
(n = 6552)
Diabetic
(n = 1113)
P*
Mean (SD) age (years) 63.4 (9.4) 63.9 (8.9) 0.1
Male gender 5,224 (80%) 860 (77%) 0.06
Current NYHA class II – III 3,004 (46%) 528 (47%) 0.3
Anginal attacks 6,040 (92%) 1,030 (93%) 0.7
History of MI 3,326 (51%) 572 (51%) 0.7
Angiographic CAD, no MI 2,088 (32%) 383 (34%) 0.1
Positive exercise or radionuclide test only 1,105 (17%) 157 (14%) 0.02
Signi cant lesions on coronary angiogram 4,442 (68%) 824 (74%) <0.001
Angiography not performed or unknown 2,023 (31%) 278 (25%) <0.001
History of PTCA 1,720 (26%) 296 (27%) 0.8
History of CABG 1,486 (23%) 303 (27%) <0.001
On drug treatment for hypertension 2,577 (39%) 621 (56%) <0.001
On drug treatment for hyperlipidaemia 4,446 (68%) 754 (68%) 0.9
On any BG lowering drug 0 853 (77%) N/A
Past use of calcium antagonists 1,389 (21%) 287 (26%) <0.001
Claudication 451 (6.9%) 174 (16%) <0.001
Transient ischaemic attack 247 (3.8%) 55 (4.9%) 0.06
Stroke 139 (2.1%) 31 (2.8%) 0.2
Any peripheral vascular disease† 752 (11%) 233 (21%) <0.001
Mean (SD) BG (mg/dl) 99 (21.2) 177 (70.8) <0.001
Casual BG ≥200 mg/dl §
In pts not on any BG lowering drug 31 (0.5%) 35 (3.1%) N/A
In pts on any BG lowering drug N/A 292 (26%) N/A
Mean (SD) total cholesterol (mmol/l) 209 (40) 206 (45) 0.008!!!
Mean (SD) creatinine (mg/dl) 1.1 (0.2) 1.1 (0.2) 0.9
Creatinine ≥1.2 mg/dl 1,645 (25%) 308 (28%) 0.1
Mean (SD) BMI (kg/m2) 27 (3.7) 29 (4.2) <0.001
Mean (SD) pulse rate (beats/min) 64 (10.1) 67 (10.7) <0.001
Mean (SD) systolic BP (mmHg) 137 (18.8) 141 (18.0) <0.001
Mean (SD) diastolic BP (beats/min) 80 (9.5) 80 (9.4) 0.7
Additional risk factors:
Current smoker 1,204 (18%) 152 (14%) <0.001
Total cholesterol ≥5.0 mmol/l 4,167 (64%) 648 (58%) <0.001
Body mass index ≥30.0 kg/m2 1,368 (21%) 376 (34%) <0.001
BP ≥140/90 mm Hg 3,309 (51%) 668 (60%) <0.001
Any of the above 5,485 (84%) 933 (84%) 0.9
Data are percentage of patients unless indicated otherwise. SD, standard deviation; NYHA, New York Heart 
Association; MI, myocardial infarction; CAD, coronary artery disease; PTCA, percutaneous transluminal 
coronary angioplasty; CABG, coronary artery bypass grafting; BG, blood glucose; BP, blood pressure. 
*p-values for comparing non-diabetics with diabetics. † Stroke, transient ischemic attacks or claudication. 
§ equivalent to 11.1 mmol/l
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pertension. Diabetics also had more commonly a history of peripheral vascular disease. Baseline 
mean blood glucose level, body mass index, pulse rate and systolic blood pressure were all higher 
in diabetics than in non-diabetics. 853 (77%) of all diabetics were on any blood glucose lowering 
drug. Of the 260 diabetics who were not, 35 (13% of 260) had a casual baseline blood glucose 
level ≥ 200 mg/dl (11.1 mmol/l). There was no di erence with respect to the fraction of patients 
who had least one of the additional risk factors listed in Table 1. Nonetheless, fewer diabetics 
were current smokers or had a total cholesterol ≥5.0 mmol/l, while more diabetics were obese 
(body mass index ≥30.0 kg/m2) or had a baseline blood pressure ≥140/90 mm Hg. At baseline, 
68% of both non-diabetics and diabetics were on any lipid lowering treatment but diabetics were 
more often on statins than non-diabetics (63% and 58% respectively). Any anti-anginal medica-
tion other than β-blockers was used by 79% of non-diabetics and 78% of diabetics. 86% in both 
groups were using aspirin, and 4% were on warfarin or similar. Any anti-arrhythmic drug was 
used by 4% in both groups.
Data on the use of blood pressure and blood glucose lowering drugs at baseline and during 
follow-up is given in Table 2. At baseline, β-blockers were used to a similar extent by both non-
diabetics and diabetics, but diabetics were more often on ACE-inhibitors, angiotensin recep-
tor blockers (ARBs) or diuretics. Patients assigned nifedipine and placebo respectively were 
comparable at baseline as regards the medications listed in Table 2 both for non-diabetics 
and diabetics.
During the study, nifedipine signi cantly reduced the need to prescribe ACE-inhibitors, ARBs 
or diuretics both among non-diabetics and among diabetics (c.f. Table 2). In both groups, nife-
dipine had no e ect on the number of patients that were prescribed any blood glucose lower-
ing drug at any time, or were started on any blood glucose lowering drug. Among diabetics, 
nifedipine signi cantly reduced the number of patients treated with insulin at any time.
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Table 2: Additional medications in non-diabetics and diabetics
Non-diabetics Diabetics
Nifedipine
(n=3,258)
Placebo
(n=3,294)
P*
Nifedipine
(n=567)
Placebo
(n=546)
P*
Baseline
Not on BG-lowering drugs 3,258 (100%) 3,294 (100%) 133 (23%) 127 (23%)
On insulin 0 0 - 86 (15%) 96 (18%) -
On metformin 0 0 - 174 (31%) 159 (29%) -
On sulfonylureas 0 0 - 302 (53%) 282 (52%) -
On any BG-lowering drug 0 0 - 434 (77%) 419 (77%) -
On β-blockade 2,583 (79%) 2,632 (80%) - 450 (79%) 434 (79%) -
On ACE-I or ARB 664 (20%) 678 (21%) - 195 (34%) 202 (37%) -
On a diuretic 350 (11%) 359 (11%) - 82 (14%) 88 (16%) -
On any blood pressure lowering 
drug 2,833 (87%) 2,879 (87%)
-
511 (90%) 494 (90%)
-
At any time during study
On insulin 18 (0.6%) 21 (0.6%) 0.7 179 (32%) 206 (38%) 0.03
On metformin 81 (2.5%) 88 (2.7%) 0.6 299 (53%) 299 (55%) 0.5
On sulfonylureas 86 (2.6%) 90 (2.7%) 0.8 376 (66%) 371 (68%) 0.6
On any BG-lowering drug† 152 (4.7%) 148 (4.5%) 0.7 497 (88%) 491 (90%) 0.2
Started on BG-lowering Rx‡ 
(rate§)
152 (0.96) 148 (0.93) 63 (14.1) 72 (16.9)
Hazard ratio (95% CI) 1.04 (0.83 – 1.30) 0.8 0.84 (0.60 – 1.18) 0.3
On β-blockade 2,843 (87%) 2,921 (89%) 0.1 503 (89%) 491 (90%) 0.5
On ACE-i or ARB 1,252 (38%) 1,545 (47%) <0.001 363 (64%) 387 (71%) 0.01
On a diuretic 1,091 (33%) 1,222 (37%) 0.002 254 (45%) 285 (52%) 0.01
On any blood pressure lowering 
drug 3,085 (95%) 3155 (96%) 0.04 553 (98%) 529 (97%) 0.5
Started on BP-lowering Rx‡ 
(rate§) 252 (19.8) 276 (24.2) 42 (32.9) 35 (27.2)
Hazard ratio (95% CI) 0.83 (0.70 – 0.98) 0.03 1.17 (0.75 – 1.83) 0.5
Numbers of patients and percentages of total number of patients at baseline, unless indicated otherwise. 
ACE-i, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BG, blood glucose; Rx, 
medication; CI, con dence interval. *p-values comparing nifedipine with placebo for non-diabetics and 
diabetics respectively. † Includes only blood glucose lowering drugs given for at least one week. ‡ Not 
on blood sugar lowering medication at baseline. § Number of patients started on blood sugar lowering 
medication for at least one week per 100 years of follow-up of patients who were not on blood sugar 
lowering medication at baseline.
Relative to placebo, mean blood pressures were 6/3 mm Hg lower among patients assigned 
to nifedipine, both among non-diabetics (p<0.001) and among diabetics (p<0.001). In both 
groups, a higher percentage of patients assigned nifedipine had blood pressures below 
140/90 mm Hg, or below 130/80 mm Hg, at all time points during follow-up (Figure 1).
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Figure 1. Evolution of fraction of patients with elevated blood pressure (BP) by diabetes at 
baseline as % of all patients with blood pressure measurements (irrespective of use of study 5 
medication or prior non-fatal clinical events). Filled plus open bars: % of patients with blood 
pressure below 140/90 mm Hg; filled bars: % of patients with blood pressure below 130/80 
mm Hg. 
Figure 1. Evolution of fraction of patients with elevated blood pressure (BP) by diabetes at baseline as % of 
all patients with blood pressure measurements (irrespective of use of study medication or prior non-fatal 
clinical events). Filled plus open bars: % of patients with blood pressure below 140/90 mm Hg;  lled 
bars: % of patients with blood pressure below 130/80 mm Hg.
As shown in Figure 2, blood glucose levels among non-diabetics gradually increased towards 
the end of the study. Among diabetics, there was an initial rise of blood glucose level dur-
ing the  rst two years with a return to baseline towards the end of the study. There was no 
statistically signi cant and consistent e ect of nifedipine on casual blood glucose levels in 
both non-diabetics and diabetics, and no e ect on the percentage of patients with a casual 
blood glucose level ≥ 200 mg/dl. Baseline creatinine values increased towards the end of the 
study in both groups, and were not signi cantly a ected by nifedipine. In non-diabetics, body 
mass index increased gradually and signi cantly more in patients assigned placebo than in 
patients assigned nifedipine. Nifedipine had no e ect on the evolution of body mass index 
in diabetics.
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Figure 2. Mean changes from baseline of blood glucose and creatinine by diabetes at baseline. Error 
bars indicate standard errors of the mean. Below each graph the number of patients with available 
measurements (irrespective of use of study medication or prior non-fatal clinical events) is given by 
treatment group. N, number; nif, nifedipine; pla, placebo. 
Among non-diabetics at baseline, hyperglycaemia was reported as an adverse event for 116 
patients assigned nifedipine (0.73/100 patient-years of follow-up) and 120 patients assigned 
placebo (0.75/100 patient-years of follow-up) respectively (hazard ratio [HR] 0.97, 95% con-
 dence interval [CI] 0.75–1.26, p=0.8). Among diabetics, hyperglycaemia was reported less 
often in patients assigned nifedipine (65 patients or 2.6/100 patient-years of follow-up) than 
in patients assigned placebo (84 patients or 3.5/100 patient-years of follow-up) respectively 
(HR 0.73, 95% CI 0.53–1.01, p=0.06). Similarly among diabetics, hypoglycaemia was reported 
less often in patients assigned nifedipine (16 patients or 0.59/100 patient-years of follow-up) 
than in patients assigned placebo (25 patients or 0.97/100 patient-years of follow-up) but the 
di erence was not statistically signi cant (HR 0.61, 95% CI 0.33–1.14, p=0.1). As regards other 
possible diabetes-related side e ects, there were no major di erences between patients as-
signed nifedipine or placebo both among non-diabetics and among diabetics.
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In Figure 3, the e ects of nifedipine (relative to placebo) on CV clinical events are compared 
between non-diabetics and diabetics at baseline. For all events shown, event-rates were high-
er among diabetics than among non-diabetics. Rates of all-cause death, CV or unknown death 
and MI were similar for patients assigned nifedipine and patients assigned placebo both 
among non-diabetics and diabetics. Nifedipine signi cantly reduced the rate of any stroke or 
transient ischaemic attack (HR 0.66, 95% CI 0.53–0.82, p=0.0001), of debilitating stroke (HR 
0.67, 95% CI 0.47–0.94, p=0.02) and the need for coronary bypass surgery (HR 0.76, 95% CI 
0.64–0.90, p=0.002) in non-diabetics, but not in diabetics. The need for coronary angiography 
was signi cantly reduced by nife dipine irrespective of the presence of diabetes (HR in both 
diabetes groups combined 0.82, 95%CI 0.75–0.90, p<0.0001). New overt HF was reduced by 
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Figure 3. Effect of nifedipine on clinical events for non-diabetics and diabetics at baseline 
respectively. Rates in number of events per 100 patient years of follow-up ‘at risk’. Hazard 
ratios with 95% confidence intervals (CI). P-values for effect modification (interaction test). 5 
Figure 3. E ect of nifedipine on clinical events for non-diabetics and diabetics at baseline respectively. 
Rates in number of events per 100 patient years of follow-up ‘at risk’. Hazard ratios with 95% con dence 
intervals (CI). P-values f r e ct modi cation (interaction test).
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nifedipine to a similar extent both among non-diabetics and among diabetics (p-value for 
interaction = 0.8) but this e ect was statistically signi cant only in all patients combined (HR 
0.71, 95% CI 0.54–0.94, p=0.02).
Figure 4 shows results for pre-de ned ACTION composite endpoints in a similar manner as 
Figure 3. Nifedipine had no e ect on the primary endpoint for e  cacy or the primary end-
point for safety both among non-diabetics and among diabetics. In both diabetes groups, 
nifedipine signi cantly reduced the combination of death, CV events and procedures. The 
e ect on vascular events or revascularization was similar, and was statistically signi cant in 
non-diabetics (HR 0.91, 95% CI 0.83–1.00, p=0.05) and in both diabetes groups combined (HR 
0.91, 95% CI 0.83–0.99, p=0.03).
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Figure 4. Effect of nifedipine on pre-defined composite endpoints for non-diabetics and 
diabetics at baseline respectively. Rates in number of events per 100 patient years of follow-
up ‘at risk’. Hazard ratios with 95% confidence intervals (CI). P-values for effect modification 5 
(interaction test). 
 
Figure 4. E ect of nifedipine on pre-de ned composite endpoints for non-diabetics and diabetics at 
baseline respectively. Rates in number of events per 100 patient years of follow-up ‘at risk’. Hazard ratios 
with 95% con dence intervals (CI). P-values for e ect modi cation (interaction test).
DISCUSSION
The main  nding of this subgroup analysis of data from the ACTION trial is that, although 
diabetics had a higher risk of events than non-diabetics, the e ects of the addition of nife-
dipine to standard treatment on clinical outcome were similar. ACTION represents the larg-
est long-term trial assessing the e ect of an anti-anginal drug relative to placebo on clinical 
outcome in patients with stable CAD and preserved left-ventricular function. The majority of 
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patients were also on beta-blockers and lipid-lowering drugs while an important fraction was 
on an ACE-inhibitor or ARB. Diabetics represented 14.5% of the population in the trial and 
had baseline characteristics that were not substantially di erent from those of non diabetic 
patients, with the exception of obesity, hypertension and peripheral arterial disease, which 
were more common. Our results show that, in diabetic patients, long-acting nifedipine was 
neither superior nor inferior to placebo in terms of safety or e  cacy as de ned by correspond-
ing prede ned primary endpoints, when used on top of β-blockers and other conventional 
anti-anginal medications. ACE-inhibitors are known to reduce CV mortality and major morbid-
ity in patients with hypertension or CAD [2,13]. In ACTION, more patients assigned placebo 
than nifedipine were prescribed ACE-inhibitors during follow-up (c.f. Table 2). This may have 
contributed to the lack of di erence between treatment groups as regards primary endpoints. 
Despite this, nifedipine signi cantly reduced by the risk of the composite endpoint of death, 
any CV event or procedure both among non-diabetics and diabetics (c.f. Figure 4). Nifedipine 
also signi cantly reduced systolic and diastolic blood pressure throughout the course of the 
trial in both subgroups. Metabolic control during follow-up was slightly better in nifedipine-
treated patients, with a lower proportion of diabetic patients needing insulin. Irrespective of 
the presence of diabetes, creatinine levels increased during the course of the trial in a similar 
fashion in patients receiving nifedipine or placebo. 
Previous long-term clinical trials with calcium antagonists were performed mainly in hyper-
tensive populations and controversial results were observed in hypertensive patients with 
diabetes [14]. In a secondary analysis of the ABCD trial [15], nisoldipine was associated with an 
increased incidence of fatal and non fatal MI in comparison to enalapril. Conversely, in the ALL-
HAT trial [16], amlodipine and chlorthalidone were equally e ective both in diabetic or non-
diabetic patients. The CONVINCE trial compared long-acting verapamil with either atenolol or 
hydrochlorothiazide in hypertensive patients [17], and was stopped earlier than planned. In 
this trial, the e  cacy of verapamil appeared more marked in diabetic patients, although there 
was no signi cant heterogeneity in the trial’s results according to diabetic status. The reverse 
was observed in the large INVEST trial [18]. In this trial, patients with CAD and hypertension 
were randomized to blood pressure lowering strategies based on long-acting verapamil or 
atenolol. The non calcium antagonist strategy appeared slightly superior (albeit not signi -
cantly so) in diabetic patients. Overall, the use of calcium antagonists in diabetic hypertensive 
patients appears to be safe [14]. Our results con rm that in patients with stable symptomatic 
CAD and preserved left ventricular function, long-acting nifedipine has no deleterious e ect 
in terms of major CV endpoints (CV death, MI), irrespective of the presence or absence of dia-
betes. Importantly, the anti-anginal e  cacy of nifedipine translated in improved CV outcomes 
in terms of CV event and intervention-free survival. New overt HF was also less frequent in 
patients receiving nifedipine. In addition and clinically relevant, nifedipine signi cantly in-
creased the proportion of patients with appropriate blood pressure levels and reduced the 
need to prescribe additional blood pressure lowering drugs.
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Beside their e ect on major CV outcomes, there is evidence that calcium antagonists might 
decrease the occurrence of diabetes mellitus or improve glycaemic control at least when 
compared to diuretics or β-blockers as antihypertensive treatment. In the ALLHAT trial [16], 
fasting glucose levels were lower after two and four years in the amlodipine than in the chlo-
rthalidone arm, although the di erence was statistically signi cant only at two years. In the 
subgroup of non-diabetics, the proportion of patients with a fasting glucose ≥ 126 mg/dL was 
signi cantly lower in the amlodipine arm both at two and at four years. In the same trial enal-
april was superior to chlorthalidone in this respect at all time-points. In the INVEST trial [18], 
in which the two antihypertensive strategies compared achieved equivalent blood pressure 
control, non-diabetic patients randomized to the calcium antagonist-based strategy had a 
statistically signi cant 15% lower risk of developing diabetes during the 2.7-year follow-up. In 
the INSIGHT trial, nifedipine signi cantly reduced the occurrence of new diabetes in patients 
without diabetes at baseline relative to co-amilozide [19]. A trend in the same direction was 
observed in the NORDIL study, which compared diltiazem with diuretics and β-blockers [20]. 
In ACTION, nifedipine was compared to placebo rather than another active agent. In diabet-
ics, there was trend towards better glycaemic control and signi cantly less need for insulin in 
patients assigned nifedipine than in patients assigned placebo. In non-diabetics we found no 
evidence that nifedipine retards the occurrence of diabetes since there were no di erences 
with respect to the introduction of anti-diabetic medications or blood glucose levels. Also, 
there were no di erences in the occurrence of adverse events which might have been related 
to diabetes.
E ects on blood glucose control seem to be independent of the reduction in blood pressure. 
Indeed, in ALLHAT blood pressure control was if anything slightly better with chlorthalidone 
than with amlodipine [16]. Similarly, in the INSIGHT trial there were more episodes of hyperg-
lycaemia reported as adverse events in the co-amilozide arm despite similar blood pressure in 
the nifedipine and co-amilozide arms respectively [21].
Despite the di erence between nifedipine and placebo as regards blood pressure control, 
there was no clinically relevant di erence between creatinine levels both among non-dia-
betics and diabetics. These results are in agreement with those of the IDNT trial [22], which 
showed no di erence between amlodipine and placebo as regards a two-fold increase of 
creatinine.
In conclusion, this sub-group analysis of the results of the ACTION trial according to diabetic 
status at baseline documents the safety of long-acting nifedipine in patients with stable symp-
tomatic CAD and preserved left ventricular function irrespective of the presence of diabetes. 
Although there was no di erence in the primary endpoint of the trial, a signi cant reduction 
was observed both among non-diabetic and diabetic patients in the combined occurrence of 
death, CV events or cardiac procedures. In addition, nifedipine signi cantly improved blood 
pressure control but did not contribute to improved diabetes control in a manner that would 
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be clinically relevant. These  ndings lend support to existing guidelines for using calcium 
antagonists in diabetics with hypertension and/or angina [23].
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Long-term evolution of blood pressure in patients with stable angina
ACTION was a multi-centre, randomised, placebo-controlled, double-blind trial designed 
to compare the e ect on clinical outcomes of long-acting nifedipine GITS or placebo in pa-
tients with symptomatic angina pectoris attributable to coronary disease. The main results 
have been published (c.f. Chapter 2). Patients with symptomatic orthostatic hypotension or 
a supine systolic blood pressure of 90 mmHg or less, a systolic blood pressure of at least 200 
mmHg and/or a diastolic blood pressure of at least 105 mmHg, were excluded. Otherwise, 
patients were not selected based on their screening blood pressure. Patients already on treat-
ment for hypertension could participate as well as patients who were not.
Because patients were not selected based on screening blood pressure, the evolution of blood 
pressure during follow-up should not be in uenced by the regression-to-the-mean phenom-
enon that would have been introduced by selection based on screening blood pressure val-
ues, combined with within-patient variability of measurements [1].
The evolution of blood pressure in all ACTION patients combined is shown in Figure 2 of Chap-
ter 2. There is no explanation for the initial drop at the  rst two follow-up measurements after 
2 and 6 weeks of treatment with either nifedipine or placebo. In the placebo group, blood 
pressure levels were the same at 6 months as at baseline. This indicates that there was indeed 
no regression-to-the-mean when all ACTION patients are considered together. During pro-
longed follow-up up to 5½ years, mean systolic blood pressures were essentially stable while 
mean diastolic blood pressure tended to decrease in both treatment groups. The mean di er-
ence between patients assigned nifedipine and placebo remained essentially stable.
That mean diastolic blood pressure levels tended to decrease is contrary to the notion that 
blood pressure tends to increase with age. There are several alternative explanations for the 
apparent decrease of mean diastolic blood pressure in ACTION. As duration of follow-up of 
the closed cohort concerned increases, less patients are available for blood pressure mea-
surement. At baseline, 3822 patients assigned nifedipine had their blood pressure recorded, 
as opposed to 3839 patients assigned placebo. After 5 ½ years of follow-up, the correspond-
ing numbers of patients with measurements were 1647 and 1683 respectively (c.f. Figure 2, 
Chapter 2). Patients with a particularly high blood pressure at baseline are at higher risk of 
death or myocardial infarction during follow-up, and tend therefore either to be no longer 
present in the cohort as follow-up increases due to death, or have decreased blood pressure 
values due to non-fatal myocardial infarction. Alternatively, patients admitted early on to the 
study during recruitment could have had lower blood pressure at baseline. This would show 
up as lower blood pressures in patients who have the longest duration of follow-up. Another 
explanation could be that patients were more intensively treated with additional blood pres-
sure lowering drugs towards the end of the study. As shown in Table 2 of Chapter 3 there was 
evidence for this in the ACTION study, in particular among patients with elevated blood pres-
sure at baseline.
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The evolution of mean blood pressure for normo- and hypertensives at baseline respectively 
is shown in Figure 1 of Chapter 3. As expected, blood pressure in normotensives (de ned in 
this case as systolic blood pressure below 140 and diastolic blood pressure below 90 mmHg 
irrespective of treatment, c.f. Chapter 3) tended to increase while the opposite was the case in 
hypertensives. As “normotension” was de ned on baseline measurements only, the explana-
tion for this must be regression-to-the-mean. These results underscore the di  culty of assess-
ing the incidence of hypertension in a closed cohort of patients who are normotensive at the 
start of follow-up, and the need for a control group in studies that aim to demonstrate the 
e ect of treatment on the incidence of hypertension [2].
In Chapter 3, data is given also on the blood pressure lowering e ect of nifedipine GITS in 
normo- and hypertensives at baseline respectively (relative to placebo). As expected (c.f. Table 
3, Chapter 3), nifedipine had a larger e ect on follow-up blood pressures in hypertensives 
than in normotensives (mean reductions of 6.6/3.5 mmHg and 3.9/2.4 mmHg respectively). 
This shows that even in normotensives blood pressure can still be lowered by blood pressure 
lowering drugs. Whether this is bene cial is controversial however [3].
EFFECT OF BLOOD PRESSURE REDUCTION ON OUTCOME IN PATIENTS WITH 
STABLE ANGINA
The main conclusions from ACTION were that the addition of nifedipine GITS to the conven-
tional treatment of angina pectoris has no e ect on major cardiovascular event-free survival 
(i.e. the combination of death from any cause, acute myocardial infarction, refractory angina, 
new overt heart failure, debilitating stroke, and peripheral revascularisation; which was the 
pre-speci ed primary outcome for e  cacy), that nifedipine GITS reduces the need for coro-
nary angiography and interventions, and is safe. The safety of nifedipine GITS is an important 
 nding as ACTION was started in response to the debate on the safety of the short-acting cap-
sule formulation of nifedipine in patients with coronary disease that arose in the mid-1990ties 
(c.f. Chapters 1 and 2).
ACTION was designed to show superiority of nifedipine GITS compared to placebo. The sam-
ple size calculation has been published in detail [4]. Assuming a primary e  cacy outcome 
rate of 5.58 per 100 patient-years and 731 patients with event among those assigned placebo, 
the study was designed to have 95% power to detect an 18% reduction of this outcome by 
nifedipine GITS, relative to placebo, at an overall 5% level of signi cance. As shown in Table 3 
of Chapter 2, the observed rate of the primary e  cacy outcome in patients assigned placebo 
was 4.75, and therefore slightly lower than expected. As shown in the same Table, the total 
number of patients with a primary outcome event – 828 – was higher than assumed. As the 
power is primarily dependent on the number of events rather than on the rate, the power of 
the study has not su ered from the lower-than-expected event-rate.
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There are several reasons why nifedipine did not have the e ect in ACTION that was assumed 
when the study was designed. The event-rate in patients assigned placebo was low, and it is 
di  cult to reduce a low absolute rate even further by treatment. That peripheral revasculari-
sation – a component of the primary endpoint for e  cacy – was more frequent in patients as-
signed nifedipine was unexpected. Patients assigned placebo were more intensively treated 
than those assigned nifedipine (c.f. Chapter 3). 
That nifedipine might have larger e ects in patients with a higher risk because of co-exis-
tent hypertension was expected when the study was designed, and was the basis for pre-
specifying a subgroup analysis contrasting e ects in patients with elevated blood pressure to 
the e ects in patients without. Apart from the expected higher event-rates in hypertensives, 
the rationale underlying this subgroup analysis was that nifedipine GITS is an e ective blood 
pressure lowering agent, and that blood pressure lowering in patients with hypertension has 
been shown to be e ective.
The results of this and other pre-speci ed subgroup analyses were given in the main results 
report (c.f. Figure 4, Chapter 2). As shown in the  gure mentioned, blood pressure level at 
baseline was the only baseline characteristic that showed a signi cant interaction with the ef-
fect of nifedipine on the primary outcome for e  cacy (p=0.015, c.f. Figure 4, Chapter 2). As this 
was also the only subgroup analysis based on a sound a-priori rationale, this was the reason to 
further explore the subgroup analysis in a separate report.
As reported in Chapter 3, an almost equal number of ACTION patients were either normoten-
sive or hypertensive based on baseline blood pressure values. Hence, this subgroup analysis 
has optimal statistical power. As shown in Figure 3 of Chapter 3, the rates of death, myocardial 
infarction, new overt heart failure, any transient ischemic attack or stroke, and debilitating 
stroke were higher in hypertensives than in normotensives.
As nifedipine signi cantly reduced the primary endpoint for e  cacy in hypertensives by 16% 
(event-rate 4.90 nifedipine, 5.61 per 100 patient-years placebo, c.f. Figure 2 of Chapter 3), this 
subgroup analysis of the ACTION study supports the addition of nifedipine GITS to the basic 
regimen of patients with stable symptomatic coronary disease who also have elevated blood 
pressure, and is in agreement with the conclusion from meta-analyses that blood pressure 
control in patients with hypertension improves outcome [5].
In hypertensives, nifedipine signi cantly reduced the event rates of any transient ischemic 
attack or stroke, debilitating stroke and new overt heart failure, relative to placebo. That nife-
dipine reduced the incidence of new overt heart failure in the ACTION study is a new and 
therefore unexpected  nding. Rather than its prevention, calcium antagonists have been as-
sociated in previous studies with an increased risk of developing new, or worsening of, heart 
failure [6,7]. This may have been due to the use of the immediate release, short-acting cap-
sule formulation of nifedipine [8-11]. Short-acting nifedipine may induce a fast drop in blood 
pressure and a compensatory increase in heart rate [12], which may result in worsening of 
heart failure symptoms or even pump failure. Another possible explanation for an increased 
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incidence of heart failure in previous studies is peripheral oedema. The latter is a typical side 
e ect of dihydropyridine calcium antagonists [13] that may be falsely interpreted clinically 
as a sign of heart failure. In the ACTION trial, peripheral oedema was indeed more commonly 
reported as an adverse event in patients assigned nifedipine than in those assigned placebo 
(c.f. Chapter 2). That the incidence of heart failure was nonetheless reduced can therefore be 
attributed to the strict procedures and criteria for the diagnosis of heart failure that were used 
by the ACTION Critical Events Committee (c.f. Chapter 2). It should be stressed in this regard 
that in ACTION, diagnoses by the Critical Events Committee were determined independently 
of the investigator diagnosis as entered on adverse events reports [14].
Interestingly, a recently published further analysis of ACTION data has suggested that the 
positive e ect on the occurrence of heart failure and stroke can be attributed to the blood 
pressure lowering e ect of nifedipine [15]. As uncontrolled hypertension is one of the most 
important modi able risk factors for the development of heart failure, the prevention of the 
development of hypertension by nifedipine in patients at risk of developing heart failure 
should therefore also result in the reduction of new overt heart failure and stroke, as was 
observed in the ACTION trial.
That nifedipine has potent anti-anginal e ects is well established. The observation in ACTION 
that nifedipine reduced the need to perform coronary angiography is therefore not surprising 
as symptom-driven coronary angiography should be related to worsening of anginal symp-
toms. In contrast to heart failure and stroke, the recently published further analysis of ACTION 
data mentioned earlier has suggested that the signi cant reduction of coronary angiography 
– which occurred both in normo- and in hypertensives (c.f. Figure 3, Chapter 3) – cannot be 
attributed to blood pressure reduction [15]. This suggests, to our knowledge for the  rst time, 
that the e ects of “blood pressure lowering” drugs are not necessarily all attributable to blood 
pressure lowering. The stroke and heart failure risk reduction by nifedipine GITS in patients 
with stable angina can apparently be attributed primarily to its blood pressure lowering ef-
fect. On the other hand, the e ects on coronary procedures are likely to be related almost 
entirely to its anti-anginal e ects, with blood pressure reduction being an epiphenomenon 
[15]. Di erent blood pressure lowering drugs should have di erent properties in this regard 
but there is little other information in the literature that supports this.
ACTION did not show that reduction of angina as evidenced by a reduced need for coronary 
angiography improves myocardial infarction-free survival in patients with stable angina and 
a normal blood pressure in an intention-to-treat comparison that disregards a rise in blood 
pressure during follow-up. Whether the results of ACTION support the addition of nifedipine 
GITS to the basic regimen of patients with stable angina and a normal blood pressure remains 
therefore a matter of debate. While nifedipine GITS can be expected to reduce the need for 
coronary angiography and the incidence of any transient ischaemic attack or stroke without 
any negative e ect on the occurrence of heart failure in these patients, these positive e ects 
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may be o set by a slightly higher rate of death and myocardial infarction due to a J-shaped 
relation between the occurrence of these events and treated blood pressure [3].
SIGNIFICANCE AND EVOLUTION OF RENAL FUNCTION IN PATIENTS WITH 
HYPERTENSION OR CORONARY DISEASE TREATED WITH NIFEDIPINE GITS
As stated in the introduction to Chapter 5, renal dysfunction is recognised as an important 
predictor of outcome in patients with hypertension and/or coronary disease. This poses three 
questions: (i) how does renal dysfunction impact on prognosis, (ii) is blood pressure control 
more di  cult in patients with renal dysfunction, and (iii) does the choice of treatment by itself 
have an e ect on renal dysfunction?
Both the INSIGHT and the ACTION studies have provided further evidence as regards each of 
these questions in patients with hypertension and with stable angina respectively. INSIGHT 
(c.f. Table 3, Chapter 4) revealed that patients with hypertension and proteinuria have a 2.35-
fold higher odds of the combined event of cardiovascular death, myocardial infarction, heart 
failure and stroke than those without proteinuria, adjusted for other confounders. The ad-
justed odds ratio for creatinine level was 1.23 per 0.2 mg/dL (20 µmol/L) increase. ACTION (c.f. 
Chapter 5) revealed that the rate of all-cause death in patients with stable angina rises 1.61-
fold per mg/dL increase of baseline creatinine level, adjusted for other risk factors. Similar 
conditionally independent associations were present for cardiovascular death or con rmed 
myocardial infarction, and for new overt heart failure. Estimated creatinine clearance was also 
signi cantly related to the rate of these events, but creatinine level was not. In Figure 3 of 
Chapter 5 event-rates in ACTION patients with stable angina are shown strati ed for markers 
of renal dysfunction at baseline. The rate of cardiovascular death or con rmed myocardial 
infarction rose from 1.79 per 100 patient-years in patients assigned placebo without markers 
of renal dysfunction to 4.01 per 100 patient-years in patients with two or three markers. Given 
these  ndings there can therefore be little doubt that renal dysfunction has a major impact on 
prognosis, both in patients with hypertension and with stable angina. 
The question whether elevated blood pressure is more di  cult to control in patients with 
hypertension in INSIGHT is addressed in Chapter 4. As is shown in Table 2, blood pressure 
changes from baseline were similar in patients with and without elevated creatinine level 
or reduced creatinine clearance. But patients with renal dysfunction needed more add-on 
medication to reduce blood pressure. In patients with normal renal function 30% of patients 
used 2 drugs and 9% used 3 drugs, as opposed to 35% and 19% respectively in patients with 
renal dysfunction. This indicates unequivocally that blood pressure is indeed more di  cult to 
control in hypertensives who also have renal dysfunction. In patients with stable angina who 
participated in ACTION, the question whether the e ect of nifedipine on blood pressure levels 
depended on renal function was not addressed. 
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The e ect of blood pressure lowering drugs on renal function has been a cause for concern 
for many years. For instance, although angiotensin-converting enzyme inhibitors were recog-
nised when they were introduced as potent blood pressure lowering drugs useful for treat-
ing hypertension, these drugs were considered contraindicated in patients with heart failure 
until the results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) 
trial appeared in 1987 [16]. The reasons for this were that patients with heart failure often 
have impaired renal function, and that angiotensin-converting enzyme inhibitors may cause 
hypotension and increase creatinine levels. CONSENSUS was the  rst study to show that an-
giotensin-converting enzyme inhibitors reduce mortality in patients with heart failure despite 
their negative e ect on creatinine levels [17], provided that an appropriately low starting dose 
is used to avoid hypotension.
It has long been recognised that high-dose diuretics worsen renal function and prognosis in 
patients with renal dysfunction [18]. As shown in Figure 1 of Chapter 4, patients with hyper-
tension assigned in INSIGHT to a nifedipine GITS based regimen had higher estimated creati-
nine clearance levels during follow than those assigned to a co-amilozide based regimen. As 
follow-up blood pressure levels were very similar [6], the di erence in creatinine clearance 
between the treatment arms cannot be attributed to progression of renal dysfunction due to 
higher blood pressure levels. Hence, the question whether creatinine clearance is increased 
by nifedipine GITS, or reduced by co-amilozide, cannot be answered from INSIGHT. Because 
of this, the data on the e ect of nifedipine GITS on creatinine from the placebo-controlled 
ACTION trial are of considerable relevance. As is shown in Figure 1 of chapter 5, nifedipine 
GITS had little or no e ect on creatinine or estimated creatinine clearance in ACTION. Hence, 
the conclusion must be that the di erence in INSIGHT is caused by a negative e ect of co-
amilozide on renal function, rather than by a positive e ect of nifedipine.
That nifedipine GITS is neutral in terms of e ect on creatinine, and lowers uric acid (c.f. Figure 
1 of chapter 5) is in theory a desirable property compared to diuretics and angiotensin-con-
verting enzyme inhibitors. One might expect that this would translate into a bene cial e ect 
of nifedipine GITS compared to co-amilozide in patients with hypertension and renal dysfunc-
tion. This subgroup analysis remains to be done in INSIGHT. As shown in Chapter 5, the e ect 
of nifedipine GITS on outcome as observed in ACTION did not depend on renal dysfunction 
(c.f. Figure 3, Chapter 5). There is little doubt that renal dysfunction is associated with a poor 
prognosis in patients with hypertension and with coronary artery disease. The extent to which 
drug-induced renal dysfunction impairs prognosis remains to be elucidated however.
Signi cance and evolution of diabetes in patients with hypertension or 
coronary disease treated with nifedipine GITS
The concurrent presence of diabetes poses the same problems in patients with hypertension 
or stable angina as renal dysfunction. Again, the questions that must be asked relate to (i) 
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the impact of diabetes on prognosis, (ii) the di  culty of controlling blood pressure in these 
patients, and (iii) the e ect that treatment may have on diabetes itself.
That the presence of diabetes is associated with an impaired prognosis has long been rec-
ognised, and was observed both in INSIGHT and in ACTION. In both INSIGHT treatment arms 
combined, the primary outcomes cardiovascular death, myocardial infarction, heart failure, 
and stroke occurred in 8.4% of hypertensives with diabetes at baseline as opposed to 5.4% of 
hypertensives without diabetes. The same was true for secondary outcomes, which includes 
all-cause death in addition to primary outcomes (16.4% among diabetics, 11.3% among non-
diabetics, c.f. Figure Chapter 6). In patients with stable angina assigned placebo in the ACTION 
study, event-rates were higher in diabetics than in non-diabetics (c.f. Figure 3, Chapter 7). As 
expected, diabetes was also a conditionally independent predictor of outcome in ACTION 
participants when other factors are controlled for in a multivariate risk model [19].
Both INSIGHT and ACTION provided evidence on the feasibility of blood pressure control in 
diabetics. In INSIGHT, a similar degree of blood pressure control was achieved irrespective of 
treatment allocation (c.f. Table 2, Chapter 6). However, patients with diabetes required more 
add-on therapy than non-diabetic patients (c.f. Table 3, Chapter 6). In the ACTION study di-
abetics responded as well as non-diabetics to blood pressure lowering by nifedipine GITS 
(mean reduction of 6/3 mmHg respectively, Chapter 7). However, the prevalence of hyperten-
sion was higher in diabetics than in non-diabetics throughout the study (c.f. Figure 1, Chapter 
7). Taken together, these  ndings imply that blood pressure control is more di  cult in diabet-
ics, as is the case in patients with renal dysfunction (see previous section).
There has been considerable debate whether blood pressure lowering drugs can induce or 
aggravate diabetes [20,21]. In INSIGHT, signi cantly more patients without diabetes at base-
line in the co-amilozide group developed newly diagnosed diabetes mellitus during follow-
up than in the nifedipine group (5.6% as opposed to 4.3%, P=0.023, Chapter 6). As INSIGHT 
did not have placebo control, these results can be explained either by a preventive e ect 
of nifedipine on the development of diabetes, or by an adverse e ect of co-amilozide. The 
evidence from ACTION allows the distinction to be made. Among ACTION participants who 
did not have diabetes at baseline, hyperglycaemia was reported as an adverse event with 
equal frequency in patients assigned nifedipine as in those assigned placebo (0.73 patients 
with event/100 patient-years of follow-up as opposed to 0.75 patients with event/100 patient-
years of follow-up, P=0.8, Chapter 7). Among non-diabetics, there was also no di erence in 
the evolution of glucose levels between nifedipine and placebo treated patients (c.f. Figure 
2, Chapter 7). Assuming that patients with hypertension are equally sensitive to adverse ef-
fects of blood pressuring lowering drugs as patients with coronary disease, the evidence from 
INSIGHT and ACTION taken together suggest that co-amilozide induces glucose intolerance, 
while nifedipine does not. Indeed, most cases of newly diagnosed diabetes in patients as-
signed co-amilozide in INSIGHT occurred after the initial dose of this was increased [22].
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This conclusion is supported by the fact that in INSIGHT, nifedipine prevented secondary out-
comes relative to co-amilozide in diabetics while there was no such di erence in non-diabet-
ics (c.f. Figure, Chapter 6). On the other hand, the e ects of nifedipine relative to placebo on 
pre-de ned composite endpoints in ACTION were similar in diabetics and non-diabetics (c.f. 
Figure 4, Chapter 7).
Taken together, the evidence from INSIGHT and ACTION suggests that avoiding newly diag-
nosed diabetes is an important consideration when deciding on blood pressure lowering 
treatment. Nifedipine GITS appears superior to the thiazide diuretic co-amilozide in this re-
gard.
CLINICAL IMPLICATIONS
In conclusion, both the INSIGHT and the ACTION study have important clinical implications.
Evidence-based clinical medicine requires that trials such as INSIGHT and ACTION 1. 
be done.
The clinical course of patients with hypertension is unpredictable and the e ect of blood pres-
sure lowering on outcome cannot be assessed by the treating physician in individual patients. 
Evidence-based clinical decision making must therefore be based on the results of appropri-
ately designed randomised clinical trials.
Apparently, treating physicians do not pay su  cient attention to the need to 2. 
control blood pressure.
In the INSIGHT study, there were four dose-titration or addition of other medication steps 
in patients whose blood pressure fell by less than 20/10 mmHg, or was higher than 140/90 
mmHg. Nonetheless, at the end of the study 42% of patients assigned nifedipine and 43% of 
patients assigned co-amilozide did not have their blood pressure controlled [6].
The ACTION protocol encouraged optimal medical treatment of elevated blood pressure and 
did not contain any restrictions as regards medications that could be added to double-blind 
nifedipine or placebo, provided that the medication was compatible with nifedipine. None-
theless, of ACTION patients with a blood pressure equal or higher than 140/90 mmHg at base-
line, 47% assigned nifedipine and 64% assigned placebo still had a blood pressure equal or 
higher than 140/90 mmHg after 4 years of follow-up (c.f. Table 3 of Chapter 3). 
Blood pressure control does matter, also in patients with stable angina.3. 
The totality of the evidence that supports blood pressure control in patients with hyperten-
sion is compelling [5]. INSIGHT showed that overall nifedipine GITS is as e ective in the pre-
vention of cardiovascular events in hypertensives as the thiazide diuretic used as comparison 
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[6]. While ACTION was not designed to assess the e ect of nifedipine GITS in patients with sta-
ble angina and hypertension, the subgroup analysis of ACTION patients with elevated blood 
pressure at baseline presented in Chapter 3 shows that controlling blood pressure in these 
patients improves prognosis. 
It matters how blood pressure is controlled.4. 
Meta-analyses have thus far failed to show that there are important di erences between 
blood pressure lowering drugs as regards their e ects on prognosis in patients with hyper-
tension [23]. Nonetheless, how blood pressure is controlled does matter as di erent drugs 
have di erent mechanisms of action and safety pro les. The INSIGHT and ACTION studies 
have demonstrated that nifedipine GITS has a favourable safety pro le compared to a thiaz-
ide as regards preservation of renal function and glucose tolerance. While controlling blood 
pressure remains the primary objective of treating patients with elevated blood pressure, 
preservation of renal function and prevention of glucose intolerance are important additional 
considerations.
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SUMMARY
It is generally accepted that blood pressure lowering drugs improve the prognosis of patients 
with elevated blood pressure. The dihydropyridine calcium antagonist nifedipine is a widely 
used blood pressure lowering drug. In the mid-1990ties questions were raised on the safety of 
the short-acting immediate release formulation of this drug, in particular in patients with cor-
onary disease. To answer these questions in the absence of any prospective safety data from 
randomised trials, two major studies using a more optimal long-acting GITS (gastro-intestinal 
therapeutic system) formulation of nifedipine were mounted in the late 1990ties.
The Intervention as a Goal in Hypertension Treatment (INSIGHT) randomised double-blind 
trial compared 30 mg nifedipine GITS (n=3157) to co-amilozide (hydrochlorothiazide 25 µg 
plus amiloride 2·5 mg; n=3164) in patients aged 55-80 years with hypertension (blood pres-
sure at least150/95 mmHg, or at least 160 mmHg systolic) who had at least one additional 
cardiovascular risk factor. There was no placebo-treated control group. The main results have 
been published elsewhere (Brown MJ et al. Lancet 2000; 356: 366–72). Up-titration followed 
by add-on medication was allowed and resulted in blood pressure control to a similar degree. 
INSIGHT showed that overall nifedipine GITS based treatment was as e ective as co-amilozide 
based treatment in preventing cardiovascular or cerebrovascular complications.
The A Coronary disease Trial Investigating Outcome with Nifedipine GITS (ACTION) study com-
pared randomly assigned 60 mg nifedipine GITS (n=3825) to double-blind placebo (n=3840) in 
patients aged at least 35 years with stable angina pectoris and proven coronary artery disease. 
ACTION demonstrated that the addition of nifedipine GITS to the conventional treatment of 
angina pectoris is safe, has no e ect on major cardiovascular event-free survival and reduces 
the need for coronary angiography and interventions. The main results of ACTION have been 
published (Poole-Wilson PA et al. Lancet 2004;364:849-57). The report is reproduced in this 
thesis as Chapter 2.
Results from both studies are presented in this thesis, with the following threefold general 
aim:
1. To describe the long-term evolution of blood pressure (Chapters 2 and 3) and to examine 
the e ect of blood pressure reduction by nifedipine GITS on outcome in ACTION patients 
with stable angina and hypertension (Chapter 3).
2. To assess the evolution of renal function and the relationship between renal function and 
mortality and morbidity in patients with hypertension treated in INSIGHT with either nife-
dipine or co-amilozide, and in patients with stable angina treated in ACTION with either 
nifedipine or placebo (Chapters 4 and 5).
3. To assess the impact of diabetes in patients with hypertension and diabetes who received 
either nifedipine or co-amilozide in INSIGHT, and in patients with stable angina treated in 
ACTION with either nifedipine or placebo (Chapters 6 and 7).
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First aim: Results presented in Chapter 2 show that in all ACTION patients with stable angina 
combined nifedipine GITS signi cantly reduced both systolic and diastolic blood pressure 
relative to placebo throughout the follow-up of almost  ve years. Results of the pre-speci ed 
subgroup analysis for ACTION patients with hypertension (baseline blood pressure at least 
140/90 mmHg, n=3977) are presented in Chapter 3 (previously published: Lubsen J et al. J 
Hypertens 23:641-648). Nifedipine GITS signi cantly reduced mean follow-up blood pres-
sures by 6.6/3.5 mmHg among hypertensives and by 3.9/2.4 mmHg among normotensives. 
In hypertensives, these blood pressure reductions resulted in a signi cant 13% reduction of 
the combined incidence of all-cause mortality, myocardial infarction, refractory angina, heart 
failure, stroke and peripheral revascularization (the ACTION primary outcome for e  cacy). In 
normotensives, no such reduction was observed. 
Nifedipine signi cantly reduced the incidence of any stroke or transient ischemic attack and 
the need for coronary angiography both in hypertensives and in normotensives with stable 
angina. An unexpected  nding was the signi cant reduction by nifedipine of new overt heart 
failure. Nifedipine did not a ect all-cause death, cardiovascular death and myocardial infarc-
tion in either normo- or hypertensives, but increased the need for peripheral revasculariza-
tion.
The salutary e ects of the addition of nifedipine GITS to the basic regimen emphasize the 
need for blood pressure control in patients with stable angina and hypertension. 
Second aim: Results from INSIGHT presented in Chapter 4 (previously published: de Leeuw 
PW et al. Arch Intern Med. 2004;164:2459-2464) and from ACTION in Chapter 5 (previously 
published: Ruilope LM et al. J Hypertens 2005;25:1711-1718) demonstrate that renal dysfunc-
tion adversely a ects the prognosis both of patients with hypertension (Chapter 4), and of 
patients with stable angina (Chapter 5). Patients with hypertension and renal failure needed 
more add-on medication to control blood pressure than those without renal failure. Overall, 
those assigned to a nifedipine GITS based regimen had higher estimated creatinine clearance 
levels during follow than those assigned to a co-amilozide-based regimen (Chapter 4). As no 
such di erence was observed in the placebo-controlled ACTION study (Chapter 5), it appears 
that co-amilozide treatment is associated with a reduction of renal function.
No subgroup analysis was performed in INSIGHT to determine whether the e ect of nife-
dipine relative to co-amilozide depended on the presence of renal failure at baseline. Such a 
subgroup analysis was done for the ACTION study (Chapter 5). The e ects of nifedipine rela-
tive to placebo appeared not to depend on the presence of renal failure.
Third aim: Results from INSIGHT presented in Chapter 6 (previously published: Mancia G et 
al. Hypertension 2003;41:431-436) and from ACTION in Chapter 7 (submitted for publica-
tion) con rm that diabetes adversely a ects the prognosis both of patients with hypertension 
(Chapter 6), and of patients with stable angina (Chapter 7). Patients with hypertension and 
diabetes in INSIGHT needed more add-on medication to control blood pressure than those 
without diabetes (Chapter 6). Patients with stable angina and diabetes had a higher preva-
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lence of hypertension throughout the ACTION study although the blood pressure lowering 
e ect of nifedipine GITS was the same in diabetics as in non-diabetics (Chapter 7). 
In INSIGHT, signi cantly more patients without diabetes at baseline in the co-amilozide group 
developed newly diagnosed diabetes during follow-up than in the nifedipine group (Chapter 
6). As no such di erence was observed in the placebo-controlled ACTION study (Chapter 7), 
it appears that co-amilozide treatment is associated with an increased incidence of new dia-
betes. 
In INSIGHT, nifedipine prevented secondary outcomes relative to co-amilozide in diabetics 
but not in non-diabetics (Chapter 6). In ACTION, e ects of nifedipine relative to placebo were 
similar in diabetics and non-diabetics (Chapter 7). These results suggest that nifedipine GITS 
appears superior to a thiazide diuretic in the prevention of diabetes.
Clinical implications: The results from INSIGHT and ACTION presented in this thesis have 
several clinical implications. 
Firstly, they underscore the need to perform large trials as basis for evidence-based clinical 
practice. 
Secondly, treating physicians apparently do not pay su  cient attention to the need to con-
trol blood pressure. In both studies, the blood pressure of a relative large number of patients 
remained elevated at the end of follow-up although the protocols concerned encouraged the 
use of additional medication to achieve blood pressure control. 
Thirdly, the present results con rm that blood pressure control with nifedipine GITS is bene -
cial in patients with hypertension irrespective of the presence of coronary disease.
Finally, the present results suggest that it does matter how blood pressure is controlled as the 
di erent metabolic e ects of blood pressure lowering drugs may be clinically relevant. While 
controlling blood pressure remains the primary objective of treating patients with hyperten-
sion, preservation of renal function and prevention of glucose intolerance are important ad-
ditional considerations.
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SAMENVATTING
Het is algemeen aanvaard dat bloeddrukverlagende middelen de prognose van patienten 
met verhoogde bloeddruk gunstig beïnvloeden. De dihydropyridine calcium-antagonist ni-
fedipine is een veel-gebruikt bloeddrukverlagend middel. Rond 1995 rezen er vragen betref-
fende de veiligheid van de kort-werkende capsule toedieningsvorm van dit middel, in het 
bijzonder bij patienten met een coronair lijden. Teneinde de gerezen vragen te beantoorden 
omdat prospectieve gegevens uit gerandomiseerd vergelijkend onderzoek ontbraken, wer-
den tussen 1995 en 2000 twee grote klinische trials opgezet met een meer optimale langwer-
kende GITS (gastro-intestinaal therapeutisch systeem) toedieningsvorm van nifedipine. 
In de “Intervention as a Goal in Hypertension Treatment” (INSIGHT) gerandomiseerde dubbel-
blinde trial werden 30 mg nifedipine GITS (n=3157) en co-amilozide (hydrochlorothiazide 25 
µg plus amiloride 2·5 mg; n=3164) met elkaar vergeleken bij hypertensie-patienten (bloed-
druk tenminste 150/95 mmHg, of systolische bloeddruk tenminste 160 mmHg) van 55-80 jaar 
bij wie tenminste één andere cardiovasculaire risicofactor aanwezig was. Er was geen met 
placebo behandelde controlegroep. De meest-belangrijke resultaten werden elders gepubli-
ceerd (Brown MJ et al. Lancet 2000; 356: 366–72). Het was toegestaan ná randomisatie de 
dosis van de toegewezen medicatie te verhogen, en vervolgens zo nodig andere bloeddruk-
verlagende middelen toe te voegen. Op deze wijze werd bereikt dat de bloeddruk tijdens de 
looptijd van het onderzoek gelijk was in beide behandelingsgroepen. Er was in INSIGHT geen 
verschil met betrekking to het optreden van cardiovasculaire en cerebrovasculaire complica-
ties tussen beide behandelingsgroepen.
In de “A Coronary disease Trial Investigating Outcome with Nifedipine GITS” (ACTION) studie 
werd random toegewezen 60 mg nifedipine GITS (n=3825) dubbel-blind vergeleken met 
placebo (n=3840) bij patienten van tenminste 35 jaar met stabiele angina pectoris en een 
bewezen coronair lijden. ACTION toonde aan dat de toevoeging van nifedipine GITS aan de 
conventionele behandeling van angina pectoris veilig is, geen e ect heeft op de overleving 
vrij van belangrijke cardiovasculaire complicaties, en de noodzaak tot het verrichten van coro-
naire angiogra e en interventies vermindert. De meest-belangrijke resultaten werden elders 
gepubliceerd (Poole-Wilson PA et al. Lancet 2004;364:849-57), en zijn in dit proefschrift opge-
nomen als Hoofdstuk 2.
In dit proefschrift worden bevindingen van beide studies gepresenteerd met de volgende 
drie-voudige doelstelling:
1. Het beschrijven van het beloop van de bloeddruk op de lange termijn (Hoofdstuk 2 en 3) 
en het vaststellen van het e ect van bloeddrukverlaging door nifedipine GITS op het klini-
sche beloop van patienten met hypertensie en stabiele angina pectoris in de ACTION studie 
(Hoofdstuk 3)
2. Het beschrijven van het beloop van de nierfunctie en de relatie tussen nierfunctie en mor-
taliteit en morbiditeit in patienten met hypertensie die in INSIGHT behandeld werden met 
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hetzij nifedipine, hetzij co-amilozide; en bij patienten met stabiele angina pectoris die in 
ACTION behandeld werden met nifedipine of placebo (Hoofdstuk 4 en 5). 
3. Het vastellen van het belang van de aanwezigheid van diabetes bij patienten met hyper-
tensie die in INSIGHT behandeld werden met hetzij nifedipine, hetzij co-amilozide; en bij 
patienten met stabiele angina pectoris die in ACTION behandeld werden met nifedipine of 
placebo (Hoofdstuk 6 en 7).
Eerste doelstelling: Gegevens in Hoofdstuk 2 laten zien dat nifedipine GITS bij alle ACTION 
patienten met stabiele angina tezamen een signi cante en blijvende bloeddrukdaling veroor-
zaakt in vergelijking to placebo gedurende een observatie-periode van bijna 5 jaar. Resulta-
ten van de subgroep analyse van ACTION patienten met hypertensie (bloeddruk bij aanvang 
van het onderzoek tenminste 140/90 mmHg, n=3977) worden gepresenteerd in Hoofdstuk 
3 (eerder gepubliceerd: Lubsen J et al. J Hypertens 23:641-648). Ni depine GITS verlaagde de 
bloeddruk signi cant met 6.6/3.5 mmHg by patienten met hypertensie, en met 3.9/2.4 mmHg 
bij patienten zonder hypertensie. Bij patienten met hypertensie ging de bloeddrukdaling ge-
paard met een signi cante vermindering van 13% van de gecombineerde incidentie van to-
tale sterfte, myocard infarct, refractaire angina pectoris, hartfalen, cerebrovasculair accident 
en perifere revascularisatie (het primaire e ectiviteitscriterium in ACTION). Bij patienten met 
een normale tensie had nifedipine geen e ect op dit criterium.
Nifedipine verminderde signi cant het optreden van een aanval van voorbijgaande cerebrale 
ischaemie of een cerebrovasculair accident, en van de noodzaak tot het doen van een coronair 
angiogram, zowel bij patienten mèt als zónder hypertensie. Het signi cante minder optreden 
van hartfalen in de nifedipine groep was een nieuwe en daarom onverwachte bevinding. De 
positieve e ecten van nifedipine benadrukken de noodzaak van het verlagen van de bloed-
druk van patienten met stabiele angina en hypertensie.
Tweede doelstelling: Gegevens uit INSIGHT in Hoofdstuk 4 (eerder gepubliceerd: de Leeuw 
PW et al. Arch Intern Med. 2004;164:2459-2464) en uit ACTION in Hoofdstuk 5 (eerder gepu-
bliceerd: Ruilope LM et al. J Hypertens 2005;25:1711-1718) laten zien dat een verminderde 
nierfunctie zowel bij patienten met hypertensie (Hoodstuk 4) als bij patienten met stabiele 
angina pectoris (Hoodstuk 5) gepaard gaat met een ongunstige prognose. Hypertensie pa-
tienten met een verminderde nierfunctie hadden méér bloeddrukverlagende medicatie no-
dig dan patienten met een normale nierfunctie. Patienten die behandeld werden met een 
op nifedipine gebaseerd regime hadden een hogere creatinineklaring gedurende de looptijd 
van de studie dan degenen die met een op co-amilozide gebaseerd regime regime behandeld 
werden (hoofdstuk 4). Aangezien een dergelijk verschil niet werd gezien in ACTION wanneer 
nifedipine wordt vergeleken met placebo volgt hieruit dat co-amilozide de nierfunctie ver-
mindert.
Een subgroep analysie van INSIGHT om na te gaan of de e ecten van nifedipine in verge-
lijking tot co-amilozide afhangen van de nierfunctie bij aanvang van het onderzoek is niet 
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uitgevoerd. Een dergelijke subgroep analyse werd wel gedaan in ACTION (Hoofdstuk 5). Deze 
analyse toonde aan dat de e ecten van nifedipine niet afhangen van de nierfunctie.
Derde doelstelling: Gegevens uit INSIGHT in Hoofdstuk 6 (eerder gepubliceerd: Mancia G et 
al. Hypertension 2003;41:431-436) en uit ACTION in Hoofdstuk 7 (ter publicatie aangeboden) 
laten zien dat de aanwezigheid van diabetes zowel bij patienten met hypertensie (Hoodstuk 
6) als bij patienten met stabiele angina pectoris (Hoodstuk 7) gepaard gaat met een ongun-
stige prognose. Patienten met hypertensie en diabetes hadden méér bloeddrukverlagende 
medicatie nodig dan patienten zonder diabetes (Hoodstuk 6). Patienten met stabiele angina 
pectoris en diabetes hadden vaker een verhoogde bloeddruk gedurende de looptijd van de 
ACTION studie dan patienten zonder diabetes. Het bloeddrukverlagende e ect van nifedi-
pine was hetzelfde bij diabeten en niet-diabeten (Hoodstuk 7).
Bij INSIGHT patienten in de co-amilozide groep zonder diabetes kwam voor het eerst vast-
gestelde diabetes gedurende de looptijd van het onderzoek signi cant vaker voor dan in de 
nifedipine groep (Hoodstuk 6). Aangezien een dergelijk verschil niet werd gezien in ACTION 
wanneer nifedipine wordt vergeleken met placebo (Hoodstuk 7) volgt hieruit dat co-amilozi-
de het optreden van diabetes ongunstig beïnvloedt.
INSIGHT liet zien dat nifedipine bij diabetici met hypertensie e ectiever is dan co-amilozide 
met betrekking tot het optreden van secondare uitkomsten (Hoofdstuk 6). Bij niet-diabetici 
was er geen verschil in dit opzicht. In ACTION waren de e ecten van nifedipine in vergelijking 
tot placebo bij diabetici gelijk aan die bij niet-diabetici (Hoofdstuk 7). Deze bevindingen sug-
gereren dat nifedipine GITS te verkiezen is boven co-amilozide met betrekking tot de preven-
tie van diabetes.
Klinische betekenis: De INSIGHT en ACTION resultaten beschreven in dit proefschrift hebben 
in meerdere opzichten klinische betekenis.
In de eerste plaats benadrukken zij de noodzaak tot het doen van grote trials als basis voor 
“evidence-based medicine”.
In de tweede plaats laten zij zien dat er in de klinische praktijk kennelijk te weinig aandacht 
wordt besteed aan de noodzaak een verhoogde bloeddruk te normaliseren. In beide studies 
hadden belangrijke aantallen patienten verhoogde bloeddruk aan het eind van het onder-
zoek ondanks het feit dat het gebruik van additionele medicatie ter controle van de bloed-
druk werd aangemoedigd.
In de derde plaats bevestigen deze gegevens dat verlaging van de bloeddruk door nifedipine 
GITS e ectief is bij patienten met hypertensie onafhankelijk van de aanwezigheid van een 
bijkomend coronair lijden. 
Tenslotte suggereren deze gegevens dat het er wel degelijk toe doet hoe de bloeddruk ver-
laagd wordt omdat de verschillende metabole e ecten van bloeddrukverlagende middelen 
klinisch relevant kunnen zijn. Alhoewel verlaging van de bloeddruk het eerste doel blijft van 
de behandeling van patienten met hypertensie, zijn het behoud van de nierfunctie en het 
voorkómen van glucose intolerantie belangrijke bijkomende overwergingen.
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